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 1.1  The mitochondrial respiratory chain 1 
1  Introduction 
1.1  The mitochondrial respiratory chain 
The respiratory chain is located in the mitochondrial inner membrane of eukaryotic cells 
and catalyzes electron transfer mainly from NADH to oxygen (Hatefi, 1985). This 
exergonic redox reaction is coupled to proton translocation across the inner mito-
chondrial membrane. The proton gradient then drives the endergonic synthesis of ATP 
by ATP-synthase (Abrahams et al., 1994; Boyer, 1997; Nakamoto et al., 1999) and 
other endergonic reactions. This fundamental principle of energy conversion in cells 
was first proposed by Peter Mitchell (Mitchell, 1961) and is known as the chemiosmotic 
theory.  
Electron transfer from NADH to oxygen is performed stepwise by three respiratory 
chain complexes (complex I, III and IV) and involves ubiquinone and cytochrome c as 
mobile electron carriers (Hatefi, 1985). Complex I (NADH:ubiquinone oxidoreductase) 
transfers electrons from matrix NADH to ubiquinone and thereby pumps two protons 
per electron across the inner mitochondrial membrane (Wikström, 1984; Galkin et al., 
1999). Complex III (cytochrome c reductase) transfers electrons from ubiquinol to 
cytochrome c and pumps one proton per electron (Wikström et al., 1981; Brandt, 1996). 
Finally, complex IV (cytochrome c oxidase) transfers electrons from cytochrome c onto 
molecular oxygen, the ultimate electron acceptor, and translocates two charges per 
electron (Michel, 1998). 
Although complex I, III and IV were isolated and studied separately, in the 
mitochondrial membrane they form large supercomplexes (respirasomes) supporting 
their stability and facilitating substrate channeling (Schägger and Pfeiffer, 2000; 
Schägger, 2002; Stroh et al., 2004; Schägger et al., 2004; Suthammarak et al., 2009). 
Due to the ubiquinone reduction activity of the succinate dehydrogenase (complex II), 
the electron-transferring flavoprotein (ETF)-ubiquinone oxidoreductase and the 
s,n-glycerolphosphate dehydrogenase additional electrons are fed into the respiratory 
chain. However, these enzymes do not translocate protons across the mitochondrial 
membrane. 2   1  Introduction  
The respiratory chain is also the main source of reactive oxygen species (ROS) 
(Fridovich, 1978). ROS production occurs at the catalytic sites of complex I (Turrens 
and Boveris, 1980; Kushnareva et al., 2002; Galkin and Brandt, 2005; Kussmaul and 
Hirst, 2006) and complex III (Boveris et al., 1976; Cadenas et al., 1977; Dröse and 
Brandt, 2008; Borek et al., 2008) by single electrons escaping to oxygen (Brand et al., 
2004). Low levels of ROS seem to be involved in cellular signaling (Bell et al., 2007; 
Starkov, 2008). However, higher rates lead to oxidative stress which plays a role in 
apoptosis, aging and several neurodegenerative diseases including Parkinson’s, 
Huntington’s and Alzheimer disease (Benzi and Moretti, 1995; Finkel and Holbrook, 
2000; Emerit et al., 2004; Lin and Beal, 2006; Zhou et al., 2008). 
 
Figure 1.1: Semi-schematic representation of the mitochondrial respiratory chain. 
Complex I (NADH:ubiquinone oxidoreductase); Complex II (succinate:ubiquinone oxido-
reductase); Cytochrome bc1 Complex (Complex III); Cytochrome c Oxidase (complex IV); 
Electron transfer (thin red arrows), sites of ROS production (thick red arrows) and sites of 
action of some inhibitors (blue) are indicated. NAD
+ (nicotinamide adenine dinucleotide, 
oxidized form); NADH (nicotinamide adenine dinucleotide, reduced form); Q (ubiquinone); 
QH2 (ubiquinol); bH (high potential heme b); bL (low potential heme b); c (cytochrome c). 
Figure was taken from (Dröse and Brandt, 2008) 1.2  Complex I 3 
1.2  Complex I 
1.2.1  Subunit composition 
Mitochondrial complex I (NADH:ubiquinone oxidoreductase) is a huge multisubunit 
membrane protein and the least understood component of the respiratory chain (Brandt, 
2006; Zickermann et al., 2008; Zickermann et al., 2009). It is composed of at least 40 
protein subunits with a total mass of ~1 MDa (Carroll et al., 2006a; Morgner et al., 
2008).  
Table 1.1: Central subunits of complex I  
Subunit nomenclature 
Redox 
centers 
B. taurus  Y. lipolytica  H. sapiens  E. coli  T. 
thermophilus 
hydrophilic subunits of the peripheral domain, nuclear coded in eukaryotes 
75-kDa NUAM  NDUFS1 NuoG  Nqo3  N1b, N4 
1, 
N5, N7 
2 
51-kDa NUBM  NDUFV1 NuoF  Nqo1 FMN,  N3 
49-kDa NUCM  NDUFS2  NuoD 
3 Nqo4  - 
30-kDa NUGM  NDUFS3  NuoC 
3  Nqo5 - 
24-kDa NUHM  NDUFV2 NuoE  Nqo2  N1a 
TYKY NUIM  NDUFS8 NuoI  Nqo9  N6a 
1, N6b 
1 
PSST NUKM  NDUFS7  NuoB  Nqo6  N2 
hydrophobic subunits of the membrane domain, mitochondrially coded in most eukaryotes 
ND1 ND1 ND1  NuoH  Nqo8  - 
ND2  ND2  ND2  NuoN  Nqo14  - 
ND3 ND3 ND3  NuoA  Nqo7  - 
ND4 ND4 ND4  NuoM  Nqo13  - 
ND5 ND5 ND5  NuoK  Nqo12  - 
ND6 ND6 ND6 NuoL  Nqo10  - 
ND4L ND4L ND4L  NuoJ Nqo11  - 
1  Iron-sulfur cluster N4 was proposed to be ligated in the TYKY instead of N6a or N6b 
(Yakovlev et al., 2007) 
2  present in some bacteria only 
3 in  E. coli NuoD and NuoC are fused to NuoCD 4   1  Introduction  
14 subunits (see Table 1.1) are conserved between eukaryotes and prokaryotes (Yagi et 
al., 1998) and are sufficient to couple the redox reaction to proton translocation. These 
14 subunits are usually called “central” in order to distinguish them from the remaining 
so called “accessory” subunits that are not directly involved in energy conversion but 
may have additional functions (Hirst et al., 2003). Of the 14 central subunits, 7 are 
rather hydrophilic and 7 are highly hydrophobic. The latter are typically encoded by 
mitochondrial DNA in eukaryotes (Anderson et al., 1982; Chomyn et al., 1985; 
Chomyn et al., 1986; Kerscher et al., 2001a). 
1.2.2  Structural data 
In contrast to other respiratory chain complexes, the crystal structure of complex I is not 
solved yet. However, single particle electron microscopy revealed that complex I has an 
L-shaped overall structure both in eukaryotes and prokaryotes (Hofhaus et al., 1991; 
Guenebaut et al., 1997; Guenebaut et al., 1998; Grigorieff, 1998; Djafarzadeh et al., 
2000; Peng et al., 2003; Radermacher et al., 2006; Morgan and Sazanov, 2008). The 
hydrophobic membrane domain of the enzyme is embedded in the mitochondrial 
membrane, whereas the hydrophilic peripheral domain protrudes into the mitochondrial 
matrix. The peripheral domain contains all known redox centers, a non-covalently 
bound FMN and 8-9 iron-sulfur clusters (Finel et al., 1992; Ohnishi, 1998; Rasmussen 
et al., 2001; Hinchliffe and Sazanov, 2005; Sazanov and Hinchliffe, 2006).  
In 2006 Sazanov and co-workers succeeded to solve the X-ray structure of the 
peripheral domain of complex I from Thermus thermophilus at 3.3 Ångström resolution 
(Sazanov and Hinchliffe, 2006). The Y shaped fragment revealed the spatial 
arrangement of the seven central hydrophilic subunits as well as the locations of all 
known redox centers of complex I (see Figure 1.2). Seven iron-sulfur clusters (N1b, N2, 
N3, N4, N5, N6a und N6b) form an approximately 95 Å long chain of redox centers. 
This chain starts with iron-sulfur cluster N3 next to the FMN molecule in the 51-kDa 
subunit, continues via the redox centers of the 75-kDa and the TYKY subunits and ends 
at iron-sulfur cluster N2 in the PSST subunit next to a broad cavity at the interface of 
the PSST and the 49-kDa subunit. In order to avoid confusion, the bovine nomenclature 
for homologous complex I subunits will by used throughout. Iron-sulfur cluster N1a in 1.2  Complex I 5 
the 24-kDa subunit is located at the opposite side of the FMN molecule. Iron-sulfur 
cluster N7 present only in some bacteria is not in electron tunneling distance to other 
iron-sulfur clusters and most probably serves to stabilize the 75-kDa subunit (Pohl et al., 
2007).  
 
Figure 1.2: The crystal structure of the peripheral domain of complex I from T. 
thermophilus contains 7 out of 14 central subunits of complex I. Subunits are shown in 
schematic representation with transparent surface and are labeled according to the bovine 
nomenclature. Iron-sulfur clusters (in gray) as well as the FMN molecule (in pink) are shown as 
space-filled models. A chain of 7 iron-sulfur clusters connects the FMN molecule with a broad 
cavity assembled by the PSST and the 49-kDa subunit. The binuclear iron-sulfur cluster N1a 
ligated by the 24-kDa subunit is located at the opposite side of the FMN molecule. Iron-sulfur 
cluster N7 (lowest cluster ligated by the 75-kDa subunit) is not in electron tunnelling distance to 
other iron-sulfur clusters. The figure was generated from PDB ID 2FUG using the PyMOL 
program. 6   1  Introduction  
No redox centers were found in the membrane domain of complex I (Carroll et al., 
2006b). However, this part of the enzyme must harbor the proton translocating 
device(s).  
Recently, the projection map of the membrane domain from Escherichia coli composed 
of subunits ND1-ND6 and ND4L was solved from 2 D crystals (Baranova et al., 2007a). 
The resolution of 8 Å allowed the identification of about 60 transmembrane α-helices. 
However, at this resolution only a tentative assignment of the densities to the subunits 
was possible.  
The ND2, the ND4 and the ND5 subunits are homologous to Na
+/H
+-antiporters 
(Fearnley and Walker, 1992) and therefore were suggested to be involved in proton 
translocation (Friedrich and Weiss, 1997; Friedrich, 2001; Mathiesen and Hägerhäll, 
2002; Mathiesen and Hägerhäll, 2003). Interestingly, the ND4 and the ND5 subunits 
were found to be located at the distal end of the membrane domain (Sazanov and 
Walker, 2000; Cardol et al., 2002; Holt et al., 2003; Baranova et al., 2007b) in 
considerable distance to the peripheral domain and thus to all known redox centers, 
suggesting long range conformational changes for driving proton translocation. 
1.2.3  The ubiquinone binding site  
It had been proposed earlier that the quinone binding pocket is formed by the PSST and 
the 49-kDa subunit of complex I (Kashani-Poor et al., 2001b; Kerscher et al., 2001c) 
that are evolutionary related to the small and large subunits of water-soluble [NiFe] 
hydrogenases as indicated by sequence comparison (Böhm et al., 1990; Albracht, 1993). 
This proposal was based on mutagenesis studies which showed that many functionally 
critical residues are located in this part of the enzyme and that mutations which target 
the former [NiFe] site conferred resistance towards complex I inhibitors which act at the 
quinone binding site (Darrouzet and Dupuis, 1997; Darrouzet et al., 1998; Prieur et al., 
2001; Kashani-Poor et al., 2001b; Loeffen et al., 2001; Mills et al., 2004). In addition, 
photoaffinity labeling studies suggested that the PSST subunit forms part of the quinone 
and inhibitor binding pocket of complex I (Schuler et al., 1999). Further support came 
from more recent mutagenesis (Grgic et al., 2004; Kerscher et al., 2005) and photo-
affinity labeling studies (Ichimaru et al., 2008) and the crystal structure of the 1.2  Complex I 7 
hydrophilic domain of complex I from T. thermophilus (Sazanov and Hinchliffe, 2006). 
The structure essentially shows a wire of iron-sulfur clusters which connect the FMN 
molecule with a broad cavity formed by the PSST and the 49 kDa subunit, which is 
believed to comprise the quinone binding site (see Figure 1.2). 
However, from the crystal structure alone it cannot be inferred where this cavity is 
located relative to the membrane and the not yet crystallized membrane domain of 
complex I. Interestingly, single particle analysis of complex I decorated with antibodies 
against the 49-kDa subunit suggested that the quinone binding pocket is located at 
considerable distance (about 60 Å) to the membrane domain of complex I (Zickermann 
et al., 2003). This result was confirmed when a subcomplex of complex I (Zickermann 
et al., 2007) was analyzed, which allowed the fitting of the structure of the hydrophilic 
domain of complex I from T. thermophilus into the holocomplex from Yarrowia 
lipolytica (Clason et al., 2007). 
1.2.4  Complex I inhibitors 
More than 60 families of natural and synthetic complex I inhibitors were described 
(Degli Esposti, 1998; Miyoshi, 1998; Lümmen, 1998; Okun et al., 1999b; Ushakova et 
al., 1999; Okun et al., 1999a; Okun et al., 2000). Most of these compounds are quite 
hydrophobic and inhibit the NADH:Q oxidoreductase activity of complex I; however, 
they do neither interfere with the NADH:ferricyanide oxidoreductase activity (Hatefi, 
1985) nor with the reduction of EPR detectable iron-sulfur clusters (Friedrich et al., 
1994). Thus it was concluded that they act at the quinone binding site of complex I.  
Based on steady state kinetics, Friedrich and coworkers grouped 12 complex I inhibitors 
into two classes (Friedrich et al., 1994). Class I inhibitors (piericidin A, fenpyroximate 
and others) act in a partially competitive manner on complex I and competitively on 
bacterial glucose dehydrogenase, both with regard to Q2, whereas class II inhibitors 
(rotenone and others) act non-competitively on complex I and do not inhibit glucose 
dehydrogenase. After an extensive literature survey, Degli Esposti grouped complex I 
inhibitors into three categories (Degli Esposti and Ghelli, 1994; Degli Esposti, 1998): 
Type A, B and C. Thereby, type A and type B largely correspond to class I and class II, 
respectively. Type C inhibitors, represented by capsaicins and their synthetic analogues 8   1  Introduction  
like CC44 (Satoh et al., 1996), form a distinct group. The n-alkyl-polyoxyethylene-ether 
detergent C12E9 (Thesit) was proposed to be a type C inhibitor as well, since it was 
found to bind competitively to CC44 (Okun et al., 2000). 
The establishment of various types or classes of complex I inhibitors lead to the concept 
that these inhibitors bind to different parts of the enzyme corresponding to multiple 
quinone reaction sites (Degli Esposti and Ghelli, 1994; Degli Esposti, 1998; Estornell, 
2000). However, direct competition binding assays revealed that all three types of 
complex I inhibitors bind to partially overlapping binding sites within a large common 
pocket (Okun et al., 1999a). Thereby, the binding site for type A inhibitors overlaps 
with that for type B inhibitors, and the binding site for type C inhibitors overlaps with 
that for type B inhibitors but not with that for type A inhibitors (see Figure 1.3). 
 
Figure 1.3: Schematic representation of the inhibitor binding 
pocket of complex I. Different types of complex I inhibitors bind 
to partially overlapping binding sites, represented as shadowed 
ovals. Figure was taken from (Okun et al., 1999a). 1.2  Complex I 9 
1.2.5  EPR spectroscopy of iron-sulfur clusters 
Complex I contains one FMN molecule and several iron-sulfur clusters as redox centers. 
Only binuclear and tetranuclear iron-sulfur clusters are found in complex I; their 
geometry is shown in Figure 1.4. Reduced binuclear and tetranuclear iron-sulfur clusters 
are paramagnetic and can be detected by electron paramagnetic resonance (EPR) 
spectroscopy (Beinert and Albracht, 1982). The spin relaxation rates of binuclear iron-
sulfur clusters are relatively slow; therefore, they give EPR signals at quite high 
temperature (~70 K). Tetranuclear iron-sulfur clusters have faster spin relaxation rates, 
so that their EPR signals are too broad to be detected at these temperatures. However, 
they can be detected at temperatures of less than 20 K. According to Ohnishi’s 
nomenclature, signals of iron-sulfur clusters from complex I are numbered in the order 
of their spin relaxation rates from slow to fast (Ohnishi, 1998). Binuclear iron-sulfur 
clusters are named N1 (N1a or N1b), faster relaxing tetranuclear iron-sulfur clusters are 
named N2, N3, N4 and so forth.  
 
Figure 1.4: Schematic representation of a binuclear and a tetra-
nuclear iron-sulfur cluster. Typically, iron-sulfur clusters are co-
ordinated by sulfur atom from four liganding cysteine residues (in 
yellow). Acid-labile sulfur atoms are shown as orange spheres. Iron 
atoms are shown as red spheres. Figure adapted from (Voet and Voet, 
1992). 
In complex I from bovine heart mitochondria six iron-sulfur clusters (N1a, N1b, N2, 
N3, N4 and N5) are detectable by EPR (Ohnishi, 1998; Reda et al., 2008; Ohnishi and 10   1  Introduction  
Nakamaru-Ogiso, 2008). In complex I from Neurospora crassa four iron-sulfur clusters 
(N1, N2, N3 and N4) were detected by EPR (Wang et al., 1991) and two more (N6a and 
N6b) by ultraviolet-visible spectroscopy (Friedrich et al., 2000; Rasmussen et al., 2001). 
Bacterial complex I from E. coli contains six EPR detectable iron-sulfur clusters (N1a, 
N1b, N2, N3, N4 and N7) (Sled et al., 1993; Leif et al., 1995; Friedrich, 1998; 
Nakamaru-Ogiso et al., 2005; Uhlmann and Friedrich, 2005). In addition, iron-sulfur 
clusters N6a and N6b were detected by ultraviolet-visible spectroscopy (Friedrich et al., 
2000; Rasmussen et al., 2001). Five EPR detectable iron-sulfur clusters (N1, N2, N3, 
N4 and N5) were described in complex I from Y. lipolytica (Djafarzadeh et al., 2000). 
Thereby, the N1 signal was shown to correspond to the N1b signal from bovine 
complex I (Zickermann et al., 2007). Figure 1.5 shows an EPR spectrum of purified 
complex I from Y. lipolytica in comparison to a calculated spectrum assembled from 
four individual simulations. The sum of simulations is very similar to the recorded 
spectrum, which shows that iron-sulfur clusters N1, N2, N3 and N4 are present in a 
1:1:1:1 stoichiometry (Kerscher et al., 2001c). Iron-sulfur cluster N5 is not detectable at 
a temperature of 12 K as used here. So far, an EPR spectrum from a second binuclear 
iron-sulfur cluster, which would be expected from the crystal structure of the 
hydrophilic domain of complex I from T. thermophilus  ((Sazanov and Hinchliffe, 
2006); see also Figure 1.2) and the EPR characterization of bovine and E. coli complex 
I, could not be detected in complex I from Y. lipolytica. 1.2  Complex I 11 
 
Figure 1.5: Comparison of an EPR spectrum recorded at 12 K and 0.1 mW from purified 
complex I from Y. lipolytica to a simulated spectrum. Contributions from iron-sulfur clusters 
N1, N2, N3 and N4 are labeled. The gxy-signals of all iron-sulfur clusters overlap quite 
extensively. The experimental spectrum can be adequately simulated by the sum of simulations 
of iron-sulfur clusters N1, N2, N3 and N4. Iron-sulfur cluster N5 is not detectable under the 
experimental conditions used here. EPR parameters for the experimental spectrum: Microwave 
frequency 9.47 GHz,
 modulation frequency
 100 kHz and modulation amplitude 6.4 Gauss. The 
experimental spectrum and the simulated spectra were kindly provided by Dr. Klaus Zwicker. 
When EPR spectra are recorded from mitochondrial membranes of Y. lipolytica, 
additional signals from paramagnetic species in complex II, III and IV are detectable 
(see Figure 1.6).  12   1  Introduction  
 
Figure 1.6: Example of an EPR spectrum from mitochondrial membranes from Y. 
lipolytica recorded at 12 K and 1 mW microwave power. Signals mainly arising from iron-
sulfur cluster N2 are highlighted in gray. Magnetic field positions where signals from other 
complex I iron-sulfur clusters arise are indicated by vertical bars. In mitochondrial membranes, 
other paramagnetic species not related to complex I also contribute to the total EPR spectrum: 
S3, iron-sulfur cluster S3 from complex II; R, organic radical of unknown origin, occasionally 
detected in mitochondrial membranes (not a quinone radical); CuA from complex III. EPR 
parameters: Microwave frequency 9.47 GHz,
 modulation frequency
 100 kHz and modulation 
amplitude 6.4 Gauss. Sample: Mitochondrial membranes from the 49-kDa parental strain (~25 
mg protein per ml) were reduced with 2 mM NADH. EPR spectrum was taken from Figure 3.23 
and was recorded by Dr. Klaus Zwicker. 
A tentative assignment of the EPR signals to individual iron-sulfur clusters resolved in 
the structure of the peripheral domain of complex I from T. thermophilus was suggested 
(Sazanov and Hinchliffe, 2006). Since this is not a trivial task, the assignment of iron-
sulfur clusters N4 and N5 to the binding motifs within the structure and even to the right 
subunits is currently debated heavily (Waletko et al., 2005; Yakovlev et al., 2007; 
Nakamaru-Ogiso et al., 2008; Ohnishi and Nakamaru-Ogiso, 2008). 
However, it is well established that iron-sulfur clusters N1a and N2 are ligated in the 
24-kDa (Yano et al., 1995; Yano et al., 1996; Yano et al., 1997; Zu et al., 2002; Barker 
et al., 2007) and PSST subunit (Friedrich, 1998; Duarte et al., 2002; Flemming et al., 
2003), respectively, which will be important in the context of this study. 1.2  Complex I 13 
1.2.6  Iron-sulfur cluster N1a 
Iron-sulfur cluster N1a ligated by the 24-kDa subunit (see Figure 1.8) is of particular 
interest, since it was suggested to prevent excessive ROS formation at the FMN site (Zu 
et al., 2002; Hinchliffe and Sazanov, 2005; Sazanov and Hinchliffe, 2006; Galkin and 
Brandt, 2005; Kussmaul and Hirst, 2006; Esterhazy et al., 2008). Like in complex I 
from Neurospora crassa (Wang et al., 1991), iron-sulfur cluster N1a is not detectable 
by EPR in complex I from Y. lipolytica (Djafarzadeh et al., 2000). However, it is 
detectable in complex I from E. coli (Leif et al., 1995; Uhlmann and Friedrich, 2005; 
Yakovlev et al., 2007; Euro et al., 2008b) and Rhodothermus marinus (Fernandes et al., 
2002; Fernandes et al., 2006) and a subcomplex of complex I from Aquifex aeolicus 
(Kohlstadt et al., 2008). Interestingly, in these species iron-sulfur cluster N1a was 
reported to have a redox midpoint potential of around -240 mV (Uhlmann and 
Friedrich, 2005; Euro et al., 2008b; Fernandes et al., 2006; Kohlstadt et al., 2008), a 
value which is quite similar to the readily detectable so-called isopotential iron-sulfur 
clusters of bovine complex I (Ohnishi, 1998) and complex I from Y. lipolytica (Klaus 
Zwicker, personal communication). In contrast, a much more negative redox midpoint 
potential (-500 to -370 mV) was determined for N1a from Bos taurus (Ohnishi et al., 
1981; Ohnishi, 1998; Zu et al., 2002). However, it is currently heavily debated whether 
iron-sulfur cluster N1a is really detectable in the bovine enzyme (Reda et al., 2008; 
Ohnishi and Nakamaru-Ogiso, 2008).  
It seems reasonable to speculate that the iron-sulfur cluster N1a from Y. lipolytica is not 
EPR detectable due to its very low redox midpoint potential, which prevents the 
reduction of this cluster by commonly used reductants like NADH or dithionite. 
1.2.7  The mechanism of energy conversion 
The mechanism by which complex I couples the redox reaction to vectorial proton 
pumping is unknown. Several constrains must be considered: (i) two protons per 
electron are translocated across the bioenergetic membrane (Wikström, 1984; Galkin et 
al., 1999) (ii) the coupling between redox reaction and proton translocation is tight and 
reversible (Vinogradov, 1998) (iii) all known redox centers are located far up in the 
peripheral domain (Carroll et al., 2006b; Clason et al., 2007). Over the years, many 14   1  Introduction  
different mechanisms were proposed (Brandt, 1997; Dutton et al., 1998; Okun et al., 
1999b; Brandt, 1999; Vinogradov, 2001; Friedrich, 2001; Brandt et al., 2003; Ohnishi 
and Salerno, 2005; Hirst, 2005b; Flemming et al., 2005; Brandt, 2006; Euro et al., 
2008a; Zickermann et al., 2008; Zickermann et al., 2009), however most of them were 
disproven based on newer results. Since electron transfer from NADH to N2 is very fast 
(90 µs) (Verkhovskaya et al., 2008) and close to the 100 µs predicted from electron 
transfer theory (Moser et al., 2006a), it is unlikely to be coupled to proton translocation. 
Energy transduction involving the redox-Bohr group associated with iron-sulfur cluster 
N2 was ruled out, since a mutant which abolished pH dependency of the redox midpoint 
potential of N2 was shown to pump protons at the same stoichiometry as the unchanged 
enzyme (Zwicker et al., 2006). Also, a direct mechanism analogous to the Q-cycle 
mechanism in complex III can be excluded, since it would require redox centers in the 
membrane part of the enzyme; in addition, no evidence for reductant-induced oxidation 
of ubiquinol was found (Sherwood and Hirst, 2006). 
Taken together, the most probable mechanism involves long range conformational 
changes in the membrane domain coupled to and driven by quinone reduction in the 
peripheral domain (Brandt, 2006; Euro et al., 2008a; Zickermann et al., 2008; 
Zickermann et al., 2009). 
1.3  Yarrowia lipolytica as a model organism 
Complex I research long time suffered from the lack of an appropriate model organism. 
Since  Saccharomyces cerevisiae has no complex I (Büschges et al., 1994), mostly 
complex I from Bos taurus (Carroll et al., 2003; Hirst et al., 2003) and Neurospora 
crassa (Videira, 1998; Marques et al., 2005) were used for characterization of this 
enzyme. However, genetic manipulations are impossible or rather difficult in these 
model organisms (Schulte and Weiss, 1995). Therefore, complex I from different 
bacteria E. coli (Weidner et al., 1993), Paracoccus denitrificans (Yano and Yagi, 1999), 
Rhodobacter capsulatus (Dupuis et al., 1998), was studied. However, complex I from 
prokaryotes tends to be rather instable. In addition, the prokaryotic enzyme lacks about 
30 subunits found in eukaryotes, which add additional, potentially important functions 
to the mitochondrial enzyme. Therefore, Yarrowia lipolytica was introduced as a yeast 1.3  Yarrowia lipolytica as a model organism 15 
genetic model to study mitochondrial complex I (Kerscher et al., 2001c; Kerscher et al., 
2002). 
Yarrowia lipolytica is a strictly aerobic yeast from the class of Saccharomycetes (Barth 
and Gaillardin, 1996). It is non pathogenic and routinely found in different food media 
like sausage, cheese and yogurts. At the optimal temperature of 28 °C, Y. lipolytica 
grows on different carbon sources like glucose, ethanol, sodium acetate, alkanes and 
fatty acids to high biomass yields (up to 100 g/l wet weight). Typical laboratory strains 
are not viable above a temperature of 34 °C. Y. lipolytica has a simple 
haplontic/diplontic life cycle. Under nutrient limiting conditions, sporulation within an 
ascus is induced. Spores have a MAT A or a MAT B mating type. Mating type 
switching does not occur; therefore, stabile cultivation of haploid cultures is possible. 
The complete mitochondrial genome (Kerscher et al., 2001a) as well as the nuclear 
genome (Dujon et al., 2004) are sequenced. The latter is relatively small (18 Mbp) and 
contains only few introns. The high frequency of homologous recombination, the 
existence of genetic markers for positive and negative selection as well as the 
availability of replicative single-copy plasmids allows genetic manipulation of Y. 
lipolytica (Barth and Gaillardin, 1997). 
Since Y. lipolytica is strictly aerobic, it contains high amounts of mitochondria with 
constitutively expressed respiratory chain complexes. The respiratory chain of Y. 
lipolytica contains complexes I-IV, as found in mammals. In addition, it also possesses 
an alternative NADH dehydrogenase (NDH2) (de Vries and Marres, 1987; Kerscher et 
al., 1999; Kerscher, 2000), which transfers electrons from NADH to ubiquinone, and an 
alternative ubiquinol oxidase (Alt. Ox.), which transfers electrons from ubiquinol to 
molecular oxygen (Medentsev and Akimenko, 1999; Kerscher et al., 2002) (see Figure 
1.7). Both enzymes do not translocate protons across the inner mitochondrial membrane 
(Kerscher, 2000; Joseph-Horne et al., 2001; Henry and Nyns, 1975; de Troostembergh 
and Nyns, 1978; Vanlerberghe and McIntosh, 1997). 16   1  Introduction  
 
Figure 1.7: The respiratory chain of Y. lipolytica strains used for mutagenesis. White 
arrows indicate electron transfer, whereas red arrows indicate proton translocation. Complex V 
(ATP-synthase); NDH2 (alternative NADH dehydrogenase); NDH2i (internal alternative 
NADH dehydrogenase); Alt. Ox. (alternative ubiquinol oxidase); FeS (iron-sulfur cluster); Q 
(ubiquinone); QH2 (ubiquinol); b (heme b); bH (high potential heme b); bL (low potential heme 
b); a (heme a); a3 (heme a3); c (cytochrome c); c1 (cytochrome c1); CuA (copper center A); CuB 
(copper center B). Figure was prepared by Prof. Dr. Ulrich Brandt and modified for this work. 
Complex I deficiency is lethal in “wild type” isolates of Y. lipolytica (Kerscher et al., 
2001b). By fusing the mitochondrial targeting signal from the 75-kDa subunit to the 
alternative NADH dehydrogenase, the enzyme was directed to the matrix side of the 
inner mitochondrial membrane (Kerscher et al., 2001b). This internal version of 
alternative NADH dehydrogenase (NDH2i) feeds electrons from matrix NADH into the 
respiratory chain, so that deletions of complex I subunits are no longer lethal in Y. 
lipolytica. In order to study the effects of point mutations, deletion strains are 
transformed with normal and mutant versions of the respective subunit, encoded on 
replicative single-copy plasmids.  
The Y. lipolytica strains used in this study also harbor a hexahistidine affinity-tag at the 
C-terminus of the 30-kDa subunit. This tag allows fast isolation of highly pure complex 
I in high yields (several milligrams of complex I per litre of liquid culture) by affinity 
chromatography on a Ni
2+-NTA column followed by size exclusion chromatography 
(Kashani-Poor et al., 2001a). 1.4  Aim of this study 17 
1.4  Aim of this study 
1.4.1  Exploring the quinone and inhibitor binding pocket 
The X-ray structure of the peripheral domain of complex I from T. thermophilus 
(Sazanov and Hinchliffe, 2006) for the first time allowed structure based mutagenesis. 
The focus in this study lies on the proposed quinone binding pocket assembled by the 
PSST and the 49-kDa subunit next to iron-sulfur cluster N2 (see Figure 1.8). This part 
of the enzyme not only reduces quinone to quinol but most probably couples this 
reaction to conformational changes which result in proton translocation across the inner 
mitochondrial membrane (Brandt, 2006; Euro et al., 2008a; Zickermann et al., 2008; 
Zickermann et al., 2009) (see chapter 1.2.7). In addition, most complex I inhibitors act 
on the quinone binding pocket (see chapter 1.2.4).  
A large number of conservative and more drastic point mutations which alter this part of 
the enzyme should be generated, with the aim to delineate the location of the quinone 
binding site within the broad cavity and to identify residues critical for catalysis. In 
addition, effects of mutants on the inhibitory action of different types of complex I 
inhibitors (Degli Esposti, 1998), exemplified by DQA/type A (Okun et al., 1999a), 
rotenone/type B and C12E8/type C (Satoh et al., 1996; Okun et al., 2000), were evaluated 
to chart their respective binding sites. 18   1  Introduction  
 
Figure 1.8: Regions which underwent mutagenesis in this study are highlighted in the 
structure of the peripheral domain of complex I from T. thermophilus. Subunits are shown 
in schematic representation with transparent surface and are labeled according to the bovine 
nomenclature. Iron-sulfur clusters (in gray) as well as the FMN molecule (in pink) are shown as 
space-filled models. The oval indicates the approximate location of the quinone and inhibitor 
binding pocket. The position of iron-sulfur cluster N1a ligated by the 24-kDa subunit is 
indicated by a thin arrow. A thick arrow indicates the putative access path for the quinone 
substrate (Q). The figure was generated from the crystal structure of the hydrophilic domain of 
complex I from T. thermophilus (PDB ID: 2FUG) using the PyMOL program. 
1.4.2  Characterization of the HRGXE-motif 
At the N-terminus of the 49-kDa subunit there is a strongly conserved HRGXE-motif 
(see chapter 3.4.1). Based on sequence comparison it had been suggested that amino 
acid residues from this motif form part of the quinone binding site (Prieur et al., 2001; 
Fisher and Rich, 2000). However, as revealed by the partial structure of complex I from 
T. thermophilus (Sazanov and Hinchliffe, 2006), amino acid residues of this motif are 1.4  Aim of this study 19 
not part of the quinone and inhibitor binding pocket (see chapter 3.4.2); instead they are 
located close to iron-sulfur cluster N2 (see chapter 4.2). Altering the HRGXE-motif by 
point mutations and characterization of the mutants should shed light on the function of 
this conserved motif. 
1.4.3  Shifting of the midpoint potential of iron-sulfur cluster N1a 
As discussed in chapter 1.2.6, iron-sulfur cluster N1a is not detectable by EPR in 
complex I from Y. lipolytica, probably due to a very low redox midpoint potential.  
The redox midpoint potential of an iron-sulfur cluster seems to depend on hydrogen 
bonds and solvent accessibility to the iron-sulfur cluster and the presence of charged 
residues in its vicinity (Stephens et al., 1996). It was shown that by removing hydrogen 
bonds from amino acid side chains to one sulfur atom of the Rieske iron-sulfur cluster 
by site directed mutagenesis, the redox midpoint potential of the cluster was strongly 
decreased (Denke et al., 1998; Schröter et al., 1998). In addition, when a histidine 
located in the vicinity of iron-sulfur cluster N2 was exchanged to methionine, the redox 
midpoint potential of the iron-sulfur cluster was strongly decreased (Zwicker et al., 
2006).  
One additional project of this study was trying to increase the redox midpoint potential 
of iron-sulfur cluster N1a by introducing polar and positively charged amino acid 
residues next to iron-sulfur cluster N1a in the 24-kDa subunit from Y. lipolytica, and 
hence make iron-sulfur cluster N1a reducible and EPR detectable.  
1.4.4  Developing a new in vivo screen for complex I deficiency 
In order to allow for convenient testing of a large number of Y. lipolytica mutants for 
complex I deficiency, a new concept for an in vivo screen should be developed. An 
earlier screening assay (Garofano et al., 2006) was found to be not applicable to the 
already existing Y. lipolytica mutants and would require the development of a new 
mutagenesis strategy for all following mutagenesis projects. In addition, this assay 
inherently cannot screen for defects in proton pumping activity of complex I. However, 20   1  Introduction  
proton pumping measurements by alternative methods are very time consuming and 
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2  Materials and Methods 
2.1  Materials 
2.1.1  Chemicals 
Acrylamide, agarose, bisacrylamide, boric acid, Coomassie blue G 250, PEG 4000, 
Triton X-100 (Serva, Heidelberg, Germany);  
agar (Gibco BRL Life Technologies, Paisley, Scotland);  
Bacto
TM Peptone, Bacto
TM Tryptone, Bacto
TM Yeast Extract (Becton, Dickinson and 
Company, Le Pont de Claix, France);  
ammonium sulfate, antifoam A, BSA, ethidium bromide, dimethyl sulfoxide, 
dNADH, FCCP, formamide, glutaraldehyde, glycerol, hexaammineruthenium(III)-
chloride, Hepes, lithium acetate, Mes, NADH, Ponceau S, PMSF, Q1, Q2, sodium 
chloride, TEMED, Tricine, Tris (= Trizma
® Base) (Sigma-Aldrich Inc., St. Louis, 
USA);  
ammonium bicarbonate, DTT, glycine, potassium chloride, potassium hydroxide, 
potassium sodium tartrate, Mops, sodium hydroxide, sucrose, hydrochloric acid 
(Carl Roth GmbH Co, Kalsruhe, Germany);  
aminocaproic acid, digitonin, glucose, imidazole, copper(II) sulfate pentahydrate, 
monosodium phosphate monohydrate, silver nitrate, sodium formate (Fluka AG, 
Buchs, Swiss);  
ethanol, isoamyl alcohol, methanol (J.T. Baker, Deventer, Netherlands);  
boric acid, chloroform, isopropanol, KCN, magnesium chloride, magnesium 
sulfate, 2-mercaptoethanol, sodium bromide, sodium deoxycholate, sodium 
dithionite, sodium iodide, sodium thiosulfate pentahydrate (Merck, Darmstadt, 
Germany);  
ATP (Pharmacia, USA);  
n-dodecyl-ß-D-maltoside (Glycon, Luckenwalde,
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EDTA, sodium acetate, sodium carbonate, phenol, SDS (AppliChem GmbH, 
Darmstadt, Germany);  
OG (BIOMOL, Hamburg, Germany):  
formaldehyde (Riedel-de Haën Laborchemikalien GmbH, Seelze, Germany); sucrose 
(Südzucker AG, Mannheim, Germany);  
acetic acid (KMF Laborchemie Handels GmbH, Lohmar, Germany); ACMA 
(Molecular Probes Europe, Leiden, Netherlands);  
Asolectin (Avanti Polar Lipids, Alabaster, USA);  
Chelating SepharoseTM Fast Flow (Amersham Biosciences AB, Uppsala, Sweden); 
Bio-Beads
® (Bio-Rad Laboratories GmbH, München, Germany);  
glass beads (diameter 0.25-0.5 mm) (Bernd Euler Biotechnologie-Mikrobiologie 
Geräte-Verbrauchsmaterialien, Frankfurt am Main, Germany). 
2.1.2  Inhibitors 
Ampicillin, antimycin A,  C12E8, EIPA,  rotenone (Sigma-Aldrich Inc., St. Louis, 
USA); 
DQA (Aventis CropScience, Biochemical Research, Frankfurt am Main, Germany); 
hygromycin B (PAA Laboratories Lucerna-chem, Luzern, Swiss); 
sodium azide (Merck, Darmstadt, Germany). 
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2.1.3  Enzymes  
Table 2.1: Enzymes used 
Enzyme Enzyme  buffer  Source 
T4 Polynucleotide Kinase (10.000U/ml)  10 x T4 PNK  New England BioLabs 
T4 DNA Ligase (1.000U/ml)  5 x T4 DNA Ligase   Invitrogen 
Phusion DNA Polymerase (2.000U/ml)  5 x Phusion HF  New England BioLabs 
ClaI Endonuclease (5.000 U/ml)  10 x NEB4  New England BioLabs 
DpnI Endonuclease (20.000 U/ml)  10 x NEB4  New England BioLabs 
EcoRI Endonuclease (20.000 U/ml)  10 x EcoRI  New England BioLabs 
NheI Endonuclease (10.000 U/ml)  10 x NEB2  New England BioLabs 
2.1.4  Plasmids 
Table 2.2: Used plasmids 
Name Size  Gene  Source 
49k/pUB26 3  10.7 kb  NheI-fragment of NUCM in pUB26  Ljuban Grgic LG2/99 
nukm pUB4  10.3 kb  EcoRI-fragment of NUKM in pUB4  Gudrun Beyer 15.03.06 
24k-WT  10.8 kb  ClaI/NheI-fragment of NUHM in 
pUB26 
Gudrun Beyer Klon 2.2 v. 
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Figure 2.1: Map of the pUB4 (and pUB26) shuttle vector: The 
location of the resistance genes AmpR and HygR, the autonomous 
replication sequence ARS68/CEN, the upstream activating sequence 
4xUAS1and the restriction sites of some endonucleases are indicated. 
The pUB4 vector was derived from the pINA443 vector (Barth and 
Gaillardin, 1996) as described in (Kerscher et al., 2001b). The pUB26 
vector is almost identical, but it does not contain the NheI restriction 
site in the autonomous replication sequence ARS68/CEN. Figure was 
prepared by Dr. Stefan Kerscher and slightly modified for this work. 
2.1.5  Strains 
Table 2.3: Escherichia coli strains used 
Name Genotype  Source 
XL-10 Gold  Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB 
lacIqZ∆M15 Tn10 (Tetr) Tn5 (Kanr) Amy] 
Stratagene, 
(Heidelberg, 
Germany) 
 
 2.1  Materials 25 
Table 2.4: Yarrowia lipolytica strains used 
Name Genotype  Source 
PIPO  30Htg Pop in Pop out, lys
-, leu
-, ura
-, MatA,   (Kerscher et al., 
2002) 
GB5.2 ndh2::ura3,  leu
-, ac
+, lys
-, MatB  Gudrun Beyer 
Δnucm  nucm::ura3, leu
-, lys
-, Htg2, ndh2i, spore L1 from 
23.02.01 
Gudrun Beyer 
Δnukm  NUKM::leu2, Htg2, ndh2i, Sporen ura
-, lys
-, kL6  Gudrun Beyer 
Δnuhm  nuhm::ura3 in GB10, leu
-, lys
-, MatB, Htg2, ndh2i, 
from 17.12.02 
Gudrun Beyer 
nucm parental  Δnucm + 49k/pUB26 3  this work 
nucm mutants   Δnucm + 49k/pUB26 3 carrying a point mutation  Gudrun Beyer, Uta 
Fendel, this work 
nukm parental   Δnukm + nukm pUB4  Gudrun Beyer 
nukm mutants  Δnukm + nukm pUB4 carrying a point mutation  Gudrun Beyer, Uta 
Fendel 
nuhm parental  Δnuhm + 24k-WT  this work 
nuhm mutants  Δnuhm + 24k-WT carrying a point mutation  this work 
2.1.6  Instruments 
Centrifuges: 
Biofuge pico (Heraeus, Osterode, Germany)  
Biofuge A (Heraeus, Osterode, Germany) 
Biofuge primo R (Heraeus, Osterode, Germany) 
Omnifuge 2 RS (Heraeus, Osterode, Germany)  
Cryofuge 8500i (Heraeus, Osterode, Germany)  
Refrigerated centrifuge J2-21 (Beckman Instruments GmbH, München, Germany)  
Ultracentrifuge L7-65 and L8-70M (Beckman Instruments GmbH, 
München, Germany)  
Rotors:  
Biofuge primo R: 7588, 7593 (Heraeus, Osterode, Germany) 
Omnifuge 2 RS: 2250 (Heraeus, Osterode, Germany) 
Cryofuge 8500i: F2 (Hereaus, Osterode, Germany) 26   2  Materials and Methods  
Refrigerated centrifuge: JA-10, JA-20 (Beckman Instruments GmbH, München, 
Germany)  
Ultracentrifuge: Ti 45, Ti 50.2 (Beckman Instruments GmbH, München, Germany) 
TFT 50.38 (Sorvall, Hanau, Germany) 
Spectrophotometers:  
UV 300 (Shimadzu, Düsseldorf, Germany)  
SpectraMax PLUS
384
(Molecular Devices GmbH, Ismaning, Germany) 
SpectraMax M2
e (Molecular Devices GmbH, Ismaning, Germany) 
MulitSpec-1501 (Shimadzu, Düsseldorf, Germany) 
Ultrospec II (LKB Biochrom, Cambridge, UK) 
Spectrofluorometers:  
Hoefer
® DyNA Quant
® 200 (Pharmacia Biotech, San Francisco, USA)  
Shimadzu RF-5001 (Shimadzu, Düsseldorf, Germany) 
Thermocyclers: 
GeneAmp
® 
PCR System 2400 (Perkin Elmer, Weiterstadt, Germany)  
Cyclone
® 
gradient, Peqlab (Biotechnologie GmbH, Erlangen, Germany)  
UV-Transluminators: 
BIO View (biostep GmbH, Jahnsdorf, Germany) 
UV-Transluminator (Vilber Lourmat Deutschland GmbH, Eberhardzell, 
Germany) 
Chromatography systems:  
ÄKTA FPLC chromatographic system (Amersham Biosciences, Piscataway, USA) 
BioLogic LP low-pressure chromatographic system (Bio-Rad Laboratories GmbH, 
München, Germany) 
Cell Disrupters: 
Fast Prep
® FP 120 (Qbiogene Inc, Illkirch, France) 
Cell-Desintegrator-C, (Bernd Euler Biotechnologie-Mikrobiologie Geräte-Verbrauchs-
materialien, Frankfurt am Main, Germany)  
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Other instruments:  
Electroporator: E. coli Pulser (Bio-Rad, Hercules, USA)  
DNA Sequencer: ABI PRISM
TM 
310 Genetic Analyzer (Perkin-Elmer, Weiterstadt, 
Germany)  
EPR-Spectrometer: ESP 300 E (Bruker, Rheinstetten, Germany) equipped with a 
continuous flow cryostat ESR 900 (Oxford Instruments, Oxon, UK) 
EPR-tubes: Quartz glass Nr.: 707-SQ-250M (length: 250 mm, diameter: 4 mm) 
(Spintec, Remshalden, Germany) 
10 l Fermenter: Biostat E (Braun, Melsungen, Germany) 
Biological safety cabinet: Microflow (Nunc GmbH, Wiesbaden, Germany) 
Microscope (Leitz, Wetzlar, Germany) 
Counting chamber: Optik Labor 0.1 mm deep, 0.0025 mm
2 (Neubauer, 
Friedrichshofen, Germany) 
Molecular Imager: ChemiDoc XRS (Bio-Rad Laboratories GmbH, München, 
Germany) 
Digital camera: COOLPIX 990 (Nikon Corporate, Japan) 
Stereoscopic glasses: NuVision 60GX (MacNaughton, Inc., Beaverton, USA) 
Pure water system: TKA-Pacific and TKA-GenePure (TKA Wasseraufbereitungs-
systeme GmbH, Niederelbert, Germany) 
2.1.7  Software 
ABI Prism 310 Collection (Applied Biosystems, Perkin-Elmer, Wellesley, USA) 
Sequencing Analysis (Applied Biosystems, Perkin-Elmer, Wellesley, USA) 
AutoAssembler 2.0 (Perkin-Elmer, Wellesley, USA) 
CorelDRAW
® Graphics Suite - Version 12.0 (Corel Corporation) 
Enzfitter Version 2.0.16.0, (Biosoft, Cambridge, UK) 
Microsoft Office 2003 Package 
PSI-Plot Version 5.02a (Poly Software International, Salt Lake City, USA) 
PyMOL
TM 0.99 (DeLano Scientific LLC, Palo Alto, USA) 
SOFTmax PRO (Molecular Devices GmbH, Ismaning, Germany) 
Unicorn 5.01 (Amersham Biosciences, Piscataway, USA) 
Winepr
® (Bruker BioSpin MRI GmbH, Ettlingen, Germany) 
Simfonia
® (Bruker BioSpin MRI GmbH, Ettlingen, Germany) 28   2  Materials and Methods  
2.2  Methods 
2.2.1  Methods of Microbiology 
2.2.1.1   Cultivation of Escherichia coli 
E. coli was cultivated in LB medium (0.5 % Bacto
TM Yeast Extract, 1 % NaCl, 1 % 
Bacto
TM Tryptone, pH 7.5) in the presence of Ampicillin (50 µg/ml) at 37 °C for 12-16 
h. Usually, 3 ml of medium were inoculated with a single colony picked from plates 
after transformation of electro-competent E. coli cells (see 2.2.1.3). 
2.2.1.2   Preparation of electro-competent Escherichia coli cells 
Electro-competent E. coli cells were prepared from the XL-10 Gold strain according to 
(Seidman et al., 1997). 
2.2.1.3   Transformation of electro-competent Escherichia coli cells 
Frozen electro-competent E. coli cells were transformed by electroporation as described 
in (Seidman et al., 1997). 
2.2.1.4   Cultivation of Yarrowia lipolytica 
Y. lipolytica cells were streaked out on YPD-agar plates (1 % Bacto
TM Yeast Extract, 2 
% Bacto
TM Peptone, 2 % glucose, 1.5 % agar) and incubated at 28 °C. For liquid 
culture, YPD medium (1 % Bacto
TM Yeast Extract, 2 % Bacto
TM Peptone, 2 % glucose) 
was inoculated with a single colony of Y. lipolytica. Cells were grown at 27 °C under 
continuous shaking. 
Plates and liquid medium contained hygromycin B (50-100 mg/l) as a selection marker 
when Y. lipolytica strains harboring the HygB
R marker gene were cultivated. 
2.2.1.5   Large scale cultivation of Yarrowia lipolytica 
In order to harvest 300-500 g of Y. lipolytica cells (wet weight), strains were grown in a 
10 l fermenter (Biostat E, Braun, Melsungen, Germany) with airflow of 30 l/min and 
vigorous stirring (500 rpm) in YPD medium (1 % Bacto
TM Yeast Extract, 2 % Bacto
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Peptone, 2 % glucose) for ~16 h. Temperature was kept at 28 °C and pH at 6.5. Y. 
lipolytica cells were harvested by centrifugation (10 min, 5000 x g, 4 °C) and 
immediately used for preparation of mitochondrial membranes (see 2.2.3.2) or shock 
frozen in liquid nitrogen and stored at -80°C. 
2.2.1.6   Transformation of Yarrowia lipolytica 
Y. lipolytica cells were transformed according to (Chen et al., 1997). 
2.2.1.7   In vivo screen for complex I deficiency 
To screen Y. lipolytica strains for complex I deficiency, mutant strains were grown on 
fresh YPD-agar plates (1 % Bacto
TM Yeast Extract, 2 % Bacto
TM Peptone, 2 % glucose, 
1.5 % agar) in the presence of 0.2-0.4 µM antimycin A and/or 0.4-0.6 mM sodium 
azide. Antimycin A was added to 20 ml warm and liquid YPD-agar plate medium. ~0.5 
ml sodium-azide were evenly distributed on chilled plates using a Drigalski glass 
spatula. Cell numbers in fresh liquid cultures of Y. lipolytica strains (see 2.2.1.4) were 
determined with a counting chamber (for best results, liquid cultures should have optical 
densities of 2-5) and diluted with YPD medium (1 % Bacto
TM Yeast Extract, 2 % 
Bacto
TM Peptone, 2 % glucose) to around 3000, 300, 30 or 3 cells per 5-7 µl. From 
these dilutions droplets of 5-7 µl volume were applied on plates with varying inhibitor 
concentrations. Plates were then incubated at 28 °C for several days. 
2.2.1.8   Storage of Yarrowia lipolytica strains 
For storage, Y. lipolytica strains were freshly grown in YPD medium (1 % Bacto
TM 
Yeast Extract, 2 % Bacto
TM Peptone, 2 % glucose). Medium contained hygromycin B 
(50-100 mg/l) as a selection marker when Y. lipolytica strains harboring the HygB
R 
marker gene were cultivated. Cells were sedimented by brief centrifugation and 0.6 ml 
of cells were added to 0.4 ml glycerol. After vortexing, strains were stored at -80 °C. 30   2  Materials and Methods  
2.2.2  Methods of Molecular Biology 
2.2.2.1   Purification of plasmid DNA from Escherichia coli 
Plasmid DNA purification was performed using the column-based-kit „NucleoSpin
® 
Plasmid“ (Macharey & Nagel, Düren, Germany) according to the manufacturer’s 
protocol. 
2.2.2.2   Total DNA isolation from Yarrowia lipolytica  
DNA was isolated according to a standard protocol (Hoffman, 1997). For plasmid DNA 
recovery, 1 µl of total DNA was used to transform electro-competent E. coli cells (see 
2.2.1.3). From transformed cells, plasmid DNA was isolated as described under 2.2.2.1. 
2.2.2.3   Determination of DNA concentration 
DNA concentration was measured using the „Hoechst 33258“ dye and standard DNA 
concentrations. Fluorescence was recorded on a DyNA Quant™ 200 fluorometer from 
Hoefer
® according to the low range (A) protocol. 
2.2.2.4   Restriction of DNA 
1µl of DNA solution was incubated with 5 units of endonuclease and the corresponding 
buffer for 2 h at 37 °C in a final volume of 10 µl. 
2.2.2.5   Agarose gel electrophoresis of DNA 
DNA-fragments were separated on 1 % agarose gels according to (Sambrook et al., 
1989). Agarose gels were prepared with TAE buffer (0.4 M tris/acetate, 10 mM EDTA, 
pH 8.3) and contained 0.5 µg/ml ethidium bromide. 
The GeneRuler™ 1kb DNA Ladder (MBI Fermentas) was used as a DNA size marker. 
Electrophoresis was performed at 120 V and 90 mA. 
2.2.2.6   Primer phosphorylation for PCR 
5’ Phosphorylation of primers was performed according to (Tabor, 1987). The reaction 
mixture contained a primer (0.1 nmoles), ATP (0.5 mM), BSA (0.2 mg/ml) the T4 PNK 2.2  Methods  31 
buffer and T4 polynucleotide kinase (10 units) in a final volume of 20 µl. This mixture 
was incubated at 37 °C for 1 h. The reaction was stopped by incubation at 65 °C for 20 
min. Phosphorylated primers were stored at -20 °C. 
2.2.2.7   PCR mutagenesis 
Desired point mutations were generated using appropriate primer pairs. The forward 
primer had a mismatch codon at the 3’ end leading to the point mutation. The reverse 
primer ended just after the mismatch codon and contained no mismatch. Primers were 
~20 bases long and were chosen to end with 1-2 guanine and/or cytosine bases (see 
chapter 8.1). Primers were phosphorylated prior to PCR (see 2.2.2.6). The PCR reaction 
mixture contained plasmid DNA harboring the target gene as template (~10 ng), both 
primers (0.5 µM each), dNTP (120 µM), Phusion HF buffer and Phusion DNA 
polymerase (2 units) in a final volume of 50 µl. The reaction was started by adding the 
Phusion DNA polymerase (manual hot start). PCR conditions were set as follows: 
  Initial denaturation: 30 sec at 98 °C 
  Denaturation: 10 sec at 98 °C 
  Annealing: 20 sec at 52.4 °C, 55.8 °C, 60.4 °C or 64.3 °C 
  Extension: 3 min at 72 °C 
  25 cycles 
  Final extension: 8 min at 72 °C 
PCR products were stored at -20 °C. 
2.2.2.8   DNA precipitation with ethanol 
Using this method a DNA solution was concentrated and purified. Added volumes refer 
to the initial volume of the DNA solution. First, 3 M NaAc (0.1 x volume), 20 µg/µl 
Dextran-Blue (1 µl) and cold (-20 °C) ethanol (3 x volume) were added. A 30 min 
incubation at -20 °C was followed by a centrifugation at 11000 x g for 15 min. The blue 
DNA sediment was washed with cold (-20 °C) 70 % ethanol and dried at 37°C. DNA 
was then solubilized in TE buffer (10 mM Tris/HCl, 1 mM EDTA, pH 8) and stored at 
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2.2.2.9   Extraction of DNA from agarose gels 
DNA bands of interest were cut out from agarose gels under weak UV light. For 
agarose removal, the „NucleoSpin
® Extract II“ (Macharey & Nagel, Düren, Germany) 
was used. 
2.2.2.10   Ligation 
Ligation of PCR products was performed in the presence of 1 unit T4 DNA ligase, 1.2 
µg BSA and T4 DNA ligase buffer (final volume ~7 µl) at 14 °C over night. 
2.2.2.11   DNA sequencing 
The complete open reading frames of the mutated subunit genes were sequenced to 
confirm the point mutations and exclude other changes. Subunit specific sequencing 
primers are listed in chapter 8.1. 
DNA was sequenced using the dye-terminator method following the protocol of 
Applied Biosystems. DNA was labeled with dideoxy-nucleotide-coupled fluorophores 
by PCR. The PCR mixture contained 250-500 ng DNA, 640 nM primer and the 
„Termination Mix“ (ABI, Perkin-Elmer, Weiterstadt, Germany) in a final volume of 10 
µl. PCR conditions were set as follows: 
  Initial denaturation: 1 min at 96 °C 
  Denaturation: 10 sec at 96 °C 
  Annealing: 5 sec at 50 °C 
  Elongation: 2 min at 60 °C 
  30 cycles 
PCR products were precipitated with sodium acetate and ethanol and solubilized in 20 
µl formamide. DNA was sequenced on a „ABI prism Genetic Analyzer 310“ (Applied 
Biosystems GmbH, Weiterstadt, Germany). DNA sequences were analyzed using the 
AutoAssembler 2.0 (ABI, Perkin-Elmer, Weiterstadt, Germany) software.  2.2  Methods  33 
2.2.3  Methods of Protein Chemistry 
2.2.3.1   Small scale preparation of mitochondrial membranes from Y.lipolytica 
Mitochondrial membranes were prepared from freshly harvested Y. lipolytica cells or 
cells that had been shock frozen in liquid nitrogen and stored at -80°C. Cells were 
harvested by centrifugation (10 min, 5300 x g, 4 °C) and washed with 50 ml H2O (10 
min, 3300 x g, 4 °C). Pelleted cells (3-8 g) were resuspended in 10 ml mito buffer (600 
mM sucrose, 20 mM Na-Mops, 1 mM EDTA, pH 7.2) in the presence of 2 mM PMSF. 
Cells were broken up in a Falcon tube by vortexing (13 x 1 min with 1 min cooling 
intervals on ice) in the presence of 10 g glass beads ( = 0.45 mm). Unbroken cells, 
nuclei and glass beads were pelleted by centrifugation (45 min, 3300 x g, 4 °C). A high-
speed centrifugation (120 min, 40000 x g, 4 °C) pelleted mitochondria and mito-
chondrial membranes. PMSF (final concentration 2 mM) was added to the homogenized 
pellet before mitochondrial membranes were shock frozen in liquid nitrogen and stored 
at -80°C. 
2.2.3.2   Large scale preparation of mitochondrial membranes from Y. lipolytica 
Fresh or shock frozen Y. lipolytica cells (200-250 g wet weight) were resuspended in 
500 ml mito buffer (600 mM sucrose, 20 mM Na-Mops, 1 mM EDTA, pH 7.2) and 2 
mM PMSF were added. Cells were broken up by glass beads ( = 0.25-0.5 mm) in a 
cooled Cell-Desintegrator-C, (Bernd Euler Biotechnologie, Frankfurt am Main, 
Germany) at 1000 rpm for 2 h. After a low speed centrifugation (30 min, 4000 x g, 4 
°C) to remove cell debris, mitochondrial membranes were pelleted by ultra-
centrifugation (60 min, 140000 x g, 4 °C). The pellet was resuspended in mito buffer 
(600 mM sucrose, 20 mM Na-Mops, 1 mM EDTA, pH 7.2) without EDTA, then 
homogenized and ultracentrifuged (60 min, 140000 x g, 4 °C) once more. Pelleted 
mitochondrial membranes were homogenized, supplemented with 1.5 mM PMSF, 20 
mM Na-Borate and 50 mM NaCl, shock frozen in liquid nitrogen and stored at -80°C. 
2.2.3.3   Determination of protein concentration 
Protein concentrations were determined using the DC Protein Assay-Kit (Bio-Rad, 
Hercules, USA) according to the manufacturer’s Microplate Assay protocol. 34   2  Materials and Methods  
2.2.3.4   NADH:HAR oxidoreductase activity measurement 
NADH:HAR oxidoreductase activity was measured as NADH oxidation at E340-400 nm (ε 
= 6.22 mM
-1cm
-1) in the presence of the electron acceptor HAR on a SpectraMax 
PLUS
384 spectrophotometer. Measurements were carried out in the presence of 200 µM 
NADH, 2 mM HAR, 20 mM Hepes, 250 mM sucrose, 0.2 mM EDTA and 2 mM NaN3 
at pH 8.0 and 30 °C. The reaction was started by the addition of mitochondrial 
membranes (final concentration 25 µg protein/ml). 
The NADH:HAR oxidoreductase activity is detergent- and inhibitor-insensitive and 
specific for complex I (Sled and Vinogradov, 1993). The activity depends on the 
presence of FMN in complex I (Gavrikova et al., 1995). 
2.2.3.5   dNADH:DBQ oxidoreductase activity measurement 
dNADH:DBQ oxidoreductase activity was determined as DQA sensitive dNADH 
oxidation at E340-400 nm (ε = 6.22 mM
-1cm
-1) in the presence of the ubiquinone analogue 
DBQ on a SpectraMax PLUS
384 spectrophotometer. Measurements were carried out in 
the presence of 100 µM dNADH, 20 mM Na-Mops, 50 mM NaCl, 2 mM KCN and 50 
µg protein/ml of mitochondrial membranes at pH 7.4 and 30 °C. The reaction was 
started by the addition of 70 µM DBQ. To determine DQA insensitive activity, 
measurements were carried out in the presence of 27 µM DQA (5 mM stock solution 
dissolved in DMSO). To address complex I specific activity, dNADH was used 
(Matsushita et al., 1987) instead of NADH, which can also be oxidized by the 
alternative NADH:ubiquinone oxidoreductase (NDH2) present in mitochondrial 
membranes from Y. lipolytica. 
2.2.3.6   Measurement of apparent Km for DBQ, Q1 and Q2 
Measurements were preformed as described under 2.2.3.5 with different concentrations 
of DBQ, Q1 or Q2, respectively. Data were fitted using the Enzfitter software package to 
the Michaelis-Menten equation. However, the value for substrate concentration [S] was 
corrected as described earlier (Eschemann et al., 2005): 
   c S S
added    2.2  Methods  35 
([S]  = substrate concentration available for binding and catalysis, [S]
added = added 
substrate concentration, c = offset value) 
2.2.3.7   Measurement of pH dependence of dNADH:DBQ oxidoreductase activity  
Determination of pH dependence of dNADH:DBQ oxidoreductase activity was 
performed as described under 2.2.3.5 with one modification; measurements were carried 
out in the presence of 100 µM dNADH, 30 mM Mes, 30 mM Mops, 30 mM sodium 
acetate, 30 mM Tris, 30 mM glycine, 50 mM NaCl, 2 mM KCN and 50 µg protein/ml 
of mitochondrial membranes at pH 5-10 and 30 °C. pH values were adjusted using 
NaOH or HCl.  
Data were fitted to a previously described equation (Brandt and Okun, 1997): 
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(v = catalytic rate under substrate saturated conditions, [H
+] = proton concentration, KA 
= dissociation constant of protonable group A, KB = dissociation constant of protonable 
group B, C = catalytic rate if group A was deprotonated and group B was protonated) 
2.2.3.8   Reactivation of dNADH:DBQ oxidoreductase activity 
In order to restore complex I activity in mitochondrial membranes from mutant strains, 
various salts and small molecules were tested; Sodium chloride (20-400 mM), sodium 
bromide (0-500 mM), sodium iodide (0-400 mM), sodium azide (0-500 mM), sodium 
formate 0-500 mM or sodium acetate (0-400 mM) were added to the assay buffer (pH 
was adjusted to 7.4) before NADH and mitochondrial membranes were added. 
Measurements were performed as described in 2.2.3.5. 
2.2.3.9   dNADH:Q1 oxidoreductase activity measurement 
The dNADH:Q1 oxidoreductase activity in mitochondrial membranes from Y . lipolytica 
was measured as described under 2.2.3.5 with the exception that 62 µM Q1 was used 
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2.2.3.10   dNADH oxidation measurement 
dNADH oxidation was measured on a SpectraMax PLUS
384 spectrophotometer at E340-
400 nm (ε = 6.22 mM
-1cm
-1). Measurements were carried out in the presence of 100 µM 
dNADH, 20 mM Na-Mops, 50 mM NaCl and 100 µg protein/ml of mitochondrial 
membranes at pH 7.4 and 30 °C. The reaction was started by the addition of 
mitochondrial membranes. To determine DQA insensitive activity, measurements were 
carried out in the presence of 27 µM DQA. 
2.2.3.11   Measurement of I50 
The I50 value was defined as the inhibitor concentration which decreased the inhibitor 
sensitive dNADH:Q oxidoreductase activity by 50 %. Measurements were carried out 
as described under 2.2.3.5 in the presence of different concentrations of complex I 
inhibitors. DQA, rotenone and EIPA were provided in DMSO. C12E8 was provided in 
20 mM Na-Mops, 50 mM NaCl and 2 mM KCN. In contrast to other inhibitors C12E8 
was pre-incubated with mitochondrial membranes for at least 30-60 s at 30 °C before 
measurements were started. 
2.2.3.12  Solubilization of membrane proteins for blue-native and clear-native             
PAGE 
Sample preparation followed the principles described in (Schägger, 2003). First, 
mitochondrial membranes (2.8 mg total protein) from Y. lipolytica were resuspended in 
190 µl buffer containing 20 mM Mops and 1 mM EDTA, pH 7.2 and centrifuged (20 
min, 1800 x g, 4 °C). The pellet was resuspended in 280 µl solubilisation buffer (50 
mM NaCl, 50 mM imidazole, 2 mM aminocaproic acid, 1 mM EDTA, 0.2 mM PMSF, 
pH 7) and 1 g n-dodecyl-ß-D-maltoside per 1 g protein or 3 g digitonin per 1 g protein 
was added. After centrifugation (15 min, 1800 x g, 4 °C) membranes and not solubilized 
proteins were pelleted.  
  For blue-native PAGE, 2 µl Coomassie blue G 250 solution (5 % in 0.5 M 
aminocaproic acid) were added to the supernatant. 
  For clear-native and high-resolution-clear-native PAGE, Ponceau S (final con-
centration 0.01 % w/v) and glycerol (final concentration 5 % v/v) were added to 
the supernatant. 2.2  Methods  37 
Samples were loaded on the corresponding native gels. 
2.2.3.13   Blue-native PAGE 
Blue-native PAGE was carried out according to the protocol of (Schägger, 2003). 
However, the acrylamide concentration in the sample gel was 3 % or 4 % and in the 
gradient separation gel 3 % or 4 % to13 %. 
2.2.3.14   Complex I in-gel activity assay 
Complex I in-gel activity assay was performed according to (Zerbetto et al., 1997) with 
minor modifications described in (Wittig et al., 2007). 
2.2.3.15   2D Gels (Tricine-SDS-PAGE second dimension after Blue-native PAGE) 
Second dimension SDS-PAGE (10 %) was performed according to the standard 
protocol described in (Schägger, 2003). 
2.2.3.16   Coomassie staining of protein gels 
Coomassie staining was carried out as described in (Schägger, 2003). 
2.2.3.17   Silver staining of protein gels 
Prior to silver staining, coomassie stained gels had to be completely destained by an 
overnight incubation in a 50 % methanol, 0.1 M ammonium bicarbonate solution and 
washed 3 times with H2O. Silver staining of 0.7 mm gels was performed as described in 
(Rais et al., 2004). 
2.2.3.18   Complex I purification 
Complex I was purified from mitochondrial membranes (see 2.2.3.2) as described 
previously (Kashani-Poor et al., 2001a) with two minor modifications: 
  after ultracentrifugation the supernatant was adjusted to 55 mM imidazole and 
pH 7.4.  
  the imidazole concentration for equilibration and washing of the Ni-NTA fast 
flow Sepharose column was reduced from 65 mM to 55 mM. 38   2  Materials and Methods  
2.2.3.19   Complex I proteoliposomes 
Reconstitution of purified complex I into proteoliposomes was performed as described 
earlier (Dröse et al., 2009). 
2.2.3.20   Measurement of proton gradient by ACMA quench 
Measurements were carried out as described earlier (Dröse et al., 2005). 
2.2.3.21   EPR spectroscopy 
EPR spectroscopy of mitochondrial membranes as well as of purified complex I was 
performed as described in (Tocilescu et al., 2007). Standard EPR parameters were the 
following: Microwave frequency 9.47 GHz, modulation frequency 100 kHz and 
modulation amplitude 6.4 Gauss. All other parameters are given in figure legends. EPR 
spectra were recorded and analyzed by Dr. Klaus Zwicker. 
2.2.4  Methods of Bioinformatics 
2.2.4.1   Multiple sequence alignment 
For multiple sequence alignment the program ClustalW was used as provided at 
http://www.ebi.ac.uk/Tools/clustalw2/index.html. 
For the alignment of the 49-kDa subunit the NCBI sequences of Y. lipolytica 
(ACCESSION CAG78336), Neurospora crassa (ACCESSION CAA38368), Bos taurus 
(ACCESSION P17694), Homo sapiens (ACCESSION AAC27453), Paracoccus 
denitrificans  (ACCESSION P29916), Rhodobacter capsulatus (ACCESSION 
AAC24988),  Thermus thermophilus (ACCESSION AAA97941) and E. coli 
(ACCESSION CAA48363) were used. 
For the alignment of the PSST subunit the NCBI sequences of Y. lipolytica 
(ACCESSION CAB65525), N. crassa (ACCESSION CAF06152), B. taurus 
(ACCESSION CAA46154), H. sapiens (ACCESSION AAI11518), P. denitrificans 
(ACCESSION P29918), R. capsulatus (ACCESSION AAC24986), T. thermophilus 
(ACCESSION AAA97939) and E. coli (ACCESSION BAA16121) were used. 2.2  Methods  39 
For the alignment of the 30-kDa subunit the NCBI sequences of Y. lipolytica 
(ACCESSION XP_504891), N. crassa (ACCESSION XP_957689), H. sapiens 
(ACCESSION NP_004542), B. taurus (ACCESSION NP_777244), R. capsulatus 
(ACCESSION AAC24987), T. thermophilus (ACCESSION AAA97940), P. 
denitrificans (ACCESSION AAA97940) and E. coli (ACCESSION BAA16115) were 
used. 
For the alignment of the 24-kDa subunit the NCBI sequences of Y. lipolytica 
(ACCESSION CAG80440), N. crassa (ACCESSION CAA54990), B. taurus 
(ACCESSION P04394), H. sapiens (ACCESSION CAG33209), P. denitrificans 
(ACCESSION AAA25588), Rhodothermus marinus (ACCESSION AAY42999), T. 
thermophilus (ACCESSION AAA979421) and E. coli (ACCESSION BAA16114) were 
used. 
2.2.4.2   Structure figure preparation 
For the interpretation of the mutagenesis results, structure figures were prepared based 
on the 3.3 Å resolution x-ray structure of the hydrophilic domain of respiratory complex 
I from T. thermophilus (PDB ID: 2FUG). Figures were generated using the PyMOL 
program version 0.99 provided at http://pymol.sourceforge.net/. Where the T. 
thermophilus sequence differed from that of Y. lipolytica, the mutagenesis wizard of the 
PyMOL package was used to match the Y. lipolytica sequence. Side chain 
conformations were chosen which resemble as closely as possible that of the T. 
thermophilus side chains and were sterically feasible. 
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3  Results 
3.1  Mutagenesis of the proposed ubiquinone and inhibitor 
binding cavity 
Taking advantage of the crystal structure of the hydrophilic part of complex I from T. 
thermophilus (Sazanov and Hinchliffe, 2006), the proposed quinone and inhibitor 
binding cavity was studied by structure based site-directed mutagenesis. In order to 
completely cover the inner surface of this cavity, 34 point mutations at 15 positions 
were introduced into the PSST and the 49-kDa subunits of complex I from Y. lipolytica. 
If possible, at least one rather conservative and one more drastic mutation were 
introduced at each position. For a comprehensive view, the obtained results will be 
discussed together with data from previously generated and described mutants. In total, 
94 point mutations on 39 positions within the proposed quinone and inhibitor binding 
cavity will be described here. 
3.1.1  Assembly of mutant complex I 
From all mutants mitochondrial membranes were isolated and complex I content was 
assessed as the NADH:HAR oxidoreductase activity. As shown in Table 3.1 and Table 
3.2, only a few mutations (8 out of 94) decreased complex I content to less than 70 % of 
the parental strain. However, none of the point mutations prevented complex I 
assembly, with the notable exception of A84V in the PSST subunit. Since alanine 84 is 
only 4 Å away from iron-sulfur cluster N2 and the side chain points towards this cluster 
(see Figure 3.3), it seems that the addition of two methyl groups in mutant A84V 
sterically interfered with iron-sulfur cluster N2 and hence complex I assembly. 
Consistently, exchanging alanine 84 to glycine did not decrease complex I content (see 
Table 3.2).  
 
Table 3.1: Effects of point mutations introduced into the 
49-kDa subunit in mitochondrial membranes from Y. 
lipolytica.  42   3  Results  
Strain 
Complex I 
content
 a 
Complex I 
activity
 b 
app. Km 
for DBQ 
 %  %  µM 
parental   100±3  100±5  15  
A94I
 i  85±3 14±2  n.d. 
H95A
 c 130  <5  n.d. 
H95M
 c 120  <5  n.d. 
H95R
 c 100  <5  n.d. 
V97G 56±1  72±1  n.m. 
V97I 96±2  82±4  n.m. 
V97W 78±2  10±2  n.d. 
L98F
 i  101±3 22±2  n.d. 
L98K
 i  71±2 15±2  n.d. 
R99D 58±2  14±2  n.d. 
R99K 
h 99  5  n.d. 
R99Q 
i 75±1  n.m. n.m. 
R99T 71±1  15±2  n.d. 
R141A
 d 130
  17
  10
 f 
R141K 
c  140 45  13 
D143A 
g 118±3  30±3  18 
D143C 
d 110 30  7 
f 
D143E 
d 170 23 9.5 
f 
D143N 
g 91±3  42±5 15 
Y144F 110±2  7±2  n.d. 
Y144H 
d 70 <5 n.d. 
Y144H 86±2  <5  n.d. 
Y144I 59±1  15±1  n.d. 
Y144R
 i  58±1 9±1  n.d. 
Y144S
 i  94±4 <5  n.d. 
Y144W 129±2  8±4 n.d. 
V145F 127±1  7±3  n.d. 
V145K 
h 71 10   n.d. 
V145M 
h 100  33 n.m. 
V145T 122±4  92±8  12   
S146A 
e 107  110 10 3.1  Mutagenesis of the proposed ubiquinone and inhibitor binding cavity 43 
Strain 
Complex I 
content
 a 
Complex I 
activity
 b 
app. Km 
for DBQ 
 %  %  µM 
parental   100±3  100±5  15  
S146C 
e 100  100 12 
S146V 
g 94±4  94±6 16 
M188C 98±3  104±5  18 
M188L 101±2  123±5  23 
M188Y 104±3  12±2  n.d. 
S192I
 i  110±3 16±2  n.d. 
S192R
 i  102±5 8±2  n.d. 
S192Y 111±2  24±2  n.d. 
M195F 
h 88 69  n.m. 
M195K 
h 95  26 n.m. 
D196E 
h 90 35  n.m. 
D196N 
h 101 29 n.m. 
L200K 
h 101 33 n.m. 
F203E 
g 97±3  28±3 14 
F203W 
g 103±3  98±6  15 
F207H 
g 117±4  92±8  15 
F207W   99±2  58±2  12 
R210I 100±2  63±2  14 
E211Q 124±4  83±6  16 
E218Q 97±2  97±4  12 
R224D 97±2  107±4  13   
R224I 93±3  102±5  14 
R224K 86±2  103±3  10   
R224N 124±2  99±7  14 
L225A 102±3  103±6  13 
L225F 95±3  110±6  13   
L225H 84±3  107±5  12   
L225V 95±2  91±3  12   
H226A 
d 100 20 n.d. 
H226C 
c 122 43  5 
H226M 
c 120  80  9 44   3  Results  
Strain 
Complex I 
content
 a 
Complex I 
activity
 b 
app. Km 
for DBQ 
 %  %  µM 
parental   100±3  100±5  15  
H226Q 
c 112 56  9 
P406A 
e 120  114  n.m. 
K407A 
e 104 85 n.m. 
K407H 80±2  78±2  13 
K407R 93±3  105±4  12 
K407W 66±1  12±2  n.d. 
L447K 
h 90 10  n.d. 
V451K 
h 87 12 n.d. 
I454K 
h 94 7  n.d. 
G455I
 i  71±3 16±2  n.d. 
G455S
 i  98±1 72±4  11   
D458A 
d  93 28 12
 f 
D458E 
g 83±1  89±3  n.m. 
L459I
 i  92±7 92±10  16 
L459K
 i  50±2 24±2  n.d. 
V460A
 d 90 <5  n.d. 
V460L
 i  83±4 21±2  n.d. 
V460M 
h  100±2 
h 16±2 
h 9
 f 
V460S
 i  82±3 21±1  n.d. 
F461W
 i  97±3 23±3  15 
E463Q 
d 60 20 5 
f 
E463T
 i  78±1 35±2  11 
Mean values ± SEM are given. 
n.d., not determinable 
n.m., not measured 
a 100 % of complex I content corresponds to 1.25 
µmol·min
-1·mg
-1 NADH:HAR oxidoreductase activity 
determined for the parental strain.  
b  DQA sensitive complex I specific dNADH:DBQ 
oxidoreductase activity (0.58 µmol·min
-1·mg
-1 was measured 
for the parental strain) was normalized to complex I content. 
The ratio of 0.58/1.25 for the parental strain was set as 100 % 
complex I activity. 
c  data from (Grgic et al., 2004) 
d  data from (Kashani-Poor et al., 2001b) 3.1  Mutagenesis of the proposed ubiquinone and inhibitor binding cavity 45 
e  data from (Grgic, Ph.D. Thesis, University Frankfurt, 2004) 
f  data from (Kashani-Poor, Ph.D. Thesis, University Frankfurt, 
2000) 
g   data from (Fendel et al., 2008) 
h  data from (Fendel, M.D. Thesis, University Frankfurt) 
i  mutations generated by U. Fendel 
Table 3.2: Effects of point mutations introduced into the 
PSST subunit in mitochondrial membranes from Y. 
lipolytica.  
Strain 
Complex I 
content 
a 
Complex I 
activity 
b 
app. Km 
for DBQ 
 %  %  µM 
parental 100±2  100±3 14 
A84G 
f 124  68  n.m. 
A84V 26±1  n.d. n.d. 
V88F 96±2  13±1  n.d. 
V88L 94±4  92±5  15 
V88M 95±2  56±3  13 
E89A 
c  145 74  19 
E89C 
c  145 67  18 
E89Q 
c  100 88  9 
M91C 
e 114±2  31±4 11 
M91K 
e 86±3  10±2  n.d. 
E185Q 
d  110 35  18 
Mean values ± SEM are given. 
n.d., not determinable 
n.m., not measured
 
a 100 % of complex I content corresponds to 1.25 
µmol·min
-1·mg
-1 NADH:HAR oxidoreductase activity 
determined for the parental strain.  
b DQA sensitive complex I specific dNADH:DBQ oxido-
reductase activity (0.6 µmol·min
-1·mg
-1 was measured for the 
parental strain) was normalized to complex I content. The 
ratio of 0.6/1.25 for the parental strain was set as 100 % 
complex I activity. 
c  data from (Ahlers et al., 2000), NBQ was used instead of 
DBQ as substrate.  
d  data from (Garofano et al., 2003) 
e   data from (Fendel et al., 2008) 
f   data from (Fendel, M.D. Thesis, University Frankfurt) 46   3  Results  
EPR spectra recorded from mitochondrial membranes of 18 most drastic mutations 
indicated that complex I was properly assembled in all cases (see Figure 3.1 and Figure 
3.2). Moreover, since iron-sulfur cluster N2 gives a strong and distinct EPR signal, 
major structural changes nearby should influence the N2 signal. However, the position 
in the spectrum as well as the line shape of the N2 signal was unchanged in all mutants 
examined. This suggests that the structural changes introduced by the mutations were 
rather local. 
Reduced complex I content in some mutants as indicated by lower NADH:HAR 
oxidoreductase activity was confirmed by lower complex I specific EPR signals, i.e. a 
lower signal to noise ratio in the EPR spectra (see spectrum from mutant L459K in 
Figure 3.1). 3.1  Mutagenesis of the proposed ubiquinone and inhibitor binding cavity 47 
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Figure 3.1: EPR spectra of mitochondrial membranes of selected 49-kDa mutants at 12 K 
and 5 mW microwave power. Field regions where mainly iron-sulfur cluster N2 gives signals 
are highlighted in gray. No significant differences in the spectrum of mutants compared to the 
parental strain could be identified. Mitochondrial membranes (10–25 mg protein per ml) were 
reduced with 2 mM NADH. Other EPR settings: microwave frequency 9.47 GHz,
 modulation 
amplitude 0.64 mT and modulation frequency
 100 kHz. The spectra were recorded by Dr. Klaus 
Zwicker. 
 
Figure 3.2: EPR spectra of mitochondrial membranes of the PSST mutant V88F at 12 K 
and 5 mW microwave power. Field regions where mainly signals from iron-sulfur cluster N2 
arise are highlighted in gray. The spectrum of mutant V88F was not significantly different from 
the spectrum of the parental strain. Mitochondrial membranes (10–25 mg protein per ml) were 
reduced with 2 mM NADH. Further EPR settings: microwave frequency 9.47 GHz,
 modulation 
amplitude 0.64 mT and modulation frequency
 100 kHz. The spectra were recorded by Dr. Klaus 
Zwicker. 
For 58 mutants complex I assembly was also confirmed by blue-native PAGE from 
mitochondrial membranes followed by complex I in-gel activity assay. No sub-
complexes of complex I were detectable, even when the incubation period for in-gel 
activity staining was prolonged from 5 min to 30 min (data not shown). In agreement 
with the results shown above, reduced complex I content in mitochondrial membranes 
from some mutants also gave rise to weaker complex I specific in-gel activity staining. 
Taking together, the NADH:HAR oxidoreductase activities, the EPR spectra as well as 
the in-gel activity assays suggest that the targeted residues are not essential for proper 
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3.1.2  Activity of mutant complex I 
In sharp contrast to complex I assembly, many mutations severely impaired complex I 
activity (Table 3.1 and Table 3.2). As expected, more drastic mutations reduced 
complex I activity more strongly than conservative mutations. However, at some 
positions all introduced mutations resulted in very low activities. For example, in the 
case of tyrosine 144 in the 49-kDa subunit even the conservative exchange to 
phenylalanine, which just removes the hydroxyl group, almost completely abolished 
complex I activity. Similarly, all arginine 99 mutants in the 49-kDa subunit dramatically 
reduced complex I activity, even when this arginine was exchanged to lysine in mutant 
R99K. The same was true for valine 460 in the 49-kDa subunit and the conservative 
V460L exchange. 
In contrast, at some positions none of the mutations reduced complex I activity. This 
was true for the highly conserved arginine 224 and leucine 225 in the 49-kDa subunit. 
The exchange of the large and positively charged arginine 224 to the smaller and 
negatively charged aspartic acid in mutant R224D as well as the exchange to the smaller 
and hydrophobic isoleucine in mutant R224I did not decrease complex I activity. 
Similarly, exchange of the hydrophobic leucine 225 to the positively charged histidine 
in mutant L225H did not affect complex I activity. 
Since exchanges of different residues gave very different results, the effects of the 
introduced mutations on complex I activity must be seen in the context of their position 
in the quinone binding cavity according to the crystal structure from T. thermophilus 
(Sazanov and Hinchliffe, 2006) and the sequence alignment of the PSST and the 49-
kDa subunits (see chapter 8.2.1 and 8.2.2). Therefore, based on the experimental results 
given in Tables 3.1 and 3.2, exchanged residues were grouped and color-coded 
according to their importance for complex I activity (Figure 3.3). When all mutations at 
a given position resulted in essentially normal complex I activity (>75 % of the parental 
strain), these positions were colored in blue. Positions where at least one exchange 
significantly reduced complex I activity (25-75 % of the parental strain) were colored in 
green. Positions where at least one exchange resulted in very low complex I activity 
(<25 % of the parental strain) were colored in yellow. When several mutations at a 
given position all resulted in very low complex I activity (<25 % of the parental strain), 50   3  Results  
these positions were colored in red. As shown in Figure 3.3, the effects of mutations 
strongly depended on the location of the targeted residue within the quinone binding 
cavity. Residues which were very critical for complex I activity (colored in red) cluster 
in an area in the 49-kDa subunit that begins at a loop of the N-terminal three stranded β-
sheet, reaches down into the cavity and ends at tyrosine 144, next to iron-sulfur cluster 
N2. Mutations in the vicinity of this region had less pronounced effects on complex I 
activity (colored in yellow and green). Mutations of residues located at the distal end of 
the cavity where the cavity narrows to form a crevice had almost no effect on complex I 
activity (colored in blue), suggesting that this part of the quinone binding cavity is not 
critical for complex I activity. 
Based on these results, the quinone binding cavity can be divided in regions critical, less 
critical and not critical for complex I activity. 3.1  Mutagenesis of the proposed ubiquinone and inhibitor binding cavity 51 
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Figure 3.3: Impact of mutations affecting the proposed ubiquinone and inhibitor binding 
cavity on complex I activity. View into the quinone binding cavity assembled by the PSST and 
the 49-kDa subunit. A, surface representation. B, schematic representation, exchanged amino 
acid residues are shown in stick representation, iron-sulfur cluster N2 is shown in gray as space-
filled model. Exchanged amino acid residues were colored according to their importance for 
complex I activity (DQA sensitive dNADH:DBQ oxidoreductase activity of mitochondrial 
membranes normalized to complex I content): Red, several exchanges of a given residue all 
resulted in very low complex I activity (<25 % of the parental strain for all exchanges). Yellow, 
at least one exchange of a given residue resulted in very low activity (<25 % of the parental 
strain for at least one exchange). Green, at least one exchange reduced complex I activity (25-75 
% of the parental strain). Blue, all exchanges of a given residue had essentially no effect on 
complex I activity (>75 % of the parental strain for all exchanges). Amino acids are labeled 
according to Y. lipolytica numbering. Residues from the PSST subunit are marked with an 
asterisk. The figure was generated from coordinates from the crystal structure of the hydrophilic 
domain of complex I from T. thermophilus (PDB ID: 2FUG) by using the PyMOL program. 
The mutagenesis wizard from the PyMOL package was used to match the Y. lipolytica sequence 
when a residue was not conserved between T. thermophilus and Y. lipolytica. 
3.1.3  Apparent Km for DBQ 
Since point mutations within the quinone binding cavity might have changed the 
affinity of complex I to its substrate, apparent Km values for DBQ were measured in 
mitochondrial membranes. However, reliable values can only be obtained from mutants 
with complex I activities well above 20 % of the parental strain. As shown in Table 3.1 
and Table 3.2, none of the mutants with sufficient complex I activity had a markedly 
changed apparent Km value. 
3.1.4  Complex I activity with Q1 and Q9 as electron acceptors 
In order to check whether the measured activity of mitochondrial membranes from 
mutant strains depended on the side chain of the ubiquinone used, also the activity with 
Q1 as electron acceptor was measured.  
In addition, the activity with the endogenous ubiquinone, which is Q9 in the case of Y. 
lipolytica, was assayed. Because of the extreme hydrophobicity of Q9, it could not be 
added at saturating concentrations to the assay. Therefore, omitting the addition of 
ubiquinone and KCN, dNADH-oxidase activity was measured to monitor electron 
transfer via the endogenous quinone Q9. However, substrate saturation was most likely 
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As shown in Table 3.3 and Table 3.4, the relative changes in activity for most mutants 
measured with DBQ were also reproduced when Q1 and Q9 were used.  
However, in mutants Y144F and F207W the activity with Q1 was considerably higher, 
and in mutants R224I, L225A and K407H Q1 activity was significantly lower than what 
was measured with DBQ (bold in Table 3.3). The dNADH:Q1 oxidoreductase activity 
of mutant Y144F will be covered in more detail in chapter 3.3.  
Interestingly, values measured with the endogenous Q9 were very similar to those 
measured with DBQ, which might indicate that measurements with DBQ reflect the 
physiological relevant activity more closely than measurements with Q1. 
Table 3.3: Complex I activity with different ubiquinones in 
mitochondrial membranes from 49-kDa subunit mutants.  
Strain 
Complex I 
activity with 
DBQ
 a 
Complex I 
activity with 
Q1
 b 
Complex I 
activity with 
Q9
 c 
 %  %  % 
parental   100±5  100±8  100±6 
V97W 10±2  <5  <5 
R99D 14±2  14±2  11±2 
R99T 15±2  9±1  5±1 
Y144F   7±2  46±3  11±1 
Y144H <5  <5  14±1 
Y144I 15±1  <5  8±1 
Y144W 8±4  5±3  8±4 
V145F 7±3  <5  <5 
V145T   92±8  107±8  120±12 
M188Y 12±2  6±1  n.m. 
S192Y 24±2  12±3  <5 
F207W   58±2  95±3  68±4 
R210I 63±2  82±3  n.m. 
E211Q 83±6  61±5  n.m. 
E218Q   97±4  94±3  117±6 
R224D    107±4 83±3 102±5 54   3  Results  
Strain 
Complex I 
activity with 
DBQ
 a 
Complex I 
activity with 
Q1
 b 
Complex I 
activity with 
Q9
 c 
 %  %  % 
parental   100±5  100±8  100±6 
R224I   102±5  70±4  105±6 
R224K 103±3  74±3  n.m. 
R224N   99±7  83±7  156±12 
L225A 103±6  61±3  n.m. 
L225F 110±6  82±4  n.m. 
L225H   107±5  78±6  109±4 
L225V   91±3  106±3  94±4 
K407H 78±2  36±1  n.m. 
K407R 105±4  93±3  n.m. 
K407W  12±2 36±1 11±1 
Mean values ± SEM are given. 
n.m., not measured 
a values taken from Table 3.1: DQA sensitive complex I 
specific dNADH:DBQ oxidoreductase activity (0.58 
µmol·min
-1·mg
-1 was measured for the parental strain) was 
normalized to complex I content. The ratio of 0.58/1.25 for 
the parental strain was set as 100 % complex I activity. 
b DQA sensitive complex I specific dNADH:Q1 oxido-
reductase activity (0.28 µmol·min
-1·mg
-1 was measured for 
the parental strain) was normalized to complex I content. The 
ratio of 0.28/1.25 for the parental strain was set as 100 % 
complex I activity. 
c  DQA sensitive complex I specific dNADH oxidase activity 
(0.16 µmol·min
-1·mg
-1 was measured for the parental strain) 
was normalized to complex I content. The ratio of 0.16/1.25 
for the parental strain was set as 100 % complex I activity. 
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Table 3.4: Complex I activity with different 
ubiquinones in mitochondrial membranes 
from PSST subunit mutants. 
Strain 
Complex I 
activity with 
DBQ
 a 
Complex I 
activity with 
Q1
 b 
 %  % 
parental 100±3  100±3 
V88F 13±1  14±2 
V88L 92±5  86±6 
V88M 56±3  59±2 
Mean values ± SEM are given. 
n.m., not measured
 
a  values taken from Table 3.2: DQA sensitive 
complex I specific dNADH:DBQ oxido-
reductase activity (0.6 µmol·min
-1·mg
-1 was 
measured for the parental strain) was 
normalized to complex I content. The ratio of 
0.6/1.25 for the parental strain was set as 100 
% complex I activity. 
b  DQA sensitive complex I specific 
dNADH:Q1 oxidoreductase activity (0.24 
µmol·min
-1·mg
-1 was measured for the 
parental strain) was normalized to complex I 
content. The ratio of 0.24/1.25 for the 
parental strain was set as 100 % complex I 
activity. 
3.1.5  I50 values for DQA, rotenone and C12E8 
Since many different complex I inhibitors act at or near the quinone binding site, some 
point mutations introduced in the broad quinone binding cavity may also influence 
inhibitor binding. Therefore, I50 values for DQA, rotenone and C12E8, each representing 
a class I/type A, class II/type B and type C inhibitor, respectively, were measured in 
mitochondrial membranes. Again, reliable values could only be obtained for mutants 
with complex I activities well above 20 % of the parental strain.  
As shown in Table 3.5 and Table 3.6, most mutations had no effect on inhibitor 
sensitivity of complex I. Others like mutants K407R and E463Q in the 49-kDa subunit 
changed the I50 value for DQA only. Mutations R224I and L225F, both in the 49-kDa 
subunit, changed the I50 value for C12E8 only. In contrast, mutant F207H in the 49-kDa 56   3  Results  
subunit and mutant M91C in the PSST subunit resulted in drastically changed I50 values 
for DQA and rotenone as well as for C12E8. I50 values which were significantly different 
from those of the parental strain are highlighted in bold in Table 3.5 and Table 3.6. 
Interestingly, most mutations which altered I50 values for DQA and rotenone caused 
resistance, whereas hypersensitivity was mostly found in mutations which altered the I50 
value for C12E8. 
Table 3.5: Effects of 49-kDa subunit mutations on inhibitor sensitivity in 
mitochondrial membranes from Y. lipolytica. 
Strain 
Complex I 
activity
 a 
I50 
DQA Rotenone C12E8 
 %  nM 
parental   100±5  16  530  3300
 e 
R141A
 c 17
  21
  570
   n.d. 
R141K 
b  45  55 1500  3400 
e 
D143A 
e 30±3 180 10000  2800 
D143C 
c 30 30  580  2700 
e 
D143E 
c 23 38  630 3100 
e 
D143N 
e 42±5 60 5000  2500
  
V145M 
f 33  n.m. n.m. 2400 
V145T 92±8  17  550  3000 
f 
S146A 
d 110 10 300  2800 
f 
S146C 
d 100 80 1500  3400 
e 
S146V 
e 94±6 29 1100  3200 
M188C 104±5  28 2500  3000 
e 
M188L 123±5  16 780  2900 
e 
M195F 
f 69  n.m. n.m. 3200 
D196E 
f 35  n.m. n.m. 3000 
D196N 
f 29  n.m. n.m. 3200 
L200K 
f 33  n.m. n.m. 2600 
F203E 
e 28±3  70 2300  2800 
F203W 
e 98±6 14  450 800 
F207H 
e 92±8 45 3000  5000 
F207W   58±2  21  850  2600
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Strain 
Complex I 
activity
 a 
I50 
DQA Rotenone C12E8 
 %  nM 
parental   100±5  16  530  3300
 e 
R210I 63±2  16  500  3300 
e 
E211Q 83±6  21  530  3200 
e 
E218Q 97±4  21  550  3000 
e 
R224D 107±4  12 550  2300 
e 
R224I 102±5  12  650  2000 
e 
R224K 103±3  11 550  2500 
e 
R224N 99±7  15  700  2400 
e 
L225A 103±6  13 550  2500 
e 
L225F 110±6  11  460  2000 
e 
L225H 107±5  14 700  2600 
e 
L225V 91±3  12  700  2300 
e 
H226A 
c 20 18 770  n.d. 
H226C 
b 43 13 600  n.m. 
H226M 
b 80  9  300  n.m. 
H226Q 
b 56 13 600  n.m. 
K407H 78±2  13 500  3400 
e 
K407R 105±4  75  550 3100 
e 
G455S
 g  72±4 22  700  3300 
f 
D458A 
c  28
   520
  5200
   3300 
e 
D458E 
e 89±3 30 2200  3400 
L459I
 g  92±10 13  620  3300 
f 
V460L
 g  21±2  130 ~9000 n.d. 
V460M 
  16±2  53
 c 760
 c  n.d. 
F461W
 g  23±3 30  800 n.d. 
E463Q 
c 20 34  780 2300 
e 
E463T
 g  35±2  8  800 2800 
e 
Mean values ± SEM are given. 
n.d., not determinable 
n.m., not measured 
a  values taken from Table 3.1
 
b  data from (Grgic et al., 2004) 
c  data from (Kashani-Poor et al., 2001b) 
d  data from (Grgic, Ph.D. Thesis, University Frankfurt, 2004) 58   3  Results  
e   data from (Fendel et al., 2008) 
f  data from (Fendel, M.D. Thesis, University Frankfurt) 
g  point mutations were generated by U. Fendel 
Table 3.6: Effects of PSST subunit mutations on inhibitor sensitivity in 
mitochondrial membranes from Y. lipolytica. 
Strain 
Complex I 
activity
 a 
  I50  
DQA Rotenone C12E8 
 %  nM 
parental 100±3 13  450  3000 
d 
A84G 
e 68  n.m. n.m. 2900  
V88L 92±5  25  500  1800 
d 
V88M 56±3  32  330  1500 
d 
E89A 
b  74 13  590  n.m. 
E89C 
b  67 14  630  n.m. 
E89Q 
b  88 11  620  n.m. 
M91C 
d 31±4  500 15000  1300 
E185Q 
c  35 20  500  2700 
e 
Mean values ± SEM are given. 
n.d., not determinable 
n.m., not measured 
a  values taken from Table 3.2 
 
b  data from (Ahlers et al., 2000), here NBQ was used instead of DBQ.  
c  data from (Garofano et al., 2003) 
d  data from (Fendel et al., 2008) 
e  data from (Fendel, M.D. Thesis, University Frankfurt) 
Based on the crystal structure from T. thermophilus (Sazanov and Hinchliffe, 2006), the 
different effects of the point mutations can be discussed in the context of their location 
within the ubiquinone and inhibitor binding pocket for a more detailed 
structure/function analysis. 
As evident from Figure 3.4, mutations with effects on inhibition by DQA and rotenone 
(highlighted in green) cluster in a subdomain of the cavity, mainly formed by the 
49-kDa subunit, which corresponds to the former [NiFe] site of the homologous water 
soluble [NiFe] hydrogenases. Effects on DQA only (highlighted in blue) were found 
deeper in this pocket. In contrast, effects on C12E8 only (highlighted in red) were found 3.1  Mutagenesis of the proposed ubiquinone and inhibitor binding cavity 59 
in a different region, where the broad cavity narrows to form a crevice at the interface of 
the 49-kDa and the PSST subunit. Consistently, mutations which resulted in changed I50 
values for all three inhibitors (highlighted in yellow) clustered at quite exposed residues 
between the subdomain where effects on DQA and rotenone were found and the crevice 
where effects on C12E8 only were found. 
These results confirm the view that different complex I inhibitors bind to different 
partially overlapping binding sites within the quinone binding pocket (Okun et al., 
1999a). In addition, based on these results the binding sites of different inhibitors can be 
assigned to distinct domains within the broad quinone binding cavity. 
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Figure 3.4: Impact of mutations affecting the proposed ubiquinone and inhibitor binding 
cavity on inhibitor binding. Similar view as in Figure 3.3. A, surface representation, the 
location of the former [NiFe] site in homologous [NiFe] hydrogenases and the crevice at the 
interface of the 49-kDa and the PSST subunit are outlined. B, schematic representation, amino 
acid residues which display effects on inhibitor binding when altered are shown in stick 
representation; for better orientation tyrosine 144 is shown in white sticks, iron-sulfur cluster 
N2 is shown in gray as space-filled model. Positions of mutations which changed the I50 value 
for C12E8 only are highlighted in red. Positions of mutations which changed the I50 value for 
DQA only are highlighted in blue. Positions where effects on DQA and rotenone were found are 
colored in green. Positions where effects on DQA, rotenone and C12E8 were found are colored in 
yellow. Amino acids are labeled according to Y. lipolytica numbering. Residues from the PSST 
subunit are marked with an asterisk. The figure was generated from the crystal structure of the 
hydrophilic domain of complex I from T. thermophilus (PDB ID: 2FUG) by using the PyMOL 
program. The mutagenesis wizard from the PyMOL package was used to match the Y. lipolytica 
sequence when a residue was not conserved between T. thermophilus and Y. lipolytica 
3.1.6  EIPA 
The amiloride derivative EIPA also inhibits complex I activity (Nakamaru-Ogiso et al., 
2003a; Nakamaru-Ogiso et al., 2003b; Stolpe and Friedrich, 2004). It had been 
proposed that EIPA acts on the ND5 subunit of complex I (Nakamaru-Ogiso et al., 
2003a), since it has decreased the photoaffinity labeling of presumably the ND5 
subunit, which shares some sequence similarity with Na
+/H
+ antiporters (Hamamoto et 
al., 1994; Hiramatsu et al., 1998; Mathiesen and Hägerhäll, 2002) which in turn are 
inhibited by amiloride (Mochizukioda and Oosawa, 1985; Kleyman and Cragoe, 1988; 
Counillon et al., 1993; Kuroda et al., 1994; Masereel et al., 2003). 
Complex I from the Y. lipolytica strain nb8mΔ lacks the ND5 subunit (Stefanie Krack, 
personal communication); however, the activity of this subcomplex of complex I is still 
inhibited by EIPA (Stefan Dröse, personal communication).  
Indeed, in mitochondrial membranes from the nb8mΔ strain an I50 value of 23 µM was 
determined for EIPA (Table 3.7) Strikingly, very similar I50 values were determined for 
EIPA in mitochondrial membranes from the 49-kDa subunit and the PSST subunit 
parental strains (Table 3.8 and Table 3.9). These results indicate that the ND4 and the 
ND5 subunit are not necessary for complex I inhibition by EIPA.  
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Table 3.7: Characteristics of mitochondrial 
membranes from the nb8mΔ strain. 
Strain 
Complex I 
activity
 a 
I50 
EIPA 
 %  µM 
nb8mΔ
b 30  23 
a  DQA sensitive dNADH:DBQ oxidoreductase 
activity normalized to complex I content 
determined as NADH:HAR oxidoreductase 
activity (determined by Stefan Kerscher).  
b The  strain  nb8mΔ was generated by Stefanie 
Krack. 
In order to identify the binding site of EIPA, I50 values for EIPA in mitochondrial 
membranes from 15 point mutations within the quinone and inhibitor binding site that 
had been found to have effects on the binding of other inhibitors were determined.  
As shown in Table 3.8 and Table 3.9, in most mutants the I50 values for EIPA were 
unchanged, and only slight changes were observed in mitochondrial membranes from 
four mutants (highlighted in orange). However, considerably changed I50 values were 
found in mutants M188C, F207H and F207W (highlighted in red). Similarly to what 
was observed for C12E8, usually hypersensitivity was found in mutants changing the I50 
value for EIPA. For comparison, significantly changed I50 values for DQA, rotenone 
and C12E8 are highlighted in bold in Table 3.8. 
Table 3.8: Effects of point mutations in the 49-kDa subunit on EIPA inhibition in 
mitochondrial membranes from Y. lipolytica. 
Strain 
Complex I 
activity
 a 
I50 
EIPA DQA  Rotenone  C12E8 
 %  µM  nM 
parental 100±5 21  16  530  3300
 b 
D143C   30 
c 19 30 
c 580 
c 2700 
b 
M188C 104±5  14  28 2500  3000 
b 
M188L 123±5  17  16 780  2900 
b 
F203W   98±6 
b 18  14 
b 450 
b  800 
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Strain 
Complex I 
activity
 a 
I50 
EIPA DQA  Rotenone  C12E8 
 %  µM  nM 
parental 100±5 21  16  530  3300
 b 
F207H   92±8 
b  13  45  3000 
b  5000 
b 
F207W 58±2 9  21 850  2600
 b 
R224D 107±4  24  12 550  2300 
b 
R224I 102±5  20 12  650  2000 
b 
R224N 99±7  23 15  700  2400 
b 
L225F 110±6  26  11 460  2000 
b 
L225H 107±5  20  14 700  2600 
b 
K407R 105±4  19  75  550 3100 
b 
D458A
  28 
c 22  520 
c  5200 
c 3300 
b 
Mean values ± SEM are given. 
a  values taken from Table 3.1
 
b   data from (Fendel et al., 2008) 
c  data from (Kashani-Poor et al., 2001b) 
Table 3.9: Effects of point mutations in the PSST subunit on EIPA inhibition in 
mitochondrial membranes from Y. lipolytica. 
Strain 
Complex I 
activity
 a 
I50 
EIPA DQA  Rotenone  C12E8 
 %  µM  nM 
parental   100±3  23  13  450  3000 
b 
V88L 92±5  18  25 500  1800 
b 
V88M 56±3  18  32  330  1500 
b 
Mean values ± SEM are given. 
a  values taken from Table 3.2 
b  data from (Fendel et al., 2008) 
Figure 3.5 highlights the location of mutations within the structure of the quinone and 
inhibitor binding cavity that changed the I50 value for EIPA considerably (colored in 
red) as well as mutations which only slightly affected the I50 value (colored in orange). 
Amino acid side chains where mutations had no effect on the I50 value for EIPA are 
shown in stick representations. Effects on EIPA binding did neither cluster in the 64   3  Results  
subdomain of the cavity corresponding to the former [NiFe] site where changes in the 
I50 values for DQA and rotenone were found, nor in the narrow crevice where changes 
in the I50 values for C12E8 are found (compare Figure 3.5 to Figure 3.4). Rather, changes 
in the I50 values for EIPA marked several exposed residues in a region where mutations 
resulted in altered I50 values for DQA, rotenone and C12E8. 
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Figure 3.5: Effects of mutants of the quinone and inhibitor binding site on the I50 value for 
EIPA.  Same view as in Figure 3.4. A, surface representation. B, schematic representation, 
positions of exchanges which were tested for effects on the I50 value for EIPA are shown in 
stick representation, for better orientation tyrosine 144 is shown in white sticks, iron-sulfur 
cluster N2 is shown in gray as space-filled model. Positions of exchanges which considerably 
changed the I50 value for EIPA are highlighted in red. Positions of exchanges which slightly 
changed the I50 value for EIPA are highlighted in orange. Amino acids are labeled according to 
Y. lipolytica numbering. Residues from the PSST subunit are marked with an asterisk. The 
figure was generated from the crystal structure of the hydrophilic domain of complex I from T. 
thermophilus (PDB ID: 2FUG) by using the PyMOL program. The mutagenesis wizard from 
the PyMOL package was used to match the Y. lipolytica sequence when a residue was not 
conserved between T. thermophilus and Y. lipolytica. 
Contrary to what was proposed before (Nakamaru-Ogiso et al., 2003a), these results 
indicate that EIPA does not act on the ND5 subunit, but rather on the quinone binding 
cavity assembled by the 49-kDa and the PSST subunits. 
3.2  In vivo screen for complex I deficiency 
3.2.1  The principle 
The  Y. lipolytica strains used for mutagenesis of complex I have a matrix directed 
(internal) copy of the alternative NADH dehydrogenase (NDH2i) (de Vries and Marres, 
1987; Kerscher et al., 2002). This membrane associated enzyme transfers electrons from 
NADH of the mitochondrial matrix to ubiquinone (Kerscher, 2000; Joseph-Horne et al., 
2001) and therefore can compensate for the redox reaction of complex I, so that 
complex I deficiency is not longer lethal to this strictly aerobic yeast (Kerscher et al., 
2001b). However, in contrast to complex I this protein cannot couple the redox reaction 
to vectorial proton translocation across the inner mitochondrial membrane. 
Interestingly, Y. lipolytica strains which lack functional complex I but have an internal 
copy of the NDH2 do not show any phenotypic growth deficiency (see also upper panel 
in Figure 3.7).  
In order to screen for complex I deficiency in vivo, a new approach was tested. When Y. 
lipolytica is grown in the presence of a complex III and/or a complex IV inhibitor, both 
complexes can be bypassed due to the alternative oxidase, which transfers electrons 
from ubiquinol to oxygen (Henry and Nyns, 1975; de Troostembergh and Nyns, 1978; 3.2  In vivo screen for complex I deficiency 67 
Vanlerberghe and McIntosh, 1997; Medentsev and Akimenko, 1999; Joseph-Horne et 
al., 2001). Since the alternative oxidase is not capable of proton pumping, under these 
conditions complex I is the only enzyme of the respiratory chain which pumps protons 
across the inner mitochondrial membrane Figure 3.6. Hence, oxidative phosphorylation 
will depend on functional complex I.  
 
Figure 3.6: The respiratory chain of Y. lipolytica strains used for mutagenesis. In the 
presence of a complex III and/or a complex IV inhibitor, complex I is the only enzyme of the 
respiratory chain capable of proton pumping. White arrows indicate electron transfer, whereas 
red arrows indicate proton translocation. Complex II (succinate:ubiquinone oxidoreductase); 
complex III (cytochrome c reductase); complex IV (cytochrome c oxidase); complex V (ATP-
synthase); NDH2 (alternative NADH dehydrogenase); NDH2i (internal alternative NADH 
dehydrogenase); alternative ubiquinol oxidase (Alt. Ox.); FeS (iron-sulfur cluster); FMN (flavin 
mononucleotide); FAD (flavin adenine dinucleotide, oxidized form); NAD
+ (nicotinamide 
adenine dinucleotide, oxidized form); NADH (nicotinamide adenine dinucleotide, reduced 
form); Q (ubiquinone); QH2 (ubiquinol); b (heme b); bH (high potential heme b); bL (low 
potential heme b); a (heme a); a3 (heme a3); c (cytochrome c); c1 (cytochrome c1); CuA (copper 
center A); CuB (copper center B). 
3.2.2  Development of a plate assay for complex I activity 
For complex III and complex IV inhibition, antimycin A and sodium azide were tested. 
These inhibitors were added to YPD-agar plates (see chapter 2.2.1.7) at various 
concentrations (0.2-10 µM antimycin A and 0.1-10 mM sodium azide). In order to find 
optimal concentrations, Y. lipolytica mutant Y144F and the parental strain were used as 
tester strains for no and full activity, respectively. Best results were achieved at 68   3  Results  
concentrations of 0.3 µM for antimycin A and 0.5 mM for sodium azide. As shown in 
Figure 3.7, mutant Y144F showed weaker growth compared to the parental strain only 
on inhibitor containing plates.  
 
Figure 3.7: On antimycin A and azide containing 
plates mutant Y144F displays diminished growth. 
For both strains ~3000, ~300, ~30 and ~3 cells per 
droplet were placed on plates. 
Antimycin A always gave better results than sodium azide. The combination of both 
inhibitors at various concentrations in one plate did not significantly improve the 
difference in growth any further (data not shown). Therefore, it seems sufficient to 
solely use 0.3 µM antimycin A. 3.2  In vivo screen for complex I deficiency 69 
For best results, it was important that YPD liquid cultures of Y. lipolytica are grown in 
the absence of hygromycin B to similar densities until they reach late exponential phase 
(2-6 OD600 nm) before aliquots of the cultures were applied to plates.  
3.2.3  Screening of complex I mutants 
As shown earlier, within the quinone binding pocket there is a region where mutations 
had no effect on the dNADH:DBQ oxidoreductase activity of complex I (see chapter 
3.1.2). This includes some charged and highly conserved residues like glutamate 218 
and arginine 224. Since these residues are not critical for the redox reaction, it seemed 
reasonable to speculate that they might have a function in coupling the redox reaction to 
vectorial proton translocation. Therefore, these mutants were assayed for complex I 
dependent proton pumping on antimycin A containing plates. As shown in Figure 3.8, 
none of the mutants displayed any growth deficiency compared to the parental strain, 
suggesting that the affected residues are not critical for proton pumping in complex I.  70   3  Results  
 
Figure 3.8: Probing of fully redox active mutants for 
proton pumping defects. Even though glutamate 218 
and arginine 224 are highly conserved, none of the 
mutations tested here had an effect on proton pumping. 
The parental strain was used as positive, mutant Y144F 
as a negative control. For each strain ~300, ~30 and ~3 
cells per droplet were placed on plates. Antimycin A 
was added at 0.3 µM.  3.3  Tyrosine 144 71 
Unfortunately, the difference in growth between the parental strain and mutant Y144F, 
which was used as negative control, was even less pronounced when compared to the 
growth difference shown in Figure 3.7. This was most likely due to the fact that the 
liquid cultures of Y. lipolytica did not reach late exponential phase in this experiment 
(0.6-1.5 OD600nm). However, from these results it still seems clear that the tested 
residues are not essential for proton pumping or the coupling of the redox reaction to 
proton pumping. 
3.3  Tyrosine 144 
The tyrosine on position 144 in the Y. lipolytica sequence of the 49-kDa subunit is 
highly conserved from bacteria to mammals (see Figure 3.9).  
Y.lipolytica     GTEKLIEYKTYMQALPYFDRLDYVSMMTNEQVFSLAVEKL 161 
N.crassa         GTEKLCEYRTYLQALPYFDRLDYVSMMTNEQCFALAVEKL 173 
B.taurus         GTEKLIEYKTYLQALPYFDRLDYVSMMCNEQAYSLAVEKL 125 
H.sapiens        GTEKLIEYKTYLQALPYFDRLDYVSMMCNEQAYSLAVEKL 158 
P.denitrificans  GTEKLMESRTYLQNLPYLDRLDYVAPMNQEHAWCLAIERL 105 
T.thermophilus   GFEKTMEHRTYLQNITYTPRMDYLHSFAHDLAYALAVEKL 104 
E.coli           GAEKMGERQSWHSYIPYTDRIEYLGGCVNEMPYVLAVEKL 101 
                  * **  * ::: . :.*  *::*:    ::  : **:*:* 
Figure 3.9: Sequence alignment of the 49-kDa subunit harboring the highly conserved 
tyrosine 144. Tyrosine 144 of Y. lipolytica is highlighted in red and bold. Tyrosines from other 
organisms are highlighted in bold. Sequences were aligned by the multiple sequence alignment 
program ClustalW. Invariant (*), highly (:) and weakly similar (.) positions are labeled.  
Moreover, according to the X-ray structure of the hydrophilic part of complex I from T. 
thermophilus, this tyrosine is located only 6-8 Å away from iron-sulfur cluster N2 in the 
proposed quinone binding pocket.  
In order to gain insight into the function of tyrosine 144, this tyrosine was exchanged to 
phenylalanine and tryptophan retaining the aromatic character, to the hydrophobic 
isoleucine and to the hydrophilic residues serine, histidine and arginine. Mutant Y144H 
had been generated and described before (Kashani-Poor et al., 2001b); however, to 
avoid effects from a different genetic background when mitochondrial membranes were 
analyzed, this mutant was reproduced.  72   3  Results  
3.3.1  Assembly and activity of tyrosine 144 mutants 
Mitochondrial membranes from the tyrosine mutants were isolated and complex I 
content and activity were measured. As listed in Table 3.10, in all mutant strains 
complex I assembly was possible. However, in mutants Y144I and Y144R, complex I 
content was reduced to ~60 %, in contrast to mutant Y144W which resulted in a slight 
increase in complex I content to ~130 %. Apparently, spacious hydrophobic or 
hydrophilic residues were less well tolerated than aromatic residues at this position.  
Measurement of complex I activity revealed that all mutations resulted in an almost 
completely inactive complex I (Table 3.10). This was also true for mutant Y144F, 
whereby only a hydroxyl group was removed. Thus, the specific features of tyrosine 
144 were found to be essential for complex I activity. 
Table 3.10: Effects of point mutations of Y144 in the 49-kDa subunit on 
complex I content, activity and N2 EPR signal in mitochondrial 
membranes from Y. lipolytica. 
Strain 
Complex I 
content 
a 
Complex I 
activity 
b 
N2 EPR signal 
(see EPR spectra below) 
 %  %   
parental 100±3  100±5  reference 
Y144F  110±2  7±2  not altered  
Y144W  129±2  8±4  N2 signal slightly shifted 
Y144H 
c  70  <5  N2 signal slightly shifted 
Y144H
  86±2  <5  N2 signal slightly shifted 
Y144S
 d  94±4  <5  reduced N2 signals  
Y144I  59±1  15±1  no N2 signals 
Y144R
 d  58±1  9±1  no N2 signals 
Mean values ± SEM are given. 
a  100 % of complex I content correspond to 1.25 µmol·min
-1·mg
-1 NADH:HAR 
oxidoreductase activity determined for the parental strain.  
b DQA sensitive complex I specific dNADH:DBQ oxidoreductase activity 
(0.58 µmol·min
-1·mg
-1 was measured for the parental strain) was normalized 
to complex I content. The ratio of 0.58/1.25 for the parental strain was set as 
100 % complex I activity. 
c   data from (Kashani-Poor et al., 2001b) 
d  mutations generated by U. Fendel   3.3  Tyrosine 144 73 
3.3.2  Iron-sulfur cluster N2 in tyrosine 144 mutants 
Since tyrosine 144 is only 6-8 Å away from iron-sulfur cluster N2 (see Figure 3.3), 
mutations of this tyrosine could have abolished complex I activity by interfering with 
iron-sulfur cluster N2. To test this hypothesis, EPR spectra of mitochondrial membranes 
from mutant strains were recorded. As shown in Figure 3.10, mutants Y144F, Y144W 
and Y144H showed no major changes in N2 EPR signals when compared to the 
parental strain. Mutant Y144S displayed clear changes in a region where mainly the gz 
and the gxy signals of iron-sulfur cluster N2 contribute to the spectrum. For mutants 
Y144I and Y144R no N2 signals were visible.  74   3  Results  
 
Figure 3.10: EPR spectra of mitochondrial membranes of tyrosine 144 mutants at 12 K 
and 5 mW microwave power. Field regions where mainly iron-sulfur cluster N2 gives signals 
are highlighted in gray. Y144F, Y144W and Y144H show essentially no difference when 
compared to the parental strain. In Y144S there were significant changes in N2 signals, whereas 
in Y144I and Y144R there were almost no signals arising from iron-sulfur cluster N2. The 
prominent signal at 3340 G in all spectra is due to oxidized iron-sulfur cluster S3 of complex 
III. Mitochondrial membranes (25 mg protein per ml) were reduced with 2 mM NADH. The 
EPR spectra were recorded by Dr. Klaus Zwicker.  3.3  Tyrosine 144 75 
Since small changes in the EPR signals of iron-sulfur cluster N2 cannot be detected in 
mitochondrial membranes, complex I from mutants Y144F and Y144W was purified for 
more detailed EPR analysis. Mutant Y144H had been analysed and described before 
(Kashani-Poor et al., 2001b). Figure 3.11 shows EPR spectra of Y144F and Y144W at 
12 K. Small changes in intensity were evident in the gxy-region where iron-sulfur 
clusters N1, N2, N3 and N4 make contributions. Changes in intensity ratios were 
mainly due to changes in N1 signal intensity, which was also obvious when the gz 
signals from cluster N1 and N2 were compared. Variations in the intensities of iron-
sulfur cluster N1 are often observed for different complex I samples even from the same 
Y. lipolytica strain (Klaus Zwicker, personal communication) and might correlate with 
lipid content in different complex I preparations. Therefore, the observed differences in 
mutant Y144F most likely reflected subtle differences during complex I preparation and 
were not caused by the mutation. 
 
Figure 3.11: EPR spectra of purified complex I from tyrosine mutants Y144F and Y144W 
at 12 K and 1 mW microwave power. Main contributions from individual iron-sulfur clusters 
are indicated. Small differences in the gxy region where iron-sulfur clusters N1, N2, N3 and N4 
give signals are visible. Samples were reduced with 5 mM NADH. Here, purified complex I 76   3  Results  
from the PIPO strain was used as a reference. To compensate for slightly different protein 
concentration, spectra were normalized to equal N3 and N4 signal intensities. The EPR spectra 
were recorded by Dr. Klaus Zwicker. 
It was not possible to directly record EPR spectra from iron-sulfur cluster N2 alone, in 
order to check whether the cluster was unchanged in mutants Y144F and Y144W. 
However, by subtracting 40 K EPR spectra (which contain only signals from iron-sulfur 
cluster N1) from 25 K EPR spectra (which contain signals from iron-sulfur cluster N1 
and N2), spectra from iron-sulfur cluster N2 were obtained. Figure 3.12 shows such 
difference spectra for mutants Y144F and the Y144W. Vertical lines indicate minima 
and maxima from the gz  and the gyx signals of iron-sulfur cluster N2. Since the 
difference spectrum from the parental strain was too noisy to unambiguously indicate 
minima and maxima, a highly concentrated complex I standard was used for this 
purpose. From Figure 3.12 it is obvious that the gyx signal of iron-sulfur cluster N2 was 
shifted towards lower field in mutant Y144W. More importantly, mutant Y144F did not 
change the N2 signal, indicating that iron-sulfur cluster N2 was not affected by 
removing the hydroxyl group of tyrosine 144. 3.3  Tyrosine 144 77 
 
Figure 3.12: 25 K minus 40 K difference EPR spectra from purified complex I of mutants 
Y144F and Y144W compared to the parental strain and to a highly concentrated complex 
I standard. Main contributions from iron-sulfur clusters N2 are indicated. A small shift of the 
gyx signal of iron-sulfur cluster N2 is evident for mutant Y144W. Mutant Y144F displayed no 
differences in signal N2 positions. Samples were reduced with NADH. Here, purified complex I 
from the PIPO strain was used as parental sample. Original 40 K and 25 K EPR spectra were 
recorded at 2 mW microwave power from samples reduced with 5 mM NADH. The EPR 
spectra were recorded by Dr. Klaus Zwicker. 
Considering that even an exchange of tyrosine 144 to tryptophan, histidine or serine did 
not interfere with complex I assembly, it seems unlikely that by removing the hydroxyl 
group in mutant Y144F major conformational changes were induced which were 
responsible for the almost complete loss of complex I activity in mutant Y144F. 
Moreover, a major impact on iron-sulfur cluster N2 is also unlikely to be responsible for 
the loss of activity, since EPR signals from iron-sulfur cluster N2 were unchanged in 
mutant Y144F. 78   3  Results  
Taking into account that tyrosine 144 is located in a central position of the proposed 
quinone binding pocket, very close to iron-sulfur cluster N2 which donates electrons for 
quinone reduction, it is reasonable to speculate that tyrosine 144 plays a critical role in 
quinone reduction. 
3.3.3  Complex I activity at higher DBQ concentrations in mutant 
Y144F  
The very low complex I activity of mutant Y144F might have been a result of a 
decreased affinity for the substrate ubiquinone. Therefore, complex I activity of 
mitochondrial membranes from mutant Y144F was measured at higher DBQ 
concentrations (0-140 µM). However, dNADH:DBQ oxidoreductase activity was not 
increased by higher DBQ concentrations and was only slightly higher than with 
mitochondrial membranes from the Δnucm strain lacking the 49-kDa subunit and hence 
assembled complex I (Figure 3.13). Therefore, the loss of dNADH:DBQ oxidoreductase 
activity in mutant Y144F probably had not been caused by a lowered affinity of the 
quinone binding site to the substrate DBQ. 3.3  Tyrosine 144 79 
 
Figure 3.13: dNADH:DBQ oxidoreductase activity of mutant Y144F at increasing DBQ 
concentrations. In mitochondrial membranes from the parental strain, complex I activity was 
increased by higher DBQ concentrations (in gray). In contrast, no increase was observed in 
mitochondrial membranes from mutant Y144F strain (in red) and the Δnucm strain (in green). 
The latter lacks assembled complex I and was used here as a negative control. Error bars 
indicate standard deviation of three measurements per data point. 
3.3.4  pH dependence of residual activity of mutant Y144F  
To check whether mutant Y144F has changed the pH optimum for quinone reduction, 
complex I activity in mitochondrial membranes was measured at different pH values 
(see Figure 3.14). 80   3  Results  
 
Figure 3.14: Dependence of complex I activity on pH in 
mitochondrial membranes from mutant Y144F. Values and 
fitted curve for mutant Y144F in red, parental strain in gray. The 
parameters used to fit the curve according to the equation given in 
chapter 2.2.3.7 are given in Table 3.11. Data points represent mean 
values from two to four measurements. 
Values obtained for pKA, pKB and Vopt by fitting experimental data (see chapter 2.2.3.7 ) 
are listed in Table 3.11. The differences in the pKA and pKB values were not highly 
significant, since p-values of 0.18 and 0.04, respectively, were determined by an 
unpaired, two-tailed t-test.  
Table 3.11: Parameters determining pH dependence of 
complex I activity in mitochondrial membranes from 
mutant Y144F and the parental strain. 
Strain pKA p KB  Vopt 
parental  5.8 ± 0.1  8.8 ± 0.1  0.77 ± 0.04 
Y144F  5.4 ± 0.3  9.3 ± 0.3  0.1 ± 0.01 
Mean values ± SEM are given. 3.3  Tyrosine 144 81 
Moreover, complex I from both the mutant Y144F and the parental strain reached 
maximal activity at pH 7.3.  
Taken together, the pH dependence was not altered by the Y144F exchange, indicating 
that the hydroxyl group is not involved in protonation/deprotonation events essential for 
complex I activity.  
3.3.5  Reactivation of mutant Y144F  
In an attempt to restore complex I activity of the mutant Y144F, several small 
molecules, sodium chloride (20-400 mM), sodium bromide (0-500 mM), sodium iodide 
(0-400 mM), sodium azide (0-500 mM), sodium formate (0-500 mM) or sodium acetate 
(0-400 mM), were added to mitochondrial membranes prior to the activity measure-
ments. Complex I activity at different additive concentrations was determined and 
Gaussian curves were fitted to the data. The degree of reactivation and the additive 
concentrations which resulted in maximal DQA sensitive complex I activity in mutant 
Y144F are shown in Figure 3.15. Chloride at ~280 mM, bromide at ~150 mM, iodide at 
~150 mM, formate at ~330 mM and acetate at ~270 mM increased complex I activity to 
a different extent in mutant Y144F but decreased complex I activity in the parental 
strain at pH 7.4. In contrast, azide decreased complex I activity in the mutant as well as 
in the parental strain. The inhibitory effect of azide was seen already at the lowest 
concentration of 20 mM and complex I activity gradually decreased with increasing 
azide concentrations. An I50 value of 170 mM was determined for the parental strain 
(data not shown). 82   3  Results  
 
Figure 3.15: Reactivation of DQA sensitive complex I activity by different additives at pH 
7.4.  For most additives there was an optimal concentration, which increases activity in 
mitochondrial membranes from mutant Y144F (red bars). However, the same additive 
concentration decreases activity for the parental strain (gray bars). The dashed line represents 
activities in the absence of the respective additives (or 20 mM in the case of chloride), which 
were set as 100 %. For the parental strain 100 % correspond to 0.65 Units/mg protein. For 
mutant Y144 100 % correspond to 0.08 Units/mg protein.  
As shown in Figure 3.16, the increase in total (DQA sensitive plus DQA insensitive) 
activity in mutant Y144F was less pronounced than that of DQA sensitive complex I 
activity shown in Figure 3.15. This discrepancy results from the inhibition of DQA 
insensitive activity by the additives. 3.3  Tyrosine 144 83 
 
Figure 3.16: Reactivation of total dNADH:DBQ activity by different additives. There was 
an optimal concentration for most additives which increase activity in mitochondrial membranes 
from mutant Y144F (red bars). However, the same additive concentration decreases activity for 
the parental strain (gray bars). Activities measured in the absence of additives (or 20 mM in the 
case of chloride was studied) were set at 100 % and are indicated by the dashed line. For 
parental strain 100 % correspond to 0.71 Units/mg protein. For mutant Y144 100 % correspond 
to 0.14 Units/mg protein. 
As shown in Figure 3.15 and Figure 3.16, the strongest reactivation was observed for 
formate and acetate. Formic acid and acetic acid are weak acids, therefore it is 
reasonable to speculate that donation or abstraction of a proton is partially restoring 
complex I activity in mutant Y144F. Since acetate has a pKa value of 4.75, which is 
closer to the optimal pH for complex I activity than that of formate (3.77), the effect of 
pH in the presence of 300 mM acetate was examined (see Figure 3.17). According to 
the Henderson-Hasselbalch equation, at pH 6.2 the concentration of acetic acid is 10.3 
mM, at pH 6.6 it is 4.2 mM, at pH 7.0 it is ~1.7 mM and at pH 7.4 it is ~0.7 mM. As 
shown in Figure 3.17, there was no qualitative difference between mutant Y144F and 
the parental strain in the dependence of complex I activity on acetic acid concentration. 84   3  Results  
This result argues against the hypothesis that the acids substitute for the hydroxyl group 
in mutant Y144F by facilitating protonation (or deprotonation) events. 
 
Figure 3.17: Reactivation of DQA sensitive complex I activity by acetic acid. The increase 
of complex I activity in mutant Y144F (in red) was not different from that of the parental strain 
(in gray). The activity values for the mutant were multiplied by 3, in order to make them 
graphically comparable to the parental strain. A pH of 6.2 corresponds to 10.3 mM acetic acid, 
pH 6.6 corresponds to 4.2 mM acetic acid, pH 7.0 corresponds to ~1.7 mM acetic acid and pH 
7.4 corresponds to ~0.7 mM acetic acid according to the Henderson–Hasselbalch equation. 
Error bars indicate standard deviation of at least two measurements per data point. 
Taken together, the highest increases in complex I activity, by 30-55 %, were observed 
with acetate, formate and bromide. However, it should be emphasized that for the 
almost inactive Y144F mutant this corresponds to an absolute increase from 7 % to 9-11 
% activity compared to the parental strain without additives. The finding that it was not 
possible to markedly restore complex I activity by the addition of different small 
molecules in mutant Y144F further highlights the essential role of tyrosine 144 and its 
hydroxyl group for ubiquinone reduction.  3.3  Tyrosine 144 85 
3.3.6  dNADH:Q1 oxidoreductase activity in tyrosine 144 mutants 
To assay complex I activity, different hydrophilic quinones are used (Di Virgilio and 
Azzone, 1982; Estornell et al., 1993; Fato et al., 1996; Degli Esposti et al., 1996; Lenaz, 
1998; Hano et al., 2003). DBQ is used predominantly because it gives the highest 
catalytic rates, which – importantly – are almost completely sensitive to complex I 
specific inhibitors. However, often the more hydrophilic Q1 is used as electron acceptor.  
Since tyrosine 144 is predicted to reside close to or to even form part of the quinone 
binding site, and since all mutants displayed almost no ubiquinone-reductase activity 
when DBQ was used, it was tested whether the tyrosine 144 mutants show any 
ubiquinone-reductase activity with Q1. Indeed, when tyrosine 144 was exchanged to 
other aromatic residues, complex I displayed considerable dNADH:Q1 oxidoreductase 
activity. The dependence of the normalized dNADH:Q1 activity on Q1 concentration is 
visualized in Figure 3.18. From these data apparent Km values and Vmax values were 
determined. 86   3  Results  
 
Figure 3.18: Normalized dNADH:Q1 oxidoreductase activity in mitochondrial membranes 
of tyrosine 144 mutants at different concentrations of Q1. The parental strain displayed the 
highest dNADH:Q1 activity. However, the tyrosine 144 mutants did not reach maximal activity 
even at a Q1 concentration of 180 µM, which reflects the increased apparent Km value for the 
mutant enzyme. The dNADH:Q1 oxidoreductase activity was normalized to complex I content 
in the mitochondrial membranes determined as NADH:HAR oxidoreductase activity. The ratio 
is a dimensionless quantity. Error bars indicate the standard error of mean of at least three 
measurements per data point. 
As shown in Table 3.12 the apparent Km value for Q1 was four times higher in mutants 
Y144F and Y144H and even six times higher when tyrosine 144 was exchanged to the 
bulkier tryptophan in mutant Y144W. In order to allow comparison of maximal 
activities from different strains the pseudo Vmax value from the Δnucm strain, which 
lacks complex I, was subtracted and the Vmax values were normalized to complex I 
content of the respective mitochondrial membrane preparations. Mutants Y144F and 
Y144W reached more than 70 % of maximal dNADH:Q1 oxidoreductase activities of 
the parental strain, whereas mutant Y144H reached only 32 % of parental strain activity. 
Interestingly, when the tyrosine was exchanged with non-aromatic residues, dNADH:Q1 
oxidoreductase activity in the respective mitochondrial membranes was very low and 
comparable to the background activity measured in mitochondrial membranes from the 3.3  Tyrosine 144 87 
Δnucm strain. These findings indicate that an aromatic ring at position 144 is essential 
for dNADH:Q1 oxidoreductase activity. 
Table 3.12: Apparent Km values and Vmax values for tyrosine 144 
mutants when Q1 was used as electron acceptor. 
Strain 
app. Km 
for Q1 
Vmax 
with Q1 
Vmax normalized 
to CI content 
a 
 µM  Units/mg  protein  %   
parental 10±1  0.43±0.01 100±2 
Y144F 39±3  0.38±0.01  71±3 
Y144W 62±4  0.47±0.01 77±7 
Y144H
  40±3 0.24±0.01  32±1 
Y144S  n.d. n.d.  n.d. 
Y144I  n.d. n.d.  n.d. 
Y144R  n.d. n.d.  n.d. 
n.d., not determinable  
Mean values ± SEM are given. 
a   for mitochondrial membranes of the Δnucm strain a pseudo Vmax value 
of 0.12 was determined. Since this strain does not contain complex I, 
this value was considered as a complex I unspecific background rate 
and was subtracted from all Vmax values. Complex I content in mito-
chondrial membranes was estimated as NADH:HAR oxidoreductase 
activity (1.03±0.02 µmol·min
-1·mg
-1 was measured for the parental 
strain). The ratio of 0.31/1.03 for the parental strain was set as 100 %.  
3.3.7  dNADH:Q2 oxidoreductase activity of mutants Y144F and 
Y144W  
In mitochondrial membranes from all tyrosine 144 mutants there was almost no 
dNADH:ubiquinone oxidoreductase activity when DBQ or the endogenous ubiquinone 
(Q9 in Y. lipolytica, see chapter 3.1.4) were used, while for mutants Y144F, Y144W and 
the Y144H there was considerable ubiquinone-reductase activity with Q1. In addition, 
especially for mutant Y144W a drastically changed apparent Km value for Q1 was 
observed. Therefore, apparent Km and Vmax values were also determined with Q2 for 
mutants Y144F and Y144W. As shown in Table 3.13, for both mutants the apparent Km 
values were significantly increased but the Vmax values were quite similar to the parental 88   3  Results  
strain after normalizing to complex I content. In comparison to the values determined 
for Q1, the effect on the apparent Km value for Q2 was less pronounced, especially in the 
mutant Y144W, and the Vmax value with Q2 was much closer to that of the parental 
strain. Therefore, in mitochondrial membranes from the tyrosine 144 mutants Q2 
seemed to be an even better electron acceptor than Q1. 
Table 3.13: Apparent Km values and Vmax values for the Y144F and 
Y144W mutants when Q2 was used as electron acceptor. 
Strain 
app. Km 
for Q2 
Vmax 
with Q2 
Vmax normalized 
to CI content 
a 
 µM  Units/mg  protein  %   
parental 8±1  0.46±0.02  100±5 
Y144F 14±2  0.4±0.02  118±4 
Y144W 14±2  0.62±0.03  92±11 
Mean values ± SEM are given. 
a   complex I content in mitochondrial membranes was determined as 
NADH:HAR oxidoreductase activity (1.03±0.02 µmol·min
-1·mg
-1 was 
measured for the parental strain). The ratio of 0.46/1.03 for the 
parental strain was set as 100 %.  
In summary, the dNADH:ubiquinone oxidoreductase activities in mitochondrial 
membranes from the tyrosine 144 mutants strongly depended on the structure of the side 
chain of the ubiquinone-derivative used. 
3.3.8  Inhibitor resistance of the tyrosine 144 mutants 
In order to find out whether tyrosine 144 is also part of the inhibitor binding site, I50 
values for DQA, rotenone, C12E8 and EIPA in the presence of 150 µM Q1 were 
measured. As shown in Table 3.14, the removal of the hydroxyl group of tyrosine 144 
by the Y144F exchange was sufficient to dramatically increase resistance towards DQA 
and rotenone. Even higher resistance was observed when the tyrosine was exchanged 
for the more spacious tryptophan. Interestingly, in both mutants the I50 values for DQA 
were much more strongly increased than the I50 values for rotenone. This might indicate 
that DQA interacts with tyrosine 144 more directly than rotenone. In contrast, the I50 3.3  Tyrosine 144 89 
values for C12E8 and EIPA were only moderately changed in these mutants. This result 
is in line with the finding that C12E8 and EIPA interact with a different region in the 
quinone binding pocket.  
For the 49-kDa subunit mutants V145T, F207W, E218Q R224D, R224I, R224N, 
L225H and L225V the inhibition of the dNADH:Q1 oxidoreductase activity by DQA 
and rotenone was also tested (at 62 µM Q1). In agreement with what was found when 
DBQ was used as an electron acceptor (Table 3.5), the I50 values for DQA and rotenone 
were not changed in any of the mutants (data not shown). 
Table 3.14: I50 values for DQA, rotenone, C12E8 and EIPA determined in 
mitochondrial membranes from tyrosine mutants in the presence of 150 
µM Q1. 
Strain 
I50 
DQA Rotenone C12E8 EIPA 
 nM  µM 
parental 10  900  3000  40 
Y144F  5000 2500 1500  35 
Y144W  7500 4500 1500  33 
 
Taken together, the findings that even conservative mutations of tyrosine 144 almost 
completely abolished dNADH:DBQ oxidoreductase activity, drastically increased the 
apparent Km value for Q1 and caused marked resistance against hydrophobic inhibitors 
suggest that tyrosine 144 is part of the quinone binding site as well as the inhibitor 
binding site of complex I. 
3.3.9  Proton pumping of complex I in mutants Y144F and Y144W  
Since mutants Y144F and Y144W displayed high dNADH:Q1 oxidoreductase activities, 
it was interesting to test whether this redox reaction was connected to vectorial proton 
pumping by complex I. For this purpose, isolated complex I from mutants Y144F and 
Y144W was reconstituted into liposomes and proton pumping was monitored as quench 
in ACMA fluorescence. As shown in Figure 3.19 and Figure 3.20, both mutants were 90   3  Results  
able to pump protons as indicated by the fluorescence quench upon NADH addition. 
Moreover, the pumping rates of the mutants seemed to be similar to the rate of complex 
I from the parental strain, since a coupling factor of 1.9 was determined for proteo-
liposomes from the parental strain and a factor of 2.6 and 2.5 was determined for 
mutants Y144F and Y144W, respectively. In order to verify that the observed quench in 
ACMA fluorescence was indeed caused by a proton gradient, the protonophore FCCP 
was added at the end of each measurement. As expected, the fluorescence quench was 
abolished by addition of FCCP and fluorescence returned to the level before or 
immediately after NADH addition. 
 
Figure 3.19: Proton pumping by mutants Y144F and Y144W assayed as quench in ACMA 
fluorescence. Following the addition of Q1 and NADH, the buildup of a proton gradient across 
proteoliposomes was monitored as a quench in ACMA fluorescence. The line shapes of the 
ACMA fluorescence signal for both mutants were comparable to that of the parental strain, 
indicating that both mutations did not interfere with proton pumping. Arrows indicate time 
points for the additions of 0.5 µM ACMA, 150 µM Q1, 100 µM NADH and 1 µM FCCP. 
Proteoliposomes and 0.5 µM valinomycin were added before measurements were started. 3.3  Tyrosine 144 91 
Figure 3.20 shows that proton pumping by complex I from the parental strain was 
inhibited by rotenone; therefore, ACMA fluorescence reached initial levels after the 
proton gradient was dissipated by proton leakage. In contrast, the quench in ACMA 
fluorescence with mutant Y144F and especially mutant Y144W were much less 
severely affected by the addition of 20 µM of rotenone. This observation may at least 
partially be explained by the higher resistance of the mutants against rotenone. 
 
Figure 3.20: Rotenone resistance of proton pumping by mutants Y144F and Y144W. The 
quench in ACMA fluorescence after NADH addition indicated proton pumping, which in the 
case of the parental strain was sensitive towards rotenone. Proton pumping by mutants Y144F 
and Y144W was almost insensitive towards rotenone. Arrows indicate time points for the 
additions of 0.5 µM ACMA, 150 µM Q1, 100 µM NADH and 20 µM rotenone. Proteoliposomes 
and 0.5 µM valinomycin were added before measurements were started. 
As detailed in Table 3.10, the tyrosine 144 mutants show some residual dNADH:DBQ 
oxidoreductase activity. Therefore, proton pumping by mutants Y144F and Y144W was 
assayed when DBQ was used as an electron acceptor. Both mutants show small but 92   3  Results  
significant proton pumping as indicated by a quench in ACMA fluorescence, which 
again was sensitive to FCCP but largely resistant against rotenone (data not shown). 
The finding that both the high dNADH:Q1 oxidoreductase activity and the marginal 
dNADH:DBQ oxidoreductase activity of the tyrosine mutants resulted in proton 
pumping indicates that both activities reflected the physiological reaction. Moreover, 
these results highlight the tight coupling between redox reaction and vectorial proton 
pumping in complex I.  
3.4  Mutagenesis study of the HRGXE-motif 
3.4.1  The HRGXE-motif in different organisms 
At the N-terminus of the 49-kDa subunit there is a charged and highly conserved 
HRGXE-motif (see Figure 3.21), which is also partially present in most sequences of 
homologous [NiFe] hydrogenases (Albracht, 1993). It is composed of a highly 
conserved histidine, a conserved arginine, an invariant glycine, a variable amino acid 
residue (usually a small and polar one) and a highly conserved glutamate. Interestingly, 
this motif is not conserved in T. thermophilus because the arginine is replaced by the 
much smaller and uncharged threonine. 
Y.lipolytica     EIIRSDPHVGLLHRGTEKLIEYKTYMQALPYFDRLDYVSM 147 
N.crassa         EIVRADPHVGLLHRGTEKLCEYRTYLQALPYFDRLDYVSM 159 
B.taurus         MVRKCDPHIGLLHRGTEKLIEYKTYLQALPYFDRLDYVSM 111 
H.sapiens        MVRKCDPHIGLLHRGTEKLIEYKTYLQALPYFDRLDYVSM 144 
P.denitrificans  IVERADPHIGLLHRGTEKLMESRTYLQNLPYLDRLDYVAP 91 
R.capsulatus     IVERADPHIGLLHRGTEKLMESRTYLQNTPYFDRLDYVAP 91 
T.thermophilus   EVLEVVPHIGYLHTGFEKTMEHRTYLQNITYTPRMDYLHS 90 
E.coli           EIVDCVPDIGYHHRGAEKMGERQSWHSYIPYTDRIEYLGG 87 
                  :    *.:*  * * **  * ::: .  .*  *::*:   
Figure 3.21: Sequence alignment of the N-terminal part of the 49-kDa subunit harboring 
the HRGXE-motif. The HRGXE-motif of Y. lipolytica is shaded in pink. Conserved residues 
within the motif are shown in bold. Sequences were aligned with the multiple sequence 
alignment program ClustalW. Invariant (*), highly (:) and weakly similar (.) positions are 
labeled. For the complete alignment see Figure 8.1. 3.4  Mutagenesis study of the HRGXE-motif 93 
3.4.2  Location of the HRGXE-motif 
As shown in Figure 3.22, the residues of the HRGXE-motif are not located at the 
surface of the proposed ubiquinone and inhibitor binding pocket of complex I. The 
HRGXE-motif is rather buried in the 49-kDa subunit and spans a distance of ~13 Å 
from iron-sulfur cluster N2 to the 30-kDa subunit, which is adjacent to the 49-kDa 
subunit. 
 
Figure 3.22: Location of the HRGXE-motif close to iron-sulfur cluster N2 but at some 
distance from the ubiquinone and inhibitor binding pocket. Amino acid residues of the 
HRGXE-motif are shown in stick representation and are highlighted in pink. Iron-sulfur cluster 
N2 is shown in gray as space-filled model. The 49-kDa, PSST, 30-kDa and TYKY subunits are 
shown in schematic representation. For better orientation, a view into the ubiquinone and 
inhibitor binding pocket similar to that in Figure 3.3 was chosen. Tyrosine 144, which delimits 
the left border of the ubiquinone binding pocket in this view, is shown in white sticks. The 
figure was generated from the crystal structure of the hydrophilic domain of complex I from T. 
thermophilus (PDB ID: 2FUG) by using the PyMOL program.  94   3  Results  
3.4.3  Complex I assembly and activity of the HRGXE-motif mutants 
In order to gain insights into the function of the HRGXE-motif, histidine 120, arginine 
121, glycine 122 and glutamate 124 in the 49-kDa subunit of Y. lipolytica were 
exchanged by mutation. The effects of the mutations on complex I content, complex I 
activity and the EPR signal of iron-sulfur cluster N2 in mitochondrial membranes as 
compared to the parental strain are summarized in Table 3.15. The exchange of histidine 
120 to arginine or tryptophan impeded complex I assembly. The histidine to alanine 
exchange introduced earlier (Kashani-Poor et al., 2001b) interfered with complex I 
activity only. The conservative exchange of arginine 121 to lysine resulted in a strong 
decrease in complex I content and activity, indicating that this arginine is crucial for 
complex I from Y. lipolytica. The exchange of glycine 122 to the small alanine residue 
did not alter complex I content and activity. However, when the larger valine residue 
was introduced into this position, complex I content was dramatically decreased. The 
same was true when glutamate 124 was exchanged with the slightly smaller aspartate or 
arginine. Interestingly, exchanging glutamate 124 with the similar sized but uncharged 
glutamine resulted in decreased complex I content; however, specific complex I activity 
was not changed. These results suggest that size and charge of the residue at position 
124 are important for proper folding of the 49-kDa subunit and the assembly of 
complex I, but not for complex I activity.  
Table 3.15: Effects of mutations introduced into the HRGXE-motif of the 
49-kDa subunit on complex I content, activity and N2 EPR signal in 
mitochondrial membranes from Y. lipolytica. 
Strain 
Complex I 
content 
a 
Complex I 
activity 
b 
N2 EPR signal 
(see Figure 3.23) 
 %  %   
parental 100±3  100±5  reference 
H120A 
c 93 39  not  altered 
H120R 20±1  n.d. n.d. 
H120W 22±1  n.d. n.d. 
R121K  38±2  24±1  no complex I signals 
G122A 120±3  96±8  not  altered 
G122V 25±1  n.d.  n.d. 3.4  Mutagenesis study of the HRGXE-motif 95 
Strain 
Complex I 
content 
a 
Complex I 
activity 
b 
N2 EPR signal 
(see Figure 3.23) 
 %  %   
parental 100±3  100±5  reference 
E124D 29±1  n.d.  n.d. 
E124R 
d 31 12 n.d. 
E124Q  55±1  98±2  weaker signal intensities 
Mean values ± SEM are given. 
n.d., not determinable 
a 100 % of complex I content corresponds to 1.25 µmol·min
-1·mg
-1 
NADH:HAR oxidoreductase activity determined for the parental strain.  
b DQA sensitive complex I specific dNADH:DBQ oxidoreductase activity 
(0.58 µmol·min
-1·mg
-1 was measured for the parental strain) was normalized 
to complex I content. The ratio of 0.58/1.25 for the parental strain was set as 
100 % complex I activity. 
c  data from (Kashani-Poor et al., 2001b) 
d  data from (Grgic, Ph.D. Thesis, University Frankfurt, 2004) 
3.4.4  EPR spectra from mutants of the HRGXE-motif 
For mutants having a complex I content of at least 35 %, also EPR spectra from 
mitochondrial membranes were recorded. Iron-sulfur clusters were reduced with 2 mM 
NADH and EPR spectra were recorded at 12 K and 5 mW microwave power. 
Unfortunately, hardly any complex I specific EPR signals could be detected for mutant 
R121K (see Figure 3.23), probably due to low complex I content. The EPR spectrum 
from mutant G122A was not significantly different from that of the parental strain (see 
Figure 3.23). In mutant E124Q lower complex I specific EPR signal intensities reflected 
lower content of assembled complex I (see Figure 3.23). Aside from this, EPR signals 
for iron-sulfur cluster N2 were not significantly altered.  96   3  Results  
 
Figure 3.23: EPR spectra of mitochondrial membranes from the HRGXE-motif mutants 
at 12 K and 1 mW microwave power. Field regions where signals mainly from iron-sulfur 
cluster N2 arise are highlighted in gray. The spectrum of mutant G122A was not significantly 
different from the spectrum of the parental strain. Spectra of mutants R121K and E124Q show 
no or markedly reduced signal intensities of iron-sulfur cluster N2, respectively. The higher 
signal/noise ratio in mutant E124Q was due to lower complex I content. Mitochondrial 
membranes (~25 mg protein per ml) were reduced with 2 mM NADH. Spectra were recorded by 
Dr. Klaus Zwicker. 
Similar observations were made when EPR spectra were recorded at 40 K for individual 
analysis of binuclear clusters (data not shown). Likewise the addition of the stronger 
reductant dithionite did not result in any complex I specific changes in EPR spectra 
(data not shown). As shown earlier (Kashani-Poor et al., 2001b), the EPR spectrum of 
complex I from mutant H120A is unchanged. 3.5  Mutagenesis of the 24-kDa subunit close to iron-sulfur cluster N1a 97 
3.4.5  Apparent Km and I50 values for mutants of the HRGXE-motif 
For mutants which had at least 25 % of complex I activity, also apparent Km values for 
DBQ and I50 values for DQA and rotenone were determined (Table 3.16). Values for 
mutant G122A were not different from the values for the parental strain. However, 
mutants H120A and E124Q displayed slight effects on the apparent Km value for DBQ 
and on the I50 value for DQA, which might indicate that the ubiquinone and inhibitor 
binding pocket was distorted in these mutants, since histidine 120 and glutamate 124 are 
not located at the proposed ubiquinone and inhibitor binding pocket (see Figure 3.22). 
Table 3.16: Effects on inhibitor sensitivity and ubiquinone 
affinity of mutations introduced into the HRGXE-motif of 
the 49-kDa subunit in mitochondrial membranes from Y. 
lipolytica. 
Strain 
app. Km 
for DBQ 
I50
 
DQA Rotenone 
 µM  nM 
parental 15 16  530 
H120A 
a 9 
b 24
 a 580
 a 
G122A 12  17  600 
E124Q 6  12  500 
a  data from (Kashani-Poor et al., 2001b) 
b  data from (Kashani-Poor, Ph.D. Thesis, University Frankfurt, 2000) 
3.5  Mutagenesis of the 24-kDa subunit close to iron-sulfur 
cluster N1a 
3.5.1  Selection of targeted residues 
Iron-sulfur cluster N1a ligated by the 24-kDa subunit is considered to be EPR silent in 
complex I from Y. lipolytica due to its very low redox midpoint potential, which does 
not allow its reduction by NADH or dithionite (see chapter 1.2.6). As reviewed by 
(Stephens et al., 1996), the redox midpoint potential of iron-sulfur clusters depends on 
the surrounding protein matrix.  98   3  Results  
In order to make iron-sulfur cluster N1a reducible and hence EPR detectable, point 
mutations were introduced which should increase the redox midpoint potential of iron-
sulfur cluster N1a. Therefore valine166, alanine 175 and methionine 177 located next to 
the C-terminal part of the N1a binding motif (see Figure 3.24) in the 24-kDa subunit 
were exchanged for polar or even positive amino acid residues.  
                  127  132                                   168 172 
                   ↓    ↓                                     ↓   ↓ 
Y.lipolytica     QICTTTPCQL--CGSDGIMEAVQNTLNIKPGETTKDNLFTLSEVECLGACVNAPMMA 180 
N.crassa         QACTTTPCQLGGCGSDVIVKAIKEHLGIKQGETTPDGLFTFIEVECLGACANAPMVQ 198 
H.sapiens        QVCTTTPCMLR--NSDSILEAIQKKLGIKVGESTPDKLFTLIEVECLGACVNAPMVQ 188 
B.taurus         QVCTTTPCMLR--NSDSILEAIQKKLGIKVGETTPDKLFTLIEVECLGACVNAPMVQ 188 
P.denitrificans  QICGTTTCMIC--GAEDLIRVCKEKIAPEPHALSADGRFSWEEVECLGACTNAPMAQ 149 
T.thermophilus   QVCATLSCKLA--GAEELWDYLTETLGIGPGEVTPDGLFSVQKVECLGSCHTAPVIQ 136 
E.coli           RYCDSVVCHIN--GYQGIQAALEKKLNIKPGQTTFDGRFTLLPTCCLGNCDKGPNMM 145 
R.marinus        DVCTCFTCQVC--GGYDILHYLEEKLGIHKGETTPDGLFTLQEVECLGACGSAPVLQ 158 
                   *    * :   .   :     : :       : *  *:   . *** * ..*    
Figure 3.24: Sequence alignment of the binding motif of iron-sulfur cluster N1a within the 
24-kDa subunit. Cysteine ligands of iron-sulfur cluster N1a are highlighted in green and are 
labeled according to Y. lipolytica numbering. Amino acid residues which were exchanged to 
increase the redox midpoint potential of iron-sulfur cluster N1a are highlighted in red. 
Sequences were aligned by the multiple sequence alignment program ClustalW. Invariant (*), 
highly (:) and weakly similar (.) positions are labeled. For the complete alignment see Figure 
8.4. 
In Figure 3.25, the spatial arrangement of the targeted amino acid residues relative to 
iron-sulfur cluster N1a and its cysteine ligands in the X-ray structure from T. 
thermophilus is shown. Since the ligation and coordination of an iron-sulfur cluster is 
expected to be highly conserved, a similar arrangement in the 24-kDa subunit from Y. 
lipolytica can be inferred. Therefore, the hydrophobic residues valine 166 and alanine 
175 reside most probably at a distance of 8-9 Å from iron-sulfur cluster N1a. 
Methionine 177 is expected to be located only few Ångströms from iron-sulfur cluster 
N1a. 3.5  Mutagenesis of the 24-kDa subunit close to iron-sulfur cluster N1a 99 
 
Figure 3.25: Ligation and coordination of iron-sulfur cluster N1a within the 
24-kDa subunit. Iron-sulfur cluster N1a is located at the interface between the 
24-kDa and the 51-kDa subunit, shown in blue and cyan schematic representation, 
respectively. Ligating cysteines and amino acids residues which were exchanged in 
order to increase the redox midpoint potential of iron-sulfur cluster N1a are shown 
in stick representation and are colored in green and red, respectively. Sulfur atoms 
of the amino acid residues are colored in yellow. Numbers indicate the distance 
between atoms in Ångströms. The figure was generated from the crystal structure 
of the hydrophilic domain of complex I from T. thermophilus (PDB ID: 2FUG) 
using the PyMOL program. The mutagenesis wizard from the PyMOL package 
was used to exchange valine 133 of T. thermophilus to methionine 177 of Y. 
lipolytica. Based on steric constraints, the most likely methionine conformation 
was chosen. 
3.5.2  Assembly and activity of complex I mutants 
The impact of the point mutations on the content and activity of complex I as well as on 
the EPR spectrum at 40 K, where binuclear iron-sulfur clusters show signals, are 
summarized in Table 3.17. Exchanging the conserved valine 166 to the similar sized, 
however polar threonine, had no effect on complex I content and activity. Surprisingly, 
this was also true when this valine was exchanged with the more spacious and charged 
lysine. When the conserved alanine 175 was exchanged with the polar serine, this had 
no effect on content and activity of complex I. An exchange to lysine dramatically 100   3  Results  
reduced complex I content. Exchange of methionine 177 to histidine was well tolerated 
by complex I with respect to content and activity. However, introducing lysine resulted 
in a dramatic decrease of complex I content. 
Table 3.17: Effects of mutations introduced next to 
iron-sulfur cluster N1a in the 24-kDa subunit on 
mitochondrial membranes from Y. lipolytica. 
Strain 
Complex I 
content 
a 
Complex I 
activity 
b 
EPR signals 
at 40 K 
(Figure 3.26)
 %  %   
parental 100±2  100±6  reference 
V166T 123±2  89±4  not  altered 
V166K 105±4  107±7  not  altered 
A175S 101±2  115±3  not  altered 
A175K 20±1  n.d. n.d. 
M177H 90±3  90±5  not  altered 
M177K 19±1  n.d. n.d. 
Mean values ± SEM are given. 
n.d., not determinable 
a  100 % of complex I content corresponds to 1.3 
µmol·min
-1·mg
-1 NADH:HAR oxidoreductase activity 
determined for the parental strain.  
b  DQA sensitive complex I specific dNADH:DBQ 
oxidoreductase activity (0.64 µmol·min
-1·mg
-1 was measured 
for the parental strain) was normalized to complex I content. 
The ratio of 0.64/1.3 for the parental strain was set as 100 % 
complex I activity. 
The flavoprotein part of complex I, which is composed of the 24-kDa and the 51-kDa 
subunits, and especially the FMN molecule in the 51-kDa subunit are essential for 
NADH:HAR oxidoreductase activity (Gavrikova et al., 1995).  
Since a mutagenesis of the 24-kDa subunit could have an impact on the adjacent 
51-kDa subunit, the values for complex I content given in Table 3.17 might not be 
reliable. Therefore, complex I content was also assessed by 2D gels (Tricine-SDS-
PAGE after blue-native PAGE) following silver staining. 2D gels verified that in 3.5  Mutagenesis of the 24-kDa subunit close to iron-sulfur cluster N1a 101 
contrast to mutants V166T, V166K, A175S and M177H, there was no assembled 
complex I in mitochondrial membranes from mutants A175K and M177K (data not 
shown). Moreover, 2D gels also revealed that the 24-kDa subunit mutations did not 
result in a subcomplex of complex I, which lacks the flavoprotein part. 
3.5.3  EPR spectra of the N1 signal 
Mitochondrial membranes from mutant strains which had a complex I content of at least 
30 % were analyzed by EPR. No changes in the line shape of the N1 signal were visible 
and no additional EPR signal appeared when mitochondrial membranes were reduced 
with 2 mM NADH and spectra were recorded at 40 K and 5 mW microwave power (see 
Figure 3.26).  
Just the spectrum from mutant V166T distinctly differed from the parental strain 
spectrum in signal intensities. However, this difference most probably originated from 
the higher complex I content in mitochondrial membranes from this mutant (see Table 
3.17). 102   3  Results  
 
Figure 3.26: EPR spectra of mitochondrial membranes from point mutants close to 
iron-sulfur cluster N1a recorded at 40 K and 5 mW microwave power. Signals arising from 
iron-sulfur cluster N1 are shaded in gray. The mutant spectra were not significantly different 
from the parental strain spectrum. Mitochondrial membranes (~20 mg protein per ml for mutant 
V166K, ~25 mg protein per ml for all other strains) were reduced with 2 mM NADH. EPR 
spectra were recorded by Dr. Klaus Zwicker. 
The finding that there were no significant changes in the EPR spectra indicates that the 
redox midpoint potential of iron-sulfur cluster N1a was not sufficiently increased by the 
point mutations to allow reduction of iron-sulfur cluster N1a with NADH to any 
considerable extent. 
Therefore, also the stronger reductant dithionite was used to reduce mitochondrial 
membranes. Dithionite has a lower redox potential (E
o' ~ -420 mV) than NADH (E
o' ~ 
-320 mV) and could possibly have reduced iron-sulfur cluster N1a when the mutation 
only moderately elevated the redox midpoint potential. However, EPR spectra of 
mutants recorded at 40 K and 5 mW microwave power were unchanged (data not 
shown). This was also true when EPR spectra from mitochondrial membranes reduced 3.5  Mutagenesis of the 24-kDa subunit close to iron-sulfur cluster N1a 103 
with NADH alone or with NADH and dithionite were recorded at different settings 
(12K and 5 mW microwave power; data not shown). These results indicate that the shift 
in the redox midpoint potential of iron-sulfur cluster N1a, if any, was not sufficient to 
make iron-sulfur cluster N1a reducible and hence EPR detectable. Alternatively, low 
redox midpoint potential of iron-sulfur cluster N1a is not the reason for its EPR silence. 
3.5.4  Mutagenesis of iron-sulfur cluster N1a ligands 
It is possible that the N1 EPR signal is composed of the EPR signal of iron-sulfur 
cluster N1b and some minor contributions from iron-sulfur cluster N1a. Under this 
assumption, changes in the N1 EPR signal could become detectable when iron-sulfur 
cluster N1a was lost completely. To selectively eliminate iron-sulfur cluster N1a, two of 
the four cysteine ligands were individually exchanged to alanines.  
The exchange of cysteine 168 or cysteine 172 in the 24-kDa subunit to alanine resulted 
in strongly decreased complex I content (see Table 3.18). Therefore, it was not possible 
to record EPR spectra from the cysteine mutants. 
Table 3.18: Effects of mutations introduced 
into the cysteine ligands of iron-sulfur 
cluster N1a in mitochondrial membranes 
from Y. lipolytica. 
Strain 
Complex I 
content 
a 
Complex I 
activity 
b 
 %  % 
parental 100±2  100±6 
C168A 13±1  n.d. 
C172A 24±1  n.d. 
Mean values ± SEM are given. 
n.d., not determinable 
a  100 % of complex I content corresponds to 
1.3 µmol·min
-1·mg
-1 NADH:HAR oxido-
reductase activity determined for the parental 
strain.  
b  DQA sensitive complex I specific 
dNADH:DBQ oxidoreductase activity (0.64 
µmol·min
-1·mg
-1 was measured for the 
parental strain) was normalized to complex I 104   3  Results  
content. The ratio of 0.64/1.3 for the parental 
strain was set as 100 % complex I activity. 
Since complex I content was assessed as NADH:HAR oxidoreductase activity, which 
requires the 51-kDa subunit, a decrease in NADH:HAR oxidoreductase activity in the 
24-kDa subunit mutants could be due to a disordered 51-kDa subunit without an effect 
on complex I assembly, or might have resulted in a subcomplex of complex I lacking 
the flavoprotein part only. However, silver stained 2D gels excluded both possibilities, 
showing that there was neither an assembled complex I, nor a subcomplex of complex I 
in mitochondrial membranes from mutant C168A and C172A (data not shown). 4.1  Exploring the proposed ubiquinone and inhibitor binding cavity 105 
4  Discussion 
4.1  Exploring the proposed ubiquinone and inhibitor binding 
cavity 
Based on the crystal structure of the hydrophilic domain of complex I from T. 
thermophilus (Sazanov and Hinchliffe, 2006), a large number of point mutations were 
introduced in order to systematically explore the entire surface of the proposed quinone 
and inhibitor binding pocket of complex I.  
4.1.1  Mapping of mutation effects into the structure  
Only very few mutations interfered with complex I assembly; however, many mutants 
decreased complex I activity to various extents (see Table 3.1). Clearly, the effects of 
the mutations should be discussed in the context of their location within the large 
putative quinone binding pocket. However, a valid interpretation of the data rests on the 
assumptions that the used structure adequately represents the putative quinone binding 
pocket of Y. lipolytica and that each point mutation primarily has a local impact. Since 
the crystal structure of complex I from Y. lipolytica or any other eukaryote has not been 
solved yet, only the structure of the hydrophilic domain from T.  thermophilus  is 
available (Sazanov and Hinchliffe, 2006). In Figure 4.1, the degree of conservation of 
the proposed quinone binding pocket between Y.  lipolytica and T.  thermophilus is 
illustrated. Invariant residues are highlighted in red, highly similar and weakly similar 
residues are colored in orange and yellow, respectively (see the corresponding multiple 
sequence alignment in Figure 8.1 and Figure 8.2). Indeed, it seems that especially amino 
acid residues within the proposed quinone and inhibitor binding cavity are highly 
conserved. Minor differences may reflect the fact that complex I from T. thermophilus 
uses menaquinone as a substrate (Yano et al., 1997). 
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Figure 4.1: Conserved regions within the quinone and inhibitor binding cavity. Same view 
as in Figure 3.3. A, surface representation. B, schematic representation, amino acid residues are 
shown in stick representation, iron-sulfur cluster N2 is shown in gray as space-filled model. 
Amino acid residues are colored according to their conservation between Y. lipolytica and T. 
thermophilus: red, invariant residues; orange, highly similar; yellow, weakly similar residues. 
Amino acid residues from the PSST subunit which are not conserved are colored in cyan. Not 
conserved residues from the 49-kDa subunit are colored in purple (see Figure 8.1 for the 
corresponding multiple sequence alignment). Especially amino acid residues from the proposed 
quinone binding cavity are highly conserved between Y. lipolytica and T. thermophilus. 
However, phenylalanine 132, alanine 398 and proline 402 from the 49-kDa subunit of T. 
thermophilus located in the left part of the pocket, distal to iron-sulfur cluster N2, are changed 
to serine 189 (in purple, hidden in A), glycine 445 (in yellow) and leucine 459 (in purple) in Y. 
lipolytica, respectively – possibly owing to the fact that complex I from T. thermophilus uses 
menaquinone as a substrate (Yano et al., 1997). Amino acid residues from the TYKY subunit 
(beige) were not analyzed. The figure was generated from the crystal structure of the 
hydrophilic domain of complex I from T. thermophilus (PDB ID: 2FUG) by using the PyMOL 
program. The mutagenesis wizard of the PyMOL package was used to match the Y. lipolytica 
sequence when a residue was not conserved between T. thermophilus and Y. lipolytica. 
Several observations indicate that the effects of the introduced point mutations are 
rather local. (i) When mitochondrial membranes carrying the most drastic changes at 
almost all positions were analyzed by EPR, the spectra of iron-sulfur cluster N2 were 
unchanged in almost all cases (see Figure 3.1 and Figure 3.2), indicating that no long 
range rearrangements were induced by the mutations. The only exceptions were some 
drastic exchanges of tyrosine 144 (see Figure 3.10). However, this observation most 
likely rather reflects the close proximity of tyrosine 144 to iron-sulfur cluster N2 than 
global structural changes of the quinone and inhibitor binding pocket. (ii) Only 8 out of 
94 mutations interfered with complex I assembly (see Table 3.1). (iii) According to the 
structure from T. thermophilus, the exchanged amino acid residues are all located at the 
surface of the proposed quinone and inhibitor binding cavity (see Figure 3.3); therefore, 
the integration of very different side chains without changing the overall structure 
seems feasible. 
Since the proposed quinone and inhibitor binding cavity is quite conserved and the 
effects of the point mutations are probably rather local, it seems valid to map the effects 
of the mutations into the structure of the proposed quinone and inhibitor binding cavity 
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4.1.2  Identification of functional domains  
Not individual mutations but the careful analysis of a large number of systematically 
chosen mutations allows the identification of domains which are critical, less critical 
and not critical for complex I activity. As illustrated in Figure 3.3, most residues that are 
critical for complex I activity form a path reaching from a loop in the N-terminal three 
stranded β-sheet into the cavity to tyrosine 144 located next to iron-sulfur cluster N2 
(colored in red). Residues located around this area are less critical for complex I activity 
(colored in yellow and green). Interestingly, residues located deeper in the cavity, where 
the PSST and the 49-kDa subunits form a narrow crevice, can be exchanged without a 
major effect on complex I activity (colored in blue). However, they still must have an 
important function, since some of them like glutamate 218 and arginine 224, are highly 
conserved (see Figure 8.1). One can speculate that they are involved in regulating 
complex I activity or might help to prevent ROS production at the putative quinone 
binding site. 
Amino acid residues which are critical for complex I activity and are located close to 
iron-sulfur cluster N2, like tyrosine 144 and valine 460 in the 49-kDa subunit, are 
probably involved in quinone binding and reduction. Especially the highly conserved 
tyrosine 144 is very critical. This residue is located only 6-8 Å away from iron-sulfur 
cluster N2 and all exchanges introduced at this position resulted in almost complete loss 
of dNADH:DBQ activity (see Table 3.10). This was even the case for the very 
conservative exchange Y144F by which only the hydroxyl group was removed. 
Moreover, it was not possible to reactivate complex I activity in this mutant with a 
variety of salts (see Figure 3.15 and Figure 3.16). EPR spectra from mitochondrial 
membranes of the drastic mutants Y144R, Y144S and Y144I showed that the N2 signal 
was severely affected, as expected from the close proximity of this residue to iron-sulfur 
cluster N2 (see Figure 3.10). Consistently, the more conservative exchanges Y144H and 
Y144W exerted only minor effects on the EPR signal of iron-sulfur cluster N2 (see 
Figure 3.10, Figure 3.11, Figure 3.12 and (Kashani-Poor et al., 2001b)). Importantly, an 
unchanged N2-signal was recorded from mitochondrial membranes as well as from the 
purified enzyme with the most conservative exchange Y144F (see Figure 3.12). This 
indicated that loss of activity in the Y144F mutant resulted from perturbation of quinone 
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Histidine 95 in the 49-kDa subunit is also critical for complex I activity (see Table 3.1). 
However, this histidine is located at least 16 Å (edge-to-edge distance) away from iron-
sulfur cluster N2, too far away for efficient electron tunneling at catalytic sites (Page et 
al., 1999; Moser et al., 2006b). Therefore it seems that histidine 95 and other critical 
residues located at some distance to iron-sulfur cluster N2 form an access path for the 
substrate quinone. The same could apply for histidine 91 (Grgic et al., 2004), aspartate 
99, aspartate 115, aspartate 136 and glutamate 140 in the PSST subunit (Garofano et al., 
2003; Ahlers et al., 2000). As an alternative explanation, currently it cannot be excluded 
that this part of the enzyme is so critical because it is involved in the tight coupling of 
the redox reaction to the conformational changes leading to proton translocation across 
the inner mitochondrial membrane. Similarly, exchanges of conserved amino acid 
residues located in the hydrophobic subunits ND1 (Zickermann et al., 1998; Kurki et al., 
2000; Kervinen et al., 2006), ND2 (Amarneh and Vik, 2003), ND3 (Kao et al., 2004a), 
ND4 (Majander et al., 1996; Torres-Bacete et al., 2007; Euro et al., 2008a), ND4L 
(Kervinen et al., 2004; Kao et al., 2005b), ND5 (Majander et al., 1996) and ND6 (Kao 
et al., 2005a; Pätsi et al., 2008) not only interfered with proton translocation but also 
with NADH:Q oxidoreductase activity of complex I. Since residues from these subunits 
are not located next to the proposed quinone binding pocket close to iron-sulfur cluster 
N2 (Sazanov and Hinchliffe, 2006), it seems that they are involved in the tight coupling 
of the redox reaction to proton pumping and that it is not possible to generate an 
“ideally uncoupled phenotype” in complex I per se (Euro et al., 2008a; Zickermann et 
al., 2008; Zickermann et al., 2009). 
4.1.3  Role of tyrosine 144 
Mutations which affect the proposed quinone binding site should change the affinity of 
the enzyme to the substrate. Interestingly, no mutant with considerable activity 
displayed a significantly altered apparent Km value for DBQ (see Table 3.1). However, 
drastically increased apparent Km values for Q1 along with moderately decreased 
dNADH:Q1 oxidoreductase activities were found in some tyrosine 144 mutants (see 
Table 3.12). Moreover, in mutants Y144F and Y144W significantly increased apparent 
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activity were measured (see Table 3.13), indicating that the quinone binding site was 
indeed targeted in this study. 
Proton pumping experiments with complex I from mutants Y144F and Y144W clearly 
showed that the dNADH:Q1 oxidoreductase activity was coupled to proton pumping 
(see Figure 3.19 and Figure 3.20), hence Q1 reduction must take place at the 
physiological site. These data also demonstrated that the tyrosine was not absolutely 
essential for proton pumping. However, it would be interesting to determine whether the 
tyrosine mutants pump protons at the same stoichiometry as the parental strain.  
There are several possibilities concerning the precise role of tyrosine 144 in the 
catalysis of quinone reduction: (i) Tyrosine 144 might be involved in governing 
conformational and/or electrostatic changes necessary for quinone binding and release. 
However, it seems unlikely that the absence of one hydroxyl group in mutant Y144F 
would lead to such a dramatic effect on activity (see Table 3.10), which in addition 
would depend on the quinone side chain (see Table 3.10, Table 3.12 and Table 3.13). 
(ii) Tyrosine 144 might be involved in protonating the semiquinone by its hydroxyl 
group. The results of reactivation attempts (see chapter 3.3.5) and the finding that the 
pH dependence of the residual activity of the Y144F mutant was unchanged (see Figure 
3.14 and Table 3.11) provide no support for this assumption; however it cannot be 
excluded that the active site is not accessible from the bulk phase during critical 
catalytical steps. Also, it is hard to envision how protonation of the semiquinone by the 
hydroxyl group would depend on the quinone side chain. (iii) Tyrosine 144 might be 
involved in electron transfer from iron-sulfur cluster N2 to the quinone. This seems 
unlikely, since the distance between donor and acceptor is much more critical for 
electron transfer than the protein matrix (Page et al., 1999; Moser et al., 2006b) and a 
tyrosine radical was never observed in complex I. Alternatively, tyrosine 144 might 
have an indirect effect on the electron transfer from iron-sulfur cluster N2. However, a 
direct or indirect effect again would not explain the difference observed with different 
quinone side chains. (iv) Tyrosine 144 might be involved in stabilization of the 
transition state, but this seems rather unlikely, since this should slow down the 
enzymatic reaction for all quinone substrates irrespective of the quinone side chain. (v) 
Tyrosine 144 might be involved in making sure that the quinone binds in a proper 
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and the quinone head group could explain why an increased apparent Km value for Q1 
and Q2 was observed in the Y144F mutant. However, the aromatic feature of tyrosine 
144 seems to be critical as well, since considerable dNADH:Q1 oxidoreductase activity 
was found only in the Y144F, Y144W and Y144H mutants. Therefore, tyrosine 144 
might help orientating the quinone substrate via stacking of the aromatic moieties.  
Taken together, it seems that tyrosine 144 is important for quinone binding and 
orientation at the quinone binding site by both hydrogen bonding and aromatic 
interactions.  
4.1.4  Properties of different quinone substrates 
Interestingly, for mitochondrial membranes from the parental strain the apparent Km 
value for Q2 was found to be smaller than that for Q1, which in turn was smaller than 
that for DBQ (see Table 3.1, Table 3.12 and Table 3.13). With partition coefficients (log 
P cyclohexane/water) of 5.1, 2.65 and 7.2, respectively (Degli Esposti et al., 1996; 
Lenaz, 1998), these quinones are all very hydrophobic, which means that almost all the 
substrate distributes to the membrane bilayer and only a small negligible fraction is 
dissolved in the aqueous phase. Thus, taking the differences in the partition coefficients 
into account would not change the general outcome that the highest affinity was 
observed for the quinone with two isoprene units whereas the lowest affinity was 
observed for the quinone with the decyl side chain. This result is consistent with what 
was found for complex I from B. taurus (Fato et al., 1996; Lenaz, 1998; Hano et al., 
2003) and P. denitrificans (Zickermann et al., 1998; Kurki et al., 2000) and further 
supports the finding that the structure of the quinone side chain is specifically 
recognized by complex I, as demonstrated earlier (Sakamoto et al., 1998). An important 
consequence of these results is that in future assays Q1 or Q2 should be used to 
determine apparent Km values for the quinone substrate. DBQ seems to be unsuitable 
for this purpose, since mutations could further decrease the already low affinity of DBQ 
to the binding site, which could result in loss of activity, as seems to be the case for the 
Y144F, Y144W and Y144H mutants. However, DBQ is the substrate of choice to assay 
maximal NADH:Q oxidoreductase activity of complex I, since it gives higher rates than 
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dNADH:DBQ oxidoreductase activity reflects complex I activity with endogenous Q9 
better than the dNADH:Q1 oxidoreductase activity (see Table 3.3 and Table 3.4).  
4.1.5  The inhibitor binding sites 
Some photoaffinity labeling studies identified the PSST (Schuler et al., 1999; Schuler 
and Casida, 2001b; Nakamaru-Ogiso et al., 2003a) and the 49-kDa subunits (Nakamaru-
Ogiso et al., 2003a; Ichimaru et al., 2008; Murai et al., 2009) to comprise the binding 
site of specific complex I inhibitors. Consistently, several exchanges at the proposed 
quinone binding pocket described here displayed drastic effects on the sensitivity of 
complex I towards specific inhibitors (see Table 3.5 and Table 3.6), further confirming 
the concept that hydrophobic complex I inhibitors act on the putative quinone binding 
pocket located at the interface of the 49-kDa and PSST subunit (Darrouzet et al., 1998; 
Kashani-Poor et al., 2001b; Prieur et al., 2001; Kerscher et al., 2001c; Brandt et al., 
2003; Kerscher et al., 2005).  
Furthermore, the results presented here show that different types of inhibitors 
apparently bind to distinct and well defined regions within the large quinone binding 
cavity (see Figure 3.4). Exchanges which affected inhibition by the type A inhibitor 
DQA and the type B inhibitor rotenone clustered in a subdomain of the quinone binding 
pocket corresponding to the former [NiFe] site in homologous hydrogenases. Thus, 
DQA seems to penetrate deeper into this subdomain. Exchanges which affected 
inhibition by the type C inhibitor C12E8 were found in a different region, where the 
49-kDa and the PSST subunits form a narrow crevice. This is consistent with the 
classification of complex I inhibitors (Friedrich et al., 1994; Degli Esposti and Ghelli, 
1994; Degli Esposti, 1998) which was rightly criticized as rather arbitrary (Okun et al., 
1999a). Not surprisingly, changing more exposed residues located inbetween the 
putative binding sites of type A, B and C inhibitors affected inhibition by all three 
inhibitors. These results confirmed the earlier concept that different types of complex I 
inhibitors bind to different but partially overlapping binding sites within a large quinone 
binding pocket as revealed by direct competition binding assays (Okun et al., 1999a). 
However, the interpretation of the competition binding assays results was questioned. It 
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negative allosteric effects, i.e. that the binding of one inhibitor to one binding site 
induces structural changes which prevent the binding of another inhibitor to a remote 
binding site (Schuler and Casida, 2001a; Ino et al., 2003; Yagi and Matsuno-Yagi, 
2003; Duval et al., 2006; Ichimaru et al., 2008). Alternatively, it was speculated that 
different inhibitors might inhibit different steps in the catalytic cycle and therefore 
compete functionally, not spatially (Hirst, 2005a). However, the data presented here 
clearly indicate that the binding sites of different types of complex I inhibitors indeed 
overlap spatially within one large binding cavity. Moreover, since these results for the 
first time allowed the localization of the binding sites of the three inhibitor types within 
the structure of the quinone binding cavity, they added some new insights: (i) It seems 
that the binding sites for type A and type C inhibitors overlap, a result which was not 
observed before (Okun et al., 1999a). (ii) Residues located in the region corresponding 
to the [NiFe] site in homologous hydrogenases are not essential for complex I activity 
but are rather responsible for inhibitor binding. However, it should be mentioned that 
the experimental setup used here does not allow for the identification of residues that 
are important for inhibitor binding and essential for catalytic activity.  
Amiloride is a known inhibitor of Na
+/H
+ antiporters (Mochizukioda and Oosawa, 
1985; Kleyman and Cragoe, 1988; Counillon et al., 1993; Kuroda et al., 1994; Masereel 
et al., 2003) and the amiloride derivative EIPA was shown to inhibit complex I 
(Nakamaru-Ogiso et al., 2003a; Nakamaru-Ogiso et al., 2003b; Stolpe and Friedrich, 
2004). Since the ND5 subunit shares some sequence similarity with Na
+/H
+ antiporters 
(Hamamoto et al., 1994; Hiramatsu et al., 1998; Mathiesen and Hägerhäll, 2002; 
Mathiesen and Hägerhäll, 2003) and EIPA was shown to decrease the photoaffinity 
labeling with a fenpyroximate analogue of a subunit tentatively assigned as ND5 
(Nakamaru-Ogiso et al., 2003a), it was suggested that the binding site of EIPA is 
located in the ND5 subunit of complex I.  
In Y. lipolytica, deletion of the NB8M subunit leads to the formation of a subcomplex of 
complex I lacking the ND5 subunit (S. Krack and L. Sokolova, personal 
communication). Surprisingly, this subcomplex was found to be sensitive to EIPA 
inhibition (Dr. Stefan Dröse, personal communication). Moreover, with mitochondrial 
membranes from the nb8mΔ strain an I50 value of 23 µM was determined for EIPA (see 
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from the 49-kDa and PSST subunits parental strains (21 µM and 23 µM, respectively, 
see Table 3.8 and Table 3.9). If no holocomplex is present in mitochondrial membranes 
from the nb8mΔ strain, this result would clearly demonstrate that the inhibitor binding 
site for EIPA is not located in the ND5 subunit.  
Since most complex I inhibitors are anticipated to act at the quinone binding site, the I50 
value for EIPA was determined for some mutants of the proposed quinone binding 
pocket. Indeed, some exchanges changed the I50 value of EIPA (see Table 3.8 and Table 
3.9). Interestingly, these exchanges clustered in a region where effects on type A, B and 
C inhibitors were found (see Figure 3.4 and Figure 3.5), indicating that EIPA is a 
typical complex I inhibitor acting at the quinone binding site. But the observed effects 
on the I50 value for EIPA were either relatively small or indicated increased sensitivity. 
However, only mutations that cause pronounced resistance would provide positive 
evidence that EIPA acts at the quinone binding site. 
4.1.6  Comparison to results obtained with other model organisms 
It would be interesting to compare the results described here to results obtained in 
mutagenesis studies with other model organisms. However, only few mutants were 
made in complex I from other species, and only nine were introduced at the proposed 
quinone binding pocket assembled by the PSST and 49-kDa subunit (see Table 4.1 and 
Table 4.2). 
Two exchanges were introduced into the 49-kDa subunit of R. capsulatus (Prieur et al., 
2001). Similar to what was found in Y. lipolytica, they did not decrease complex I 
content; however, mutation D405E decreased complex I activity more strongly, whereas 
mutation V407M did not decrease complex I activity to the same extent when compared 
to the corresponding mutations in Y. lipolytica (see Table 4.1). Both exchanges were 
introduced in a region of the proposed quinone and inhibitor binding cavity where 
effects on the I50 values for DQA and rotenone were identified in Y. lipolytica. 
Consistently, mutant V407M displayed a drastic effect on the I50 value for rotenone. 
Two spontaneous mutations affecting the 49-kDa subunit from Helicobacter pylori 
conferred hypersensitivity towards rotenone (Mills et al., 2004). Although the 
corresponding mutation in Y. lipolytica did not significantly change the I50 value for 4.1  Exploring the proposed ubiquinone and inhibitor binding cavity 115 
rotenone, both residues are located right in the region, where drastic effects on the I50 
values for rotenone and DQA were observed in Y. lipolytica. 
In complex I from E. coli, two exchanges were introduced in the 49-kDa subunit at the 
proposed quinone and inhibitor binding cavity (Belevich et al., 2007). The results from 
mutants H228A and R274A largely corroborated the results found in Y. lipolytica (see 
Table 4.1). However, mutant R274A decreased complex I content in E. coli, whereas 
mutant H228A showed some residual complex I activity. 
Table 4.1: Mutations affecting the 49-kDa subunit at the quinone and 
inhibitor binding cavity in other model organisms. 
Mutant in 
Y. lipolytica 
Equivalent in
other species
Complex I 
content
  
Complex I 
activity
  
I50 for CI 
inhibitors 
   %  %  nM 
   Y. l.  Other Y. l.  other  Y. l.  other 
   E. coli      Type  A 
a 
parental 
b, c parental 
d  100 100 100 100  13-17 ~2 
H95A 
b H228A
 d 130  96 <5 33  n.d. ~2 
R141A
 c  R274A
 d 130  49 17  <5  n.d. ~2 
  R. capsulatus       Rotenone 
parental parental
 e 100±3 100  100±5 100 530  ~100 
D458E 
f D405E
 e 83±1  ~100  89±3  ~50  2200  ~140 
V460M 
  V407M
 e 100±2 ~200  16±2  ~50  760
 c ~600 
  H. pylori       Rotenone 
parental parental 
g 100±3 - 100±5 -  530 ref. 
G455S
 h G398S 
g 98±1 - 72±4 -  700  hyper. 
-  F404S 
g - - - - -  hyper. 
n.d., not determinable 
ref., reference; hyper., hypersensitivity 
a   DQA was used for Y. lipolytica and rolliniastatin was used for E. coli
  
b  data from (Grgic et al., 2004)
 
c  data from (Kashani-Poor et al., 2001b) 
d   data from (Belevich et al., 2007)
  
e   data from (Prieur et al., 2001) 
f   data from (Fendel et al., 2008) 
g  data from (Mills et al., 2004) 
h  point mutations were generated by U. Fendel 116   4  Discussion  
Three amino acid changes were introduced into the PSST subunit from E. coli 
(Flemming et al., 2006). Mutant E87Q strongly decreased complex I activity, whereas 
mutant E163Q only slightly interfered with complex I activity in E. coli (see Table 4.2). 
Interestingly, the opposite effects were found in complex I from Y. lipolytica.  
Table 4.2: Mutations affecting the PSST subunit at the quinone and 
inhibitor binding cavity in other model organisms. 
Mutant in 
Y. lipolytica 
Equivalent in 
E. coli 
Complex I 
content
  
Complex I 
activity
  
I50 for CI 
inhibitors 
   %  %  effect 
   Y. l.  E. c.  Y. l.  E. c.  Y. l.  E. c. 
parental
 b, c parental 
a  100 100 100 100 ref.  s. 
E89Q 
b E67Q 
a 100  ~75  88  10  n.a.  n.s. 
- E67D
 a -  ~88  -  78  -  s. 
E185Q 
c E163Q
 a 110  ~63  35  76  n.a.  s. 
ref., reference 
n.a., not altered 
s., complex I activity sensitive to piericidin A 
n.s., residual complex I activity not sensitive to piericidin A 
a  data (Flemming et al., 2006) 
b  data from (Ahlers et al., 2000), 
c  data from (Garofano et al., 2003) 
Taken together, the effects of the few exchanges introduced at the putative quinone and 
inhibitor binding pocket of other model organisms overall correspond well to those 
observed with complex I from Y. lipolytica. Larger variations may be due to different 
protocols for sample preparation and kinetic measurements used in different 
laboratories. However, in order to exclude fundamental differences between the 
eukaryotic and the prokaryotic enzyme broader mutagenesis studies in prokaryotes will 
be needed.  
4.1.7  Location of the quinone binding site(s) 
Clearly, the active site for quinone reduction must be located within electron tunnelling 
distance to its immediate electron donor. Iron-sulfur cluster N2, ligated by the PSST 4.1  Exploring the proposed ubiquinone and inhibitor binding cavity 117 
subunit, is presumably the electron donor to quinone, since it was found to undergo 
spin-spin interactions to the semiquinone species SQNf and a distance of 8-12 Å 
between the two paramagnetic species was calculated (Vinogradov et al., 1995; Yano et 
al., 2005). Together with the structure of the hydrophilic domain of complex I from T. 
thermophilus (Sazanov and Hinchliffe, 2006), this finding reveals that the enzymatically 
relevant quinone binding site(s) must be located at the interface of the PSST and the 
49-kDa subunit. This is consistent with the results presented here and earlier results 
from mutagenesis (Darrouzet et al., 1998; Kashani-Poor et al., 2001b; Prieur et al., 
2001; Grgic et al., 2004; Mills et al., 2004) and photoaffinity labeling studies (Schuler 
et al., 1999; Schuler and Casida, 2001b; Nakamaru-Ogiso et al., 2003a; Nakamaru-
Ogiso et al., 2003a; Ichimaru et al., 2008). 
It should be mentioned that other studies gave indications for quinone binding sites in 
other subunits. Sequence comparison suggested that the ND4 and the ND5 subunits 
harbour a conserved putative quinone binding motif (aliphatic-(X)3-H-(X)2/3-(L/T/S) 
(Fisher and Rich, 2000). However, this suggestion is difficult to reconcile with the 
finding that the ND4 and ND5 subunits are located in the distal part of the membrane 
domain (Sazanov and Walker, 2000; Cardol et al., 2002; Holt et al., 2003; Baranova et 
al., 2007b) and therefore around 100 Å away from iron-sulfur cluster N2, the immediate 
electron donor to quinone. In addition, exchanging conserved histidines in the ND4 
subunit which were predicted to be central to this motif had no significant effects on 
quinone or inhibitor binding (Torres-Bacete et al., 2007). 
Various other mutagenesis studies suggested that the quinone and inhibitor binding 
pocket of complex I was located in the ND1 (Ghelli et al., 1997; Majander et al., 1996; 
Zickermann et al., 1998; Kurki et al., 2000), ND4 (Degli Esposti et al., 1994; Ghelli et 
al., 1997) and/or the ND6 subunit (Jun et al., 1996; Carelli et al., 1999; Pätsi et al., 
2008). However, it cannot be excluded that these mutations might have caused long 
range effects on the quinone binding pocket at the interface between the PSST and the 
49-kDa subunit, especially since a tight and reversible coupling between the quinone 
reduction site near iron-sulfur cluster N2 and subunits of the membrane domain is 
assumed to be fundamental for proton translocation (Euro et al., 2008a; Zickermann et 
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In addition, photoaffinity labeling studies with different complex I inhibitors and a 
ubiquinone derivative suggest that the ND1 (Earley and Ragan, 1984; Earley et al., 
1987; Yagi, 1987; Yagi and Hatefi, 1988; Hassinen and Vuokila, 1993; Schuler and 
Casida, 2001a; Murai et al., 2007; Murai et al., 2009), the ND4 (Gong et al., 2003), the 
ND5 (Nakamaru-Ogiso et al., 2003a) and/or even the mammal- specific B9 subunit 
(Heinrich and Werner, 1992; Heinrich et al., 1992) may comprise inhibitor and thus 
quinone binding sites. However, these studies are prone to generate false positive 
results, since hydrophobic inhibitors have a preference to associate with and thus 
predominantly label hydrophobic subunits. In addition, in some studies the photolabile 
group was attached at a large distance to the toxophoric moiety and therefore on rather 
flexible parts of the inhibitor. While this design can avoid a decrease in affinity, it also 
makes the labeling of protein parts not involved in inhibitor binding more likely, as 
criticized by Miyoshi and coworkers (Ichimaru et al., 2008; Murai et al., 2009).  
Nevertheless, it is remarkable that many mutagenesis as well as photoaffinity labeling 
studies identified the ND1 subunit to harbour the quinone and inhibitor binding site. 
From these results it may be inferred that the large extramembraneous domains of the 
ND1 subunit may form a quinone ramp or channel to the proposed quinone binding 
pocket at the interface between the PSST and the 49-kDa subunits, as proposed by 
(Zickermann et al., 2009). This interpretation is consistent with other results which 
suggested that the ND1 subunit is in close proximity to subunits from the hydrophilic 
domain (Darrouzet et al., 1998; Sazanov et al., 2000; Dupuis et al., 2001; Di Bernardo 
and Yagi, 2001; Schuler and Casida, 2001a; Yagi and Matsuno-Yagi, 2003; Holt et al., 
2003; Kao et al., 2004b; Baranova et al., 2007a; Sinha et al., 2009). 
The identification of two (Suzuki and King, 1983; Burbaev et al., 1989; Vinogradov et 
al., 1995; Ohnishi et al., 2005) (temporarily even three (Magnitsky et al., 2002)) distinct 
ubisemiquinone species stimulated the proposal of different and spatially separated 
quinone binding site in complex I (Vinogradov, 1993; Vinogradov et al., 1995; Dutton 
et al., 1998; Ohnishi, 1998; Ohnishi and Salerno, 2005). However, the sum of the spin 
concentrations was never found to exceed 1 per complex I (van Belzen et al., 1997)(Dr. 
Klaus Zwicker, personal communication). In addition, fully active complex I from Y. 
lipolytica and E. coli was shown to contain 0.2-1 quinone molecules per complex I 
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more likely that the spectroscopically different semiquinone species represent the same 
molecule in different states rather than two quinone molecules simultaneously bound at 
two spatially separated quinone binding sites.  
The presence of only one large binding pocket for the substrate quinone was also 
deduced from the finding that all tested inhibitors, which are assumed to act at the 
quinone binding pocket, were shown to bind to overlapping binding sites (Okun et al., 
1999a). 
Taken together, there is no compelling evidence that in addition to the PSST and the 
49-kDa subunits other subunits of complex I also harbor catalytically relevant quinone 
binding site(s). As a consequence, since the PSST and the 49-kDa subunits were shown 
to be located far up in the peripheral arm of complex I (Zickermann et al., 2003; Clason 
et al., 2007; Zickermann et al., 2008), all suggested coupling mechanisms which 
postulate quinone reduction in the membrane domain of complex I (Brandt, 1997; 
Dutton et al., 1998; Ohnishi and Salerno, 2005) can be ruled out. 
4.1.8  Properties of the quinone binding site 
Several observations suggest that the specificity of the quinone binding site of complex 
I is not very high. (i) Structurally very different quinone analogs like DBQ, Q0, Q1, Q2 
and even duroquinone can serve as electron acceptors to assay the NADH:Q 
oxidoreductase activity (Di Virgilio and Azzone, 1982; Estornell et al., 1993; Hano et 
al., 2003) and all seem to accept electrons at the physiological site (Lenaz, 1998). In 
addition, studies with systematically modified quinone analogs showed that many 
structural alterations at the quinone head or tail are tolerated by the quinone binding site 
(Sakamoto et al., 1996; Ohshima et al., 1998; Sakamoto et al., 1998). Moreover, 
menaquinone is the natural substrate of complex I from T. thermophilus (Yano et al., 
1997) and E. coli (Tran et al., 1997), although the proposed quinone binding pocket in 
T. thermophilus seems to be very similar to those which bind ubiquinone as a substrate 
(see Figure 4.1). (ii) In complex I from Y. lipolytica the apparent Km values for DBQ, 
Q1 and Q2 are in the range of 8-15 µM (see Table 3.1, Table 3.12 and Table 3.13). Since 
these quinones are very hydrophobic (log P cyclohexane/water 2.65-7.2 (Degli Esposti 
et al., 1996; Lenaz, 1998)), they almost completely distribute to the hydrophobic 120   4  Discussion  
membrane phase. Assuming that the concentration in the membrane phase is the 
relevant one and that the hydrophobic membrane phase comprises 0.1-1 % of the total 
volume under the assay conditions, a very high real Km in molar range can be expected. 
Similar values were determined for complex I from B. taurus (Fato et al., 1996; Lenaz, 
1998; Hano et al., 2003) and P. denitrificans (Zickermann et al., 1998; Kurki et al., 
2000). (iii) A plethora of structurally very different inhibitors are thought to bind at the 
quinone binding site (Degli Esposti, 1998; Miyoshi, 1998; Lümmen, 1998; Okun et al., 
1999b; Ushakova et al., 1999; Okun et al., 1999a; Okun et al., 2000). Therefore, it 
seems that the quinone binding site has been optimized for tight and efficient coupling 
of quinone reduction to conformational changes which lead to proton pumping rather 
than to specifically recognize the substrate. 
4.2  The HRGXE-motif 
It had been suggested that amino acid residues from the conserved HRGXE-motif form 
part of the quinone binding site (Prieur et al., 2001), since the HRGXE-motif shows 
some similarity to a proposed common sequence motif of quinone binding sites (Fisher 
and Rich, 2000). However, amino acid residues from the HRGXE-motif are not located 
within the putative quinone binding pocked, as revealed by the crystal structure of the 
hydrophilic domain of complex I from T. thermophilus (Sazanov and Hinchliffe, 2006) 
(see also Figure 3.22). Instead, it seems that the HRGXE-motif plays an important 
structural role, since most exchanges described here interfered with complex I 
assembly. This was even true for the very conservative exchanges R121K and E124D. 
Arginine 121 is highly conserved in Y. lipolytica, N. crassa, B. taurus, H. sapiens, and 
also in bacteria like P. denitrificans, R. capsulatus and E. coli. However, a threonine is 
found at this position in the T. thermophilus sequence (see Figure 3.21). The structure of 
the hydrophilic domain of complex I from T. thermophilus reveals that this threonine 
(64 in T. thermophilus) forms a hydrogen bound to an arginine residue from the PSST 
subunit (83 in T. thermophilus) (see Figure 4.2). Interestingly, this arginine is located in 
close proximity to iron-sulfur cluster N2 and forms a hydrogen bond to a sulfur atom of 
iron-sulfur cluster N2 through a backbone nitrogen.  4.2  The HRGXE-motif 121 
 
Figure 4.2: Spatial arrangement of the HRGXE-motif which reaches from iron-sulfur 
cluster N2 to the 30-kDa subunit. Amino acid residues from the motif are highlighted in pink 
and are shown in stick representation. Additional amino acid residues which interact with those 
of the motif are also shown in stick representation. Numbers indicate the distances between 
atoms in Ångströms. Amino acid residues are labeled according to T. thermophilus numbering, 
Y. lipolytica numbering is given in brackets. For a rough orientation tyrosine 144 is highlighted 
in white stick representation. Iron-sulfur cluster N2 is shown as a space fill model, the PSST, 
49-kDa and 30-kDa subunits are shown in schematic representation. The figure was generated 
from the crystal structure of the hydrophilic domain of complex I from T. thermophilus (PDB 
ID: 2FUG) by using the PyMOL program. 
However, at the position of this arginine a conserved threonine is found in the amino 
acid sequence of Y. lipolytica, N. crassa, B. taurus, H. sapiens, P. denitrificans, R. 
capsulatus and E. coli (see Figure 4.3). This might explain why the conserved HRGXE-
motif is changed to HTGXE-motif in T. thermophilus. The concomitant exchange of 
arginine to threonine in the 49-kDa subunit and threonine to arginine in the PSST 
subunit in T. thermophilus allows the formation of a hydrogen bound with reversed 
polarity, preserving the overall structure. The R121K mutation in the 49-kDa subunit 
from Y. lipolytica may disrupt the hydrogen bound and thereby destabilize complex I. 
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Y.lipolytica     RASPRQSDIMIVAGTLTNKMAPVLRQVYDQMPEPRWVISMGSCANGGGYYHFSYSVV 164 
N.crassa         RASPRQSDVMIVAGTLTNKMAPALRQVYDQMPDPRWVISMGSCANGGGYYHYSYSVV 180 
P.denitrificans  RASPRQSDLMIVAGTLTNKMAPALRKVYDQMPEPRYVISMGSCANGGGYYHYSYSVV 132 
R.capsulatus     RASPRQSDVMIVAGTLTNKMAPALRKVYDQMPEPRYVISMGSCANGGGYYHYSYSVV 135 
B.taurus         RASPRQSDVMIVAGTLTNKMAPALRKVYDQMPEPRYVVSMGSCANGGGYYHYSYSVV 170 
H.sapiens        RASPRQSDVMIVAGTLTNKMAPALRKVYDQMPEPRYVVSMGSCANGGGYYHYSYSVV 167 
T.thermophilus   RASPRQADVMIVAGRLSKKMAPVMRRVWEQMPDPKWVISMGACASSGGMFN-NYAIV 124 
E.coli           RASPRQADLMVVAGTCFTKMAPVIQRLYDQMLEPKWVISMGACANSGGMYD-IYSVV 142 
                 ******:*:*:***   .****.::::::** :*::*:***:**..** :.  *::* 
Figure 4.3: Multiple sequence alignment of a highly conserved part of the PSST subunit. 
The highly conserved threonine 122 and tyrosine 161 are highlighted in cyan. Threonine 122 is 
replaced by an arginine in the sequence of T. thermophilus. Tyrosine 161 forms a hydrogen 
bond to histidine 120 from the HRGXE-motif. The third cysteine ligand of iron-sulfur cluster 
N2 is highlighted in bold. Sequences of Y. lipolytica, N. crassa, P. denitrificans, R. capsulatus, 
B. taurus, H. sapiens, T. thermophilus and E. coli were aligned by the multiple sequence 
alignment program ClustalW. Invariant (*), highly (:) and weakly similar (.) positions are 
labeled. For the complete multiple sequence alignment see Figure 8.2. 
The highly conserved histidine 120 is hydrogen bonded to tyrosine 161 from the PSST 
subunit (see Figure 4.2). Interestingly, the H120A mutation decreased complex I 
activity; however, it did not interfere with complex I assembly (Kashani-Poor et al., 
2001b). In contrast, mutations H120R and H120W prevented complex I assembly. This 
indicates that a spacious arginine or tryptophan at this position disrupts the overall 
structure, while a histidine at this position is important for normal complex I activity. 
A closer look into the structure might also explain why complex I is not assembled in 
mutant E124D. Glutamate 124 is located adjacent to three positively charged and highly 
conserved residues (lysine 424, lysine 426 and arginine 466, see Figure 4.4) and 
therefore potentially forms essential salt bridges (see Figure 4.2).  
Y.lipolytica     MGVYVVSDGSERPYKCKIRAPGFAHLGAFDHIARGHFLPDAVAIIGTMDLVFGEVDR 466 
N.crassa         MGVYVVSDGSERPYRVHIRAPGFAHLGGFDHLSRGHMLADAVAVIGTMDLVFGEVDR 478 
B.taurus         FGVYLVSDGSSRPYRCKIKAPGFAHLAGLDKMSKGHMLADVVAIIGTQDIVFGEVDR 430 
H.sapiens        FGVYLVSDGSSRPYRCKIKAPGFAHLAGLDKMSKGHMLADVVAIIGTQDIVFGEVDR 463 
P.denitrificans  FGVYLVADGTNKPWRAKLRAPGFAHLQSIDWMSRGHMLADVPAIIATLDIVFGEVDR 412 
R.capsulatus     FGVYLVADGTNKPYRAKIRAPGYAHLQSIDAVAKGHQLADVSAIIGTMDVVFGEIDR 413 
T.thermophilus   LGYYIVSDGGSMPYRVKVRAPSFVNLQSLPYACKGEQVPDMVAIIASLDPVMGDVDR 409 
E.coli           NSYYLTSDGSTMSYRTRVRTPSFAHLQQIPAAIRGSLVSDLIVYLGSIDFVMSDVDR 407 
                  . *:.:**   .:: ::::*.:.:*  :    :*  :.*  . :.: * *:.::** 
Figure 4.4: C-terminal highly conserved part of the multiple sequence alignment from the 
49-kDa subunit. Lysine 424, lysine 426 and arginine 466 are highlighted. Sequences of Y. 
lipolytica, N. crassa, B. taurus, H. sapiens, P. denitrificans, R. capsulatus, T. thermophilus and 
E. coli were aligned by the multiple sequence alignment program ClustalW. Invariant (*), 
highly (:) and weakly similar (.) positions are labeled. See Figure 8.1 for the complete multiple 
sequence alignment. 4.2  The HRGXE-motif 123 
In turn, lysine 426 and arginine 466 may form salt bridges to a nearby aspartate from 
the 30-kDa subunit. This aspartate (184, Y. lipolytica numbering) seems to have an 
important function as well, since it is highly conserved and is located in a remarkably 
conserved region of the 30-kDa subunit (see Figure 4.5).  
Y.lipolytica     P-VPSITCLYEGANWFEREAYDMYGVFFEGHPDLRRIMTDYGFEGHPLRKDFPLTGY 219 
N.crassa         P-VPSITPLYDGANWYEREVYDLFGVFFTGHPDLRRIMTDYGFDGHPLRKDFPMTGY 221 
H.sapiens        P-IESAVSVFKAANWYEREIWDMFGVFFANHPDLRRILTDYGFEGHPFRKDFPLSGY 207 
B.taurus         P-IESSVPVYKAANWYEREIWDMFGVFFANHPDLRRILTDYGFEGHPFRKDFPLSGY 209 
R.capsulatus     M-CPSIVEVYPAANWYEREVFDMFGILFSGHPDLRRLLTDYGFRGHPLRKDFPTTGY 153 
T.thermophilus   PRLPTVTDLWGSANFLEREVYDLFGIVFEGHPDLRKILTPEDLEGHPLRKDYPLGET 155 
P.denitrificans  PRLPTVTDLWGSANFLEREVYDLFGIVFEGHPDLRKILTPEDLEGHPLRKDYPLGET 155 
E.coli           LHVPTFTKLFPNANWYERETWDLFGITFDGHPNLRRIMMPQTWKGHPLRKDYPARAT 175 
                     : . ::  **: *** :*::*: * .**:**:::      ***:***:*        
Figure 4.5: Highly conserved part of the of the amino acid sequence of the 30-kDa subunit. 
The invariant aspartate 184 is highlighted in green. Sequences of Y. lipolytica, N. crassa, H. 
sapiens, B. taurus, R. capsulatus, T. thermophilus, P. denitrificans and E. coli were aligned by 
the multiple sequence alignment program ClustalW. Invariant (*), highly (:) and weakly similar 
(.) positions are labeled. The complete multiple sequence alignment is shown in Figure 8.3. 
This extensive network of electrostatic interactions may explain the effects observed 
when glutamate 124 was exchanged. Mutant E124D shows no complex I assembly, 
indicating that the carboxyl group of the aspartate cannot be placed in sufficient 
proximity to form essential interactions with lysine 424, lysine 426 and/or arginine 466. 
Interestingly, mutant E124Q displayed about 55 % of assembled complex I compared to 
the parental strain; however, complex I activity was rather normal. This seems to 
indicate that the amide from the glutamine is able to support the electrostatic 
interactions in the mutant upon some rearrangements which do not interfere with 
complex I activity. Since glutamate 124 is not located immediately within the quinone 
binding pocket, the slight changes in the apparent Km value for DBQ and the I50 value 
for DQA that were observed in mutant E124Q (see Table 3.16) suggest that these 
rearrangements also reach into the quinone and inhibitor binding pocket. 
Based on the structure of the [NiFe] hydrogenase from D. fructosovorans (PDB 1FRF) 
(Rousset et al., 1998), it had been noticed before that glutamate 124 and arginine 466 
might form a salt bridge; therefore a double mutant E124R/R466E was generated (L. 
Grgic, unpublished data). However, similar to what was found for mutant E124R, no 
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glutamate 124 is an essential part of a larger network of electrostatic interactions critical 
for proper complex I assembly. 
Arginine 466 is not as important for complex I assembly as arginine 121 or glutamate 
124, since even drastic exchanges did not prevent complex I assembly (Grgic et al., 
2004). However, some mutants displayed slight changes in the apparent Km value for 
DBQ and in the I50 values for DQA and rotenone. Consistently, a slightly changed 
sensitivity towards rotenone and piericidin was observed when this arginine was 
mutated to lysine in complex I from R. capsulatus (Prieur et al., 2001). Therefore, 
similar to what was found for glutamate 124, exchanges of arginine 466 seem to induce 
structural rearrangements which reach into the quinone and inhibitor binding pocket. 
Taken together, it seems that the HRGXE-motif and especially glutamate 124 play an 
essential structural role in complex I. It is tempting to speculate that this conserved 
motif, which reaches from iron-sulfur cluster N2 to the 30-kDa subunit and also affects 
the quinone binding pocket, is involved in transferring conformational changes which 
finally result in proton translocation across the inner mitochondrial membrane. 
4.3  Iron-sulfur cluster N1a 
Iron-sulfur cluster N1a in complex I from Y. lipolytica is not detectable by EPR. 
However, it must be present, since its ligation motif is highly conserved in the 24-kDa 
subunit from Y. lipolytica as in its homologues (see Figure 3.24). Only reduced 
binuclear and tetranuclear iron-sulfur clusters are paramagnetic, and therefore a very 
low redox midpoint potential could explain why this cluster is EPR silent. 
By mutating valine 166, alanine 175 and methionine 177 located close to iron-sulfur 
cluster N1a (see Figure 3.25) to polar and positively charged residues, it might be 
possible to shift the redox midpoint potential of this cluster to more positive values.  
The drastic exchanges A175K and M177K as well as the exchange of the cysteine 
ligands to alanine in mutants C168A and C172A prevented complex I assembly. This is 
often observed when iron-sulfur cluster ligands or residues in close proximity to an 
iron-sulfur cluster are mutated (Aurelio Garofano, unpublished data; Antje Waletko, 
unpublished data; see also mutant A84V in the PSST subunit in chapter 3.1.1), further 4.3  Iron-sulfur cluster N1a 125 
supporting the premise that the 24-kDa subunit from Y. lipolytica ligates iron-sulfur 
cluster N1a. 
The rather conservative exchanges V166T, V166K, A175S and M177H displayed 
normal complex I assembly and activity. However, the EPR spectra from mitochondrial 
membranes of these mutants were not significantly different from the parental strain. 
The same was found when mitochondrial membranes were reduced with dithionite, 
which has a lower redox potential (E
o' ~ -420 mV) than NADH (E
o' ~ -320 mV). 
These results indicated that the introduced mutations did not or not sufficiently increase 
the redox midpoint potential of iron-sulfur cluster N1a to make it EPR detectable. 
However, in addition to the signals from complex I, EPR spectra from mitochondrial 
membranes also display signals from other respiratory chain complexes (see Figure 
1.6). Therefore, purification of complex I from the mutants would be necessary to 
exclude small changes in the complex I spectrum. 
Possibly, further exchanges at additional positions (threonine 129, threonine 130, 
glutamine 133, glutamate 167, leucine 169 and alanine 171) next to iron-sulfur cluster 
N1a or a combination of several exchanges which did not interfere with complex I 
assembly could be suited to sufficiently increase the redox midpoint potential of this 
cluster. 
Alternatively, stronger reductants like deazaflavin (E
o' = -650 mV) (Blankenhorn, 1976) 
or Eu
II-DTPA (approaching -1 V) (Vincent et al., 2003) could be tested. 
Although quite unlikely, it cannot be excluded that the EPR signal from iron-sulfur 
cluster N1a is not detectable due to other reasons than a very low redox midpoint 
potential. The EPR signal of iron-sulfur cluster N1a might be hidden by the signal from 
iron-sulfur cluster N1b. The observation that a stoichiometry of 1.3:1 of the N1 signal to 
the N2 signal is determined when complex I is reduced with dithionite in redox titra-
tions (Klaus Zwicker, personal communication) points into this direction. Alternatively, 
iron-sulfur cluster N1a could have an unusual ground state, as proposed for iron-sulfur 
cluster N5 (Yano et al., 2003) and for iron-sulfur clusters of ferredoxins (Conover et al., 
1990; Duderstadt et al., 1999), which might be difficult to detect. Similarly, a very fast 
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detection of the EPR signal. In addition, it was speculated that cluster N1a may not be 
reducible for kinetic reasons (Reda et al., 2008). 
Further studies will be necessary to answer these questions and to gain insight to the 
function of iron-sulfur cluster N1a. 
4.4  In vivo screen for complex I deficiency 
Due to the redirection of the alternative NADH dehydrogenase (NDH2) to the matrix 
side of the inner mitochondrial membrane, complex I deficient Y. lipolytica strains are 
viable (Kerscher et al., 2001b). Moreover, these strains do not have any phenotypic 
growth disadvantages (see upper panel in Figure 3.7). Therefore, in an earlier attempt to 
develop a screening assay for complex I deficiency and resistance towards complex I 
specific inhibitors, the expression of the internal alternative NADH dehydrogenase was 
controlled by inducible promoters (Garofano et al., 2006). However, this assay has 
several disadvantages. Firstly, Y. lipolytica strains have to be grown on minimal media. 
Secondly, the expression of the internal alternative NADH dehydrogenase could not be 
controlled stringently enough. Thirdly, this assay inherently would not identify strains 
in which only proton pumping of complex I is affected. Finally, the screen is not 
compatible with the preferred mutagenesis strategy.  
Therefore, a new in vivo plate assay was developed. By growing Y. lipolytica on 
antimycin A or azide containing full medium agar plates, complex III and complex IV 
were inhibited; thus, oxidative phosphorylation in this obligate aerobic yeast relied on 
the proton pumping activity of complex I (see Figure 3.6). Indeed, slower growth of the 
complex I deficient Y144F mutant compared to the parental strain was observed (see 
Figure 3.7), proving the general concept. With regard to the growth difference between 
mutant Y144F and the parental strain, best results were obtained at concentrations of 0.3 
µM antimycin A or 0.5 mM azide, whereby antimycin A always worked better than 
azide. In order to shut down complex III and complex IV more tightly and/or to 
decrease the concentrations of inhibitors to avoid side effects, combinations of both 
inhibitors with varying concentrations were tested. However, the combination of 
antimycin A and azide on the same plate did not enhance the growth difference between 
the mutant and the parental strain. Therefore, it seems sufficient to solely use antimycin 4.4  In vivo screen for complex I deficiency 127 
A, especially since no resistant colonies appeared. Interestingly, it was important though 
that the strains reached the late exponential phase in the liquid culture before they were 
spotted on plates. This might indicate that expression and/or activity levels of complex I 
and/or the alternative oxidase are upregulated in the late exponential phase of growth. 
Some exchanges of highly conserved amino acid residues located at the proposed 
quinone binding cavity unexpectedly displayed normal complex I content and activity 
(see chapter 3.1.1 and chapter 3.1.2); therefore, one could speculate that these residues 
are important for the coupling of the redox reaction to proton pumping. Since the 
aforementioned screen identifies strains with defects in complex I assembly, stability, 
oxidoreductase activity as well as proton pumping, these strains were examined on 
antimycin A-containing plates. Interestingly, none of the mutants displayed any growth 
deficiency (see Figure 3.8), confirming that complex I assembly and activity are not 
affected by these mutations. Furthermore, these results also indicate that proton 
pumping by complex I was unaffected as well, consistent with the emerging concept 
that the redox reaction is strictly coupled to proton translocation in complex I (Euro et 
al., 2008a; Zickermann et al., 2008; Zickermann et al., 2009). However, the function of 
these highly conserved amino acid residues is still elusive.  
It should be mentioned that slight impairment of complex I is difficult to determine with 
this plate assay. Since it was proven here that the basic principle of this assay is valid, 
one could think of recording growth curves in liquid medium in the presence and 
absence of antimycin A. Thus, differences in growth i.e. doubling time of different 
strains could be quantified and evaluated statistically. 
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5  Summary and Outlook 
5.1  Summary  
The NADH:ubiquinone oxidoreductase (complex I) is a large membrane bound protein 
complex coupling the redox reaction of NADH oxidation and quinone reduction to 
vectorial proton translocation across bioenergetic membranes (Brandt, 2006). Despite 
extensive research, the mechanism of proton pumping is still unknown; it seems 
however that the reduction of quinone induces conformational changes which drive 
proton uptake from one side and release at the other side of the membrane (Euro et al., 
2008a; Zickermann et al., 2009). 
In this study the proposed quinone and inhibitor binding pocket located at the interface 
of the 49-kDa and PSST subunits was explored by a large number of point mutations 
introduced into complex I from our model organism, the strictly aerobic yeast Yarrowia 
lipolytica. Point mutations were systematically chosen based on the 3.3 Å crystal 
structure of the hydrophilic domain of complex I from Thermus thermophilus (Sazanov 
and Hinchliffe, 2006). In total, the properties of 94 mutants at 39 positions which 
completely cover the lining of the large putative quinone and inhibitor binding cavity 
seen in the partial structure of complex I are described and discussed here.  
It turned out that most mutations did not interfere with complex I assembly or stability, 
but many of them drastically decreased complex I activity. A structure/function analysis 
allowed the identification of functional domains within the large putative quinone 
binding cavity. A possible quinone access path ranging from the N-terminal β-sheet of 
the 49-kDa subunit into the pocket to tyrosine 144 could be defined, since all exchanges 
introduced here, including the most conservative ones, caused an almost complete loss 
of dNADH:DBQ oxidoreductase activity of complex I. A region located deeper in the 
proposed quinone binding pocket is apparently not important for complex I activity, 
despite the fact that highly conserved amino acid residues are found here. Tyrosine 144 
located next to iron-sulfur cluster N2 (the immediate electron donor to quinone) was 
found to be especially interesting. All exchanges of this tyrosine, even the very 
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activity of complex I. However, with higher concentrations of Q1 or Q2 the dNADH:Q 
oxidoreductase activity of complex I was largely restored in the mutants with the more 
conservative exchanges. Proton pumping experiments showed that this activity was also 
coupled to proton translocation, indicating that these quinones were reduced at the 
physiological site. However, the apparent Km values for Q1 or Q2 were drastically 
increased, clearly demonstrating that tyrosine 144 is central for quinone binding and 
reduction. These results further prove that the enzymatically relevant quinone binding 
site of complex I is located at the interface of the 49-kDa and PSST subunits. 
Kinetic measurements with different ubiquinone derivatives suggested that DBQ is the 
substrate of choice when the oxidoreductase activity of complex I is to be assayed, since 
it gave the highest catalytic rates that were also almost completely sensitive towards 
specific complex I inhibitors. However, if changes in the apparent Km values of 
complex I mutants are to be identified, Q1 or Q2 were better suited because of their 
higher affinity to complex I. 
The quinone binding pocket is thought to comprise the binding sites for a plethora of 
specific complex I inhibitors that are usually grouped into three classes (Degli Esposti, 
1998). The large array of mutants targeting the quinone binding cavity was examined 
with a representative of each inhibitor class. Many mutants conferring resistance were 
identified which, depending on the inhibitor tested, clustered in well defined and 
partially overlapping regions of the large putative quinone and inhibitor binding cavity. 
Mutants with effects on type A (DQA) and type B (rotenone) inhibitors were found in a 
subdomain corresponding to the former [NiFe] site in homologous hydrogenases, 
whereby the type A inhibitor DQA seems to bind deeper in this domain. Mutants with 
effects on the type C inhibitor (C12E8) exclusively were found in a narrow crevice which 
seems not to be important for complex I activity. Exchanging more exposed amino acid 
residues at the border of these well defined domains affected all three inhibitor types. 
Therefore, the results as a whole provide further support for the concept that different 
inhibitor classes bind to different but partially overlapping binding sites within a single 
large quinone binding pocket (Okun et al., 1999a). In addition, they also indicate the 
approximate location of the binding sites of different complex I inhibitor classes within 
the structure of the large quinone and inhibitor binding cavity at the interface of the 
49-kDa and the PSST subunit. 5.1  Summary 131 
The main results from the mutagenesis study of the quinone and inhibitor binding cavity 
are illustrated in Figure 5.1. 
EIPA, an amiloride derivative and a complex I inhibitor, was suggested to bind to the 
ND5 subunit of complex I (Nakamaru-Ogiso et al., 2003a). However, a subcomplex of 
complex I which lacks the ND5 subunit can still be inhibited by EIPA (Dr. Stefan 
Dröse, personal communication). Moreover, the I50 value of EIPA determined with 
mitochondrial membranes from the strain containing the subcomplex was found to be 
unchanged. However, exchanging more exposed amino acid residues within the quinone 
binding pocket not only altered the I50 value for all three types of complex I inhibitors 
but also affected the I50 value of EIPA. Therefore, it seems that EIPA, similar to 
classical complex I inhibitors, acts on the quinone binding pocket of complex I. 
 
Figure 5.1: Schematic representation of the quinone and 
inhibitor binding cavity. The cavity is located next to iron-
sulfur cluster N2 (in black) at the interface of the 49-kDa (in 
violet) and the PSST subunits (in cyan). The color gradient 
indicates the position of amino acid residues which are 
critical (red), less critical (yellow and green) and not critical 
(blue) for complex I activity. A possible access path for the 
quinone substrate (Q) is indicated by an arrow. Approximate 
binding sites of the three types of complex I inhibitors are 
depicted: --- type A only; -··- type A and B; ··· type C. Figure 
was adapted from (Zickermann et al., 2009). 132   5  Summary and Outlook  
It has been proposed earlier that the highly conserved HRGXE-motif in the 49-kDa 
subunit forms a part of the quinone binding site of complex I (Prieur et al., 2001). 
Mutagenesis of the HRGXE-motif, revealed that these residues and especially glutamate 
124 are rather critical for complex I assembly and seem to have an important structural 
role. They may also be involved in transferring large conformational changes, consistent 
with the finding that these residues are not located at the quinone binding pocket but 
structurally connect iron-sulfur cluster N2 located in the PSST via the 49-kDa subunit to 
the 30-kDa subunit, as revealed by the crystal structure from T. thermophilus (Sazanov 
and Hinchliffe, 2006).  
The question why iron-sulfur cluster N1a is not detectable by EPR in complex I from Y. 
lipolytica and many other models organisms is not solved yet. Introducing polar and 
positively charged amino acid residues close to this cluster in order to increase its 
midpoint potential did not result in the appearance of the cluster N1a EPR signal in 
mitochondrial membranes from the mutants. Clearly, further research will be necessary 
to gain insights to the function of this iron-sulfur cluster in complex I. 
In an additional project, a new and simple in vivo screen for complex I deficiency in our 
model organism Y. lipolytica was developed and optimized. This assay probes for 
defects in complex I assembly and stability, oxidoreductase activity and also proton 
pumping activity by complex I. Most importantly, this assay is applicable to all Y. 
lipolytica strains and could be used to identify loss-of-function mutants, gain-of-
functions mutants (i.e. resistance towards complex I inhibitors) and revertants due to 
mutations in both nuclear and mitochondrially encoded genes of complex I subunits. 
5.2  Outlook 
5.2.1  Mutagenesis of the proposed quinone and inhibitor binding 
cavity 
The results obtained with a large array of quinone binding pocket mutants suggest that 
the binding site for the quinone head group is located next to tyrosine 144 and that the 
quinone access path is partially formed by the N-terminal part of the 49-kDa subunit. 
Focusing the same approach more on the PSST subunit could help to identify further 5.2  Outlook 133 
amino acid residues which extend this access path further down towards the membrane 
plane. In addition, testing ubiquinone analogues with different side chains in 
combination with structure-based mutagenesis could result in the identification of 
amino acid residues which are involved in the specific binding of the quinone side chain 
and hence in substrate recognition by complex I. 
Based on steady state kinetics it has been proposed earlier that Δlac-acetogenins form a 
new type of complex I inhibitors (Hamada et al., 2004; Ichimaru et al., 2005; Murai et 
al., 2006; Murai et al., 2007) and it has been speculated that the binding site of these 
inhibitors is very different from the binding sites of classical complex I inhibitors. 
However, to date it was not possible to identify the amino acid residues or even the 
subunit(s) which are involved in binding of Δlac-acetogenins by photoaffinity labeling. 
This hypothesis could be tested by measuring the inhibitory action of Δlac-acetogenins 
on mutants which displayed marked effects on classical complex I inhibitors. 
More importantly, the results presented here together with a crystal structure of holo-
complex I and modeling studies could provide clues on how quinone reduction is 
coupled to proton pumping and how different inhibitors interfere with this machinery. 
5.2.2  Iron-sulfur cluster N1a 
Iron-sulfur cluster N1a is not detectable by EPR in complex I from Y. lipolytica and this 
peculiarity was not altered by changing nearby amino acid residues. However, it has 
been shown earlier with the 24-kDa subunit from other species that an EPR signal from 
iron-sulfur cluster N1a was detectable in the overexpressed and purified subunit. (Yano 
et al., 1994b; Crouse et al., 1994; Yano et al., 1994a; Zu et al., 2002). 
In cooperation with the group of Dr. Judy Hirst (MRC, Dunn Human Nutrition Unit, 
Cambridge, U.K.) the mutants generated and described in this work as well as the 
unchanged version of the 24-kDa subunit from Y. lipolytica will be overexpressed and 
analyzed by EPR and protein-film voltammetry in order to gain more insights into the 
function of iron-sulfur cluster N1a. 134   5  Summary and Outlook  
5.2.3  In vivo screen for complex I deficiency 
On antimycin A or azide containing plates, complex I deficient Y. lipolytica strains 
grow significantly slower than the parental strains. This phenotypic difference could be 
used to screen for loss-of-function mutations induced by random mutagenesis with 
mismatch primers in nuclear encoded complex I subunits or loss-of-function mutations 
in mitochondrially encoded subunits upon induction by the MnCl2 method (Putramen et 
al., 1973; Tzagoloff et al., 1975; Meunier et al., 1993) or by acriflavine (Duby and 
Matagne, 1999). In addition, second site revertants or gain-of-functions mutations 
which confer resistance towards complex I specific inhibitors could be identified.  
The general principle of this screen should also apply to Y. lipolytica strains grown in 
liquid culture in microtiter plates. With such a setup one could directly record growth 
curves of different strains in parallel and statistically evaluate growth differences.  6  Zusammenfassung 135 
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Komplex I (NADH:Ubichinon Oxidoreduktase) ist Teil der mitochondrialen Atmungs-
kette, die den schrittweisen Elektronentransfer, überwiegend von NADH, auf den 
gemeinsamen terminalen Akzeptor Sauerstoff katalysiert (Hatefi, 1985). Die einzelnen 
Redoxreaktionen zwischen NADH und Sauerstoff werden durch drei membranständige 
Atmungskettenkomplexe (Komplex I, Komplex III und Komplex IV) bewerkstelligt, die 
diese exergone Reaktion an die endergone Protonentranslokation über die innere 
Mitochondrienmembran koppeln. Der so aufgebaute elektrochemische Gradient dient 
dann zur ATP-Synthese durch die ATP-Synthase (Nakamoto et al., 1999). Dieses 
grundlegende Prinzip wurde von Peter Mitchell vorgeschlagen (Mitchell, 1961) und 
wird als die chemiosmotische Theorie bezeichnet.  
Mit einer Masse von ~1 MDa ist Komplex I der größte und gleichzeitig auch der am 
wenigsten verstandene Atmungskettenkomplex (Brandt, 2006). Das membranständige 
Enzym katalysiert den Elektronentransfer von NADH auf Ubichinon und pumpt dabei 
vier Protonen über die Mitochondrienmembran (Wikström, 1984;Galkin et al., 1999). 
Interessanterweise sind alle bekannten Redox-Kofaktoren, ein Flavinmononucleotid 
(FMN) und 8 bis 9 Eisen-Schwefel-Zentren im hydrophilen Arm des L-förmigen 
Proteinkomplexes lokalisiert (Carroll et al., 2006b), während die Protonentranslokation 
über den membranständigen hydrophoben Arm erfolgen muss. Der Mechanismus, der 
die Redoxreaktion an die räumlich getrennte Protonentranslokation koppelt, ist noch 
völlig unbekannt. Jedoch deuten neuere Ergebnisse darauf hin, dass die Reduktion des 
Substrates Ubichinon Konformationsänderungen hervorruft, die letztlich in der 
Protonenaufnahme auf der einen Seite der Membran und Protonenabgabe auf der 
anderen Seite der Membran resultieren (Zickermann et al., 2009). Aus der 
Kristallstruktur des hydrophilen Arms von Komplex I von Thermus thermophilus 
(Sazanov and Hinchliffe, 2006) ist bekannt, dass die Eisen-Schwefel-Zentren eine 
Elektronentransportkette bilden, die das FMN mit einer großen Proteintasche verbindet. 
Diese Tasche wird durch die 49-kDa- und die PSST-Untereinheiten aufgebaut und liegt 
neben dem Eisen-Schwefel-Zentrum N2, dem direkten Elektronendonor für das Chinon. 136   6  Zusammenfassung  
Es ist daher anzunehmen, dass die Bindestelle für das Ubichinon sich in dieser 
Proteintasche befindet.  
 
In der vorliegenden Arbeit wurde die putative Ubichinonbindetasche von Komplex I 
mittels Mutagenese charakterisiert. Als Modellorganismus für zielgerichtete Muta-
genese von Komplex I diente die zuvor im Labor von Prof. Brandt etablierte obligat 
aerobe Hefe Yarrowia lipolytica (Kerscher et al., 2001), da die Bäckerhefe 
Saccharomyces cerevisiae keinen Komplex I besitzt (Büschges et al., 1994). Basierend 
auf der Kristallstruktur des hydrophilen Arms von Komplex I von T. thermophilus 
(Sazanov and Hinchliffe, 2006) wurden Punktmutationen so eingeführt, dass jeder 
Aminosäurerest in der Ubichinonbindetasche in der Regel gegen eine strukturell 
ähnliche und eine strukturell andersartige Aminosäure ausgetauscht wurde. Insgesamt 
werden hier die Ergebnisse von 34 Aminosäureaustauschen an 15 Positionen vorgestellt 
und mit den Ergebnissen aus früheren Mutagenesestudien an Komplex I von Y. 
lipolytica diskutiert. Somit basieren die Schlussfolgerungen dieser Arbeit auf der 
Auswertung von insgesamt 94 Mutanten an 39 Aminosäurepositionen. 
Mittels Elektronenspinresonanz-Spektroskopie, Blau-nativer Elektrophorese mit an-
schließender Komplex I Färbung sowie Aktivitätstests (NADH:HAR Oxidoreduktase-
aktivität) an mitochondrialen Membranen aus Mutantenstämmen wurde gezeigt, dass 
die meisten Aminosäurenaustausche die Assemblierung und Stabilität von Komplex I 
nicht störten. Jedoch beeinträchtigten viele die Aktivität von Komplex I (dNADH:DBQ 
Oxidoreduktaseaktivität). Wie zu erwarten war, hatten konservative Austausche in der 
Regel geringere Effekte auf die Komplex I Aktivität zur Folge als nicht konservative 
Austausche. An einigen Positionen führten allerdings selbst sehr konservative 
Austausche zum fast vollständigen Aktivitätsverlust. Betrachtet man die Lage dieser 
essenziellen Reste in der Struktur der Chinonbindetasche, dann fällt auf, dass alle in 
einem bestimmten Bereich der Tasche liegen. Dieser Bereich beginnt an einem 
N-terminalen β-Faltblatt in der 49-kDa Untereinheit, führt dann in die Tasche und endet 
am Tyrosin 144 der 49-kDa Untereinheit. Es ist daher anzunehmen, dass Aminosäuren, 
die essenziell für die Komplex I Aktivität sind aber nicht im Elektrontransferabstand 6  Zusammenfassung 137 
zum Eisen-Schwefel-Zentrum N2 liegen, einen Zugang für das Chinon in die Tasche 
bilden.  
Jedoch scheint das streng konservierte Tyrosin 144, das nur 6 bis 8 Ångström vom 
Eisen-Schwefel-Zentrum N2 entfernt ist, eine andere Funktion zu haben. Alle 
Austausche des Tyrosins, selbst der sehr konservative von Tyrosin nach Phenylalanin, 
bei dem nur eine Hydroxylgruppe entfernt wird, eliminierten fast vollständig die 
dNADH:DBQ Oxidoreduktaseaktivität von Komplex I. Wurden als Ubichinonderivate 
jedoch Q1 oder Q2 statt DBQ zur Ermittlung der dNADH:Q Oxidoreduktaseaktivität 
von Komplex I verwendet, so zeigten alle Mutanten, bei denen das Tyrosin durch einen 
ebenfalls aromatischen Rest ersetzt wurde, beinahe normale Komplex I Aktivität. 
Protonenpumpmessungen haben gezeigt, dass diese Aktivität auch tatsächlich zur 
vektoriellen Protonentranslokation führte. Dies bedeutet, dass diese Chinone an der 
physiologischen Substratbindestelle reduziert werden. Die apparente Km für Q2 und 
insbesondere Q1 waren jedoch drastisch erhöht. Offenbar ist das Tyrosin 144 von 
zentraler Bedeutung, aber nicht in jedem Fall essentiell für die Bindung und Reduktion 
von Ubichinonen am katalytischen Zentrum.  
Andere Austausche an Positionen, die tiefer in der Proteintasche liegen (an der Stelle, 
wo sich die Tasche zur einer Furche verengt), hatten so gut wie gar kein Einfluss auf die 
Komplex I Aktivität – und dies, obwohl hier auch einige streng konservierte Reste wie 
Glutamat 218 und Arginin 224 der 49-kDa Untereinheit zu finden sind. Weitere 
Experimente haben gezeigt, dass diese Reste auch für die Protonentranslokation nicht 
essenziell sind. 
Aktivitätsmessungen mit verschiedenen Ubichinonderivaten an mitochondrialen 
Membranen zeigten, dass DBQ am geeignetsten ist, um die Aktivität von Komplex I zu 
bestimmen, da es deutlich höhere Aktivitätsraten ermöglichte als Q1 oder Q2 und diese 
zudem fast vollständig inhibitorsensitiv waren. Des Weiteren entsprachen die 
Aktivitätsraten mit DBQ eher den relativen Raten, die mit dem endogenen Ubichinon 
bestimmt wurden, als den Raten mit Q1. Für die Bestimmung der apparenten Km 
scheinen jedoch Q1 und Q2 aufgrund der höheren Affinität besser geeignet zu sein, da 
eine starke Erhöhung der apparenten Km nicht zum Aktivitätsverlust führt, wie dies 
beim DBQ der Fall zu sein scheint. 138   6  Zusammenfassung  
Es wird allgemein angenommen, dass die Chinonbindetasche auch gleichzeitig die 
Bindestellen für eine große Anzahl spezifischer Komplex I Inhibitoren beherbergt, die 
aufgrund von kinetischen Messungen für gewöhnlich in drei Klassen unterteilt werden 
(Degli Esposti, 1998). Mit je einem Inhibitor aus jeder Klasse wurde getestet, welche 
Aminosäureaustausche einen Effekt auf welche Inhibitorklasse hatten. Dabei zeigte 
sich, dass einige Austausche in einer Region, an der in homologen Hydrogenasen das 
[NiFe]-Zentrum zu finden ist, zu Resistenzen gegenüber DQA (einem Typ A Inhibitor) 
und Rotenon (einem Typ B Inhibitor) führten. Tiefer in diesem Bereich wurden Reste 
identifiziert, die beim Austausch ausschließlich Effekte auf DQA zeigten; dies könnte 
bedeuten, dass DQA tiefer in diesen Bereich eintaucht als Rotenon. Effekte auf den Typ 
C Inhibitor C12E8 wurden in einer anderen Region der Chinonbindetasche gefunden, 
und zwar in der Furche, in der Aminosäurereste zu finden sind, die nicht essenziell für 
die Komplex I Aktivität waren. Austausche von exponierten Aminosäureresten, die sich 
zwischen dieser Furche und dem Bereich des ehemaligen [NiFe]-Zentrums (hier gab es 
Effekte auf DQA und Rotenon) befinden, beeinflussten die Inhibition mit allen drei 
Inhibitoren. Diese Ergebnisse bestätigen die Hypothese, dass die drei Inhibitorklassen 
an verschiedene, jedoch teilweise überlappende Bindestellen innerhalb einer großen 
Ubichinonbindetasche binden (Okun et al., 1999). Darüber hinaus zeigen die hier 
diskutierten Ergebnisse die annähernde Lage der Bindestellen der unterschiedlichen 
Inhibitoren innerhalb der Struktur der Chinonbindetasche auf. 
Amilorid und das Amiloridderivat EIPA sind bekannte Inhibitoren von Na
+/H
+ 
Antiportern (Masereel et al., 2003). Da die ND5 Untereinheit von Komplex I Sequenz-
ähnlichteit zu Na
+/H
+ Antiportern aufweist (Mathiesen and Hägerhäll, 2002;Mathiesen 
and Hägerhäll, 2003) und zudem gezeigt wurde, dass EIPA nicht nur Komplex I hemmt 
(Nakamaru-Ogiso et al., 2003b), sondern auch mit der Photoaffinitätsmarkierung von 
vermutlich der ND5 Untereinheit durch Inhibitoren interferiert, wurde vorgeschlagen, 
dass EIPA Komplex I durch die Bindung an die ND5 Untereinheit inhibiert (Nakamaru-
Ogiso et al., 2003a). Jedoch ist ein Subkomplex von Komplex I, bei dem die ND5 
Untereinheit fehlt, immer noch mit EIPA hemmbar (Dr. Stefan Dröse, persönliche 
Kommunikation). Zudem war in mitochondrialen Membranen aus dem Subkomplex-
generierenden Y. lipolytica Stamm nb8m die I50 von EIPA unverändert. Des Weiteren 
hat sich herausgestellt, dass Aminosäureaustausche in der Ubichinonbindetasche die 6  Zusammenfassung 139 
EIPA Hemmung beeinflussten. Diese Ergebnisse deuten darauf hin, dass EIPA wie die 
klassischen Komplex I Inhibitoren an die Ubichinonbindetasche und nicht an die ND5 
Untereinheit bindet.  
 
Aufgrund von Sequenzvergleichsstudien wurde vermutet, dass das streng konservierte 
HRGXE-Motiv der 49-kDa Untereinheit Teil eines konservierten Chinonbindemotivs 
ist (Prieur et al., 2001). Aminosäureaustausche in diesem Motiv interferierten jedoch 
mit der Komplex I Assemblierung bzw. Stabilität. Wie aus der Kristallstruktur des 
hydrophilen Arms von Komplex I von T. thermophilus hervorgeht (Sazanov and 
Hinchliffe, 2006), befinden sich die Aminosäurereste des HRGXE-Motivs nicht in der 
Chinonbindetasche, sondern formen eher eine Verbindung zwischen dem Eisen-
Schwefel-Zentrum N2 in der PSST Untereinheit, der 49-kDa Untereinheit und der 30-
kDa Untereinheit. Dabei bildet das Histidin 120 und vermutlich auch das Arginin 121 
des Motivs Wasserstoffbrücken zu benachbarten Resten aus, während das Glutamat 124 
an einem Netzwerk aus ionischen Wechselwirkungen beteiligt ist. Offenbar hat das 
HRGXE-Motiv eine strukturelle Funktion in Komplex I. 
 
Das Eisen-Schwefel-Zentrum N1a der 24-kDa Untereinheit moduliert möglicherweise 
die ROS-Produktion von Komplex I (Esterhazy et al., 2008). Leider ist dieses Eisen-
Schwefel-Zentrum im Komplex I von Y. lipolytica und einigen anderen Organismen 
nicht mit Elektronenspinresonanz-Spektroskopie detektierbar. Als möglicher Grund 
hierfür wird ein sehr niedriges Mittelpunktspotential erwogen, sodass dieses Eisen-
Schwefel-Zentrum meist im oxidiertem, nicht paramagnetischem Zustand vorliegt 
(Reda et al., 2008). Das Einführen von polaren oder positiv geladenen Aminosäure-
resten in die Nähe des Eisen-Schwefel-Zentrums N1a interferierte jedoch entweder mit 
der Komplex I Assemblierung oder hatte kein Einfluss auf die Elektronenspinresonanz-
Spektren von mitochondrialen Membranen der Mutanten. Es ist daher ungeklärt, ob und 
im welchem Ausmaß diese Mutationen das Mittelpunktspotential von Eisen-Schwefel-
Zentrum N1a heraufsetzen konnten und auch, ob ein zu niedriges Mittelpunktspotential 
tatsachlich der Grund für die Nichtdetektierbarkeit von Eisen-Schwefel-Zentrum N1a 
ist. Zur Beantwortung dieser Fragen sollen die mutagenisierten Versionen der 24-kDa 140   6  Zusammenfassung  
Untereinheit in Kooperation mit der Arbeitsgruppe von Dr. Judy Hirst (MRC, Dunn 
Human Nutrition Unit, Cambridge, England) überexprimiert und mit der Proteinfilm-
voltammetrie analysiert werden. 
 
In einem weiteren Teilprojekt der vorliegenden Arbeit wurde ein neuer und einfacher in 
vivo  Screen zur Identifizierung von Komplex I defizienten Y. lipolytica Stämmen 
entwickelt. Auf Antimycin A oder Azid-haltigen Vollmediumplatten ist die Oxidative 
Phosphorylierung von Y. lipolytica gänzlich auf einen funktionsfähigen Komplex I 
angewiesen. Y. lipolytica Stämme mit Komplex I Defekten haben auf solchen Platten 
einen Wachstumsnachteil. Daher könnten Stämme isoliert werden, die eine Störung in 
der Assemblierung, Oxidoreduktaseaktivität oder Protonenpumpaktivität von Komplex 
I aufweisen. Neben diesen Funktionsverlustmutanten könnten auch Revertanten oder, 
mit Hilfe von Komplex I spezifischen Inhibitoren, auch Funktionsgewinnmutanten 
aufgrund von Resistenzen identifiziert werden. Nach einer induzierten Zufalls-
mutagenese könnte dieser in vivo Screen eine schnelle und einfache Identifizierung von 
essenziellen Aminosäureresten sowohl in kernkodierten als auch in mitochondrial-
kodierten Komplex I Untereinheiten ermöglichen.  
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8.1  Genes and primers 
8.1.1  NUCM gene (ACCESSION AJ249783) 
                         TCTAGAATGTGGTTGGTCGTTTCCTTTTTTGGCGT     35 
TTTTGAAGGGTTAATCTTGCATCTCATTCACAAAATATGGTGGATTCTGAAGGAGAGAGA     95 
TGTAGGTTCAAATTTGGGGGAAATATAAGCCGAAACCGTAGTAGGGGTGAAGTTGAGGGG    155 
GAGGTCGTTGGGACGCCATAATATACTGTGTTGTAGGATATTCTGTGCTAAAATCAACAC    215 
AAATTAATGGAATAGAGTCCTTTAGAAGTAAATATTCGCAAATTGCGTCCAAAAAATACA    275 
CCCCTACAGAGCCCGCTCACAGTCACCTGAATCAACTCATTAAACGTTGCTAACCAACTT    335 
TATCCACTACTTGGAATAAAACAAAGCAGTCTTCAAACTCCCCCAAAAGATCACTTATTG    395 
AAACTATGAAACTTGCATTACAATAACCGTCCCTTTTTATCCCCTTTTGTATCTTTATAT    455 
CTTCCTGTTAAACCTCTCAAACTCGCAAAACGTGATTCCTTTGAGCTTGGGAAGTTTGGC    515 
 
   Primer n49knc1 
 ◄───────────────── 
TGGTCAGACTTCCACACATAAACCTCCACCCAATGAAAGCCGAGCTATTGAAAGAGGGAG    575 
ATGGTAGAACGATGCAATTGGGCTTTTTCCACGGGACAAGTCGTGAATTATATAGCTACG    635 
GGCCAATTGTCTTAATCTACTGACTTCTTACCACCACAACCACCCCCACAACCTATATAC    695 
ACTCCTTCAACCCTAACCCCCGTTTGCGCCAATCAGCGTTCTCGGAATACTCCCATCTGG    755 
 
             ─────── 
ACTAAACTCTTCACAGCGACCGAACCTCTGTTACACACCAAAAGCACAACCCCTCACACA    815 
 
Primer 49-1 
──────────► 
ATGCTGCGATCTGCTGCTGCCCGAGCCGTCAGGGCTGTGCGCCCCCGGCTGTCTGCTCGA    875 
MetLeuArgSerAlaAlaAlaArgAlaValArgAlaValArgProArgLeuSerAlaArg     20 
 
TACATGGCCACCACCGCTCTGCCCCAGGACCCCATCCCCTCCGGAGCTCTGGGCCAGAAG    935 
TyrMetAlaThrThrAlaLeuProGlnAspProIleProSerGlyAlaLeuGlyGlnLys     40 
 
           Primer n49nc2 
        ◄─────────────────── 
GTGCCTCACGTCGATGAGAGCCACCAGGACCTGCTGTTCCGAACCTCTCACATGGTGGAG    995 
ValProHisValAspGluSerHisGlnAspLeuLeuPheArgThrSerHisMetValGlu     60 
 
                                                          ──        
GATCTCGAGACCTACGACGAGGACTCCCCTATCAACACGTCGGACGCCAACACCCGAATC   1055 
AspLeuGluThrTyrAspGluAspSerProIleAsnThrSerAspAlaAsnThrArgIle     80 
 
   Primer 49-4 
─────────────────► 
CGAGCCTTCACCATCAACTTTGGTCCCCAGCATCCCGCTGCCCACGGTGTGCTGCGTCTG   1115 
ArgAlaPheThrIleAsnPheGlyProGlnHisProAlaAlaHisGlyValLeuArgLeu    100 
 
ATTCTGGAGCTGTCTGGAGAGGAAATCATTCGATCGGACCCCCACGTCGGTCTGCTGCAC   1175 
IleLeuGluLeuSerGlyGluGluIleIleArgSerAspProHisValGlyLeuLeuHis    120 
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                                      Primer 49-2 
                                  ───────────────────► 
CGAGGAACCGAGAAGCTCATTGAGTACAAGACTTACATGCAGGCGCTGCCATACTTTGAT   1235 
ArgGlyThrGluLysLeuIleGluTyrLysThrTyrMetGlnAlaLeuProTyrPheAsp    140 
 
CGTCTGGATTACGTGTCCATGATGACCAACGAGCAGGTTTTCTCTCTGGCTGTCGAGAAG   1295 
ArgLeuAspTyrValSerMetMetThrAsnGluGlnValPheSerLeuAlaValGluLys    160 
 
CTGCTCAACGTGGAGGTGCCCCTGCGAGGCAAGTACATCCGAACCATGTTCGGAGAGATC   1355 
LeuLeuAsnValGluValProLeuArgGlyLysTyrIleArgThrMetPheGlyGluIle    180 
 
ACCCGAGTGCTCAACCATCTCATGTCCGTGTGTTCACACGCCATGGATGTCGGTGCTCTG   1415 
ThrArgValLeuAsnHisLeuMetSerValCysSerHisAlaMetAspValGlyAlaLeu    200 
 
ACCCCCTTCCTTTGGGGTTTTGAGGAGCGAGAAAAGCTTATGGAGTTCTACGAGCGAGTC   1475 
ThrProPheLeuTrpGlyPheGluGluArgGluLysLeuMetGluPheTyrGluArgVal    220 
 
                        Primer 49i2 
                     ─────────────────► 
TCTGGAGCCCGTCTGCACGCCGCGTACGTGCGACCTGGAGGAGTCTCCCAGGACCTGCCC   1535 
SerGlyAlaArgLeuHisAlaAlaTyrValArgProGlyGlyValSerGlnAspLeuPro    240 
 
GCCGGCCTGCTGGACGATATTTACATGTGGGCTACACAGTTCGGTGACCGTCTGGACGAA   1595 
AlaGlyLeuLeuAspAspIleTyrMetTrpAlaThrGlnPheGlyAspArgLeuAspGlu    260 
 
        Primer 49-3 
    ───────────────────► 
ATCGAGGAGCTGCTGACCGATAACCGAATTTGGAAGCTACGAACCGTCAACATTGGAACC   1655 
IleGluGluLeuLeuThrAspAsnArgIleTrpLysLeuArgThrValAsnIleGlyThr    280 
 
GTGACCGCCCAGGACGCCTTGAACCTTGGTCTTTCCGGCCCCATGCTGCGAGGATCCGGT   1715 
ValThrAlaGlnAspAlaLeuAsnLeuGlyLeuSerGlyProMetLeuArgGlySerGly    300 
 
ATCCCCTTTGACATTCGAAAGAACGCCCCCTACGACGCATACGACAAGGTCGACTTCGAC   1775 
IleProPheAspIleArgLysAsnAlaProTyrAspAlaTyrAspLysValAspPheAsp    320 
 
GTCCCCGTCGGCATGAACGGAGATTGTTACGACCGATACCTGATTCGAATGGCCGAGTTC   1835 
ValProValGlyMetAsnGlyAspCysTyrAspArgTyrLeuIleArgMetAlaGluPhe    340 
 
CGACAGTCGCTGCGAATCATCGAGCAGTGCTGCAACGACATGCCTGCCGGCGCCGTTAAG   1895 
ArgGlnSerLeuArgIleIleGluGlnCysCysAsnAspMetProAlaGlyAlaValLys    360 
 
                                              Primer n49i1 
                                            ◄──────────────         
GTGGAGGACTTCAAGATTAACTCGCCTCCTAGAAACCTCATGAAGGAGGATATGGAGGCC   1955 
ValGluAspPheLysIleAsnSerProProArgAsnLeuMetLysGluAspMetGluAla    380 
 
                                                   ─────────        
CTGATCCACCACTTCCTGCTCTACACAAAGGGATACTCTGTTCCTCCCGGAGAGACCTAC   2015 
LeuIleHisHisPheLeuLeuTyrThrLysGlyTyrSerValProProGlyGluThrTyr    400 
 
Primer 49-2.5 
───────────► 
ACCGCCATCGAGGCCCCCAAGGGAGAGATGGGTGTCTACGTCGTCTCCGACGGTAGTGAG   2075 
ThrAlaIleGluAlaProLysGlyGluMetGlyValTyrValValSerAspGlySerGlu    420 
CGACCATACAAGTGCAAGATCCGAGCCCCCGGATTTGCCCATCTCGGAGCCTTTGATCAC   2135 8.1  Genes and primers 171 
ArgProTyrLysCysLysIleArgAlaProGlyPheAlaHisLeuGlyAlaPheAspHis    440 
 
                           Primer n49kc2 
                         ─────────────────► 
ATTGCCCGAGGACATTTCCTTCCCGACGCCGTGGCCATTATTGGTACCATGGATCTTGTG   2195 
IleAlaArgGlyHisPheLeuProAspAlaValAlaIleIleGlyThrMetAspLeuVal    460 
 
TTTGGAGAGGTTGATCGATAGTCATAGAATACATACTAAGCAGAGTCGCATATGCGTGTG   2255 
PheGlyGluValAspArg***                                           466 
 
CTCGTGGAATGTACTGTAGAGGGTTGTACACTGTATGTGAGAGCAGAGTTGCTATAAGGA   2315 
GAGGTGGTGGATGCGTGACTGTTAGTTGGACTGTGAGTCAGAATGGTCCGTTGAGAGCAA   2375 
TGTGGGTCATGCTAAATCTCTTAATGCTTTCTCTTCTACTATGGTGATGTTACCTCACAG   2435 
ATACAACAATCGAGATACGGGTCGCGAGACGAGTAGATGTGAGACTACAAATACTGTACA   2495 
CTTGTATAACTAATCTACAGGACAGGTGAATGCGAAAGTAAAATGCGATCATCTCTCGGC   2555 
CGTAGATGGTCATATTAGTCACATATAATCTGATGCCGGTAAATTTCACATGTCAAGCAT   2615 
 
           Primer n49kc3 
         ─────────────────► 
GTCCATATGGATCTGTCATCAAGCGAGACAGCCACCAAGACTGGAACCAATGCCGCTGGT   2675 
AGTAATGGACCTTCTGGTACCAGAGCTGTCATCATTTGCTTGAACCACCTCCTTCATATG   2735 
CTCACAAAATCACATGGCTGTGGTTCATCTCACACCAATCCTTTGAGCATATGTCATTCA   2795 
TGTAGCATGCATAAACATGTCATCAAAGAAACATATTGGGGCGATGGGAACTGATAAGGG   2855 
GGTGGATGAACATCTGATCTATTGGATGAACTCGATATAAATGATCGTTAATTGAACTAC   2915 
TTGTAGTTATTACAAACACTTTTGCAAGTGCTAGATCATGATTACTTGTGTACACCTACT   2975 
GATGCGTGATCAATAGGTAAACCATGATCTGGTGAATACCATTACCTGTCCCCTGGTGTA   3035 
CATAAGCATACTACGGGACAACTTCTGCACAGAGAGAGATC                      3076 
Table 8.1: Sequencing primers for the NUCM gene. 
Name   Sequence 
n49knc1 (reverse) 5’-ATGTGTGGAAGTCTGACC-3’ 
49-1  5’-TCACACAATGCTGCGATC-3’ 
n49nc2 (reverse)  5’-CCTGGTGGCTCTCATCGACG-3’ 
49-4 5’-TCCGAGCCTTCACCATCAAC-3’ 
49-2 5’-ACATGCAGGCGCTGCCATAC-3’ 
49i2 5’-GCGTACGTGCGACCTGGA-3’ 
49-3 5’-AGGAGCTGCTGACCGATAAC-3’ 
n49i1 (reverse)  5’-GCCTCCATATCCTCC-3’ 
49-2.5 5’-GAGACCTACACCGCCATCGAG-3’ 
n49kc2 5’-ACGCCGTGGCCATTATTG-3’ 
n49kc3 5’-GATCTGTCATCAAGCGAG-3’ 
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Table 8.2: Mutagenesis primers for the NUCM gene. 
Mutant Name  Sequence 
V97G NUCM  V97Gf  5’-GGGCTGCGTCTGATTCTGGAGC-3’ 
  NUCM V97r (reverse)  5’-ACCGTGGGCAGCGGGATGCTG-3’ 
V97I NUCM  V97If  5’-ATACTGCGTCTGATTCTGGAGC-3’ 
  NUCM V97r (reverse)  5’-ACCGTGGGCAGCGGGATGCTG-3’ 
V97W NUCM  V97Wf  5’-TGGCTGCGTCTGATTCTGGAGC-3’ 
  NUCM V97r (reverse)  5’-ACCGTGGGCAGCGGGATGCTG-3’ 
R99D NUCM  R99Df  5’-GATCTGATTCTGGAGCTGTCTG-3’ 
  NUCM R99r (reverse)  5’-CAGCACACCGTGGGCAGCGGGATG-3’ 
R99T NUCM  R99Tf  5’-ATCCTGATTCTGGAGCTGTCTG-3’ 
  NUCM R99r (reverse)  5’-CAGCACACCGTGGGCAGCGGGATG-3’ 
H120R NUCM  H120Rf  5’-CGCCGAGGAACCGAGAAGCTCATTG-3’ 
  NUCM H120r (reverse)  5’-CAGCAGACCGACGTGGGGGTC-3’ 
H120W NUCM  H120Wf  5’-TGGCGAGGAACCGAGAAGCTCATTG-3’ 
  NUCM H120r (reverse)  5’-CAGCAGACCGACGTGGGGGTC-3’ 
R121K NUCM  R121Kf  5’-AAAGGAACCGAGAAGCTCATTG-3’ 
  NUCM H120Hr (reverse)  5’-GTGCAGCAGACCGACGTGG-3’ 
G122A NUCM  G122Af  5’-GCAACCGAGAAGCTCATTGAGTAC-3’ 
  NUCM R121Rr (reverse)  5’-TCGGTGCAGCAGACCGACG-3’ 
G122V NUCM  G122Vf  5’-GTAACCGAGAAGCTCATTGAGTAC-3’ 
  NUCM R121Rr (reverse)  5’-TCGGTGCAGCAGACCGACG-3’ 
E124D NUCM  E124Df  5’-GACAAGCTCATTGAGTACAAGAC-3’ 
  NUCM T123Tr (reverse)  5’-GGTTCCTCGGTGCAGCAGACC-3’ 
E124Q NUCM  E124Qf  5’-CAGAAGCTCATTGAGTACAAGAC-3’ 
  NUCM T123Tr (reverse)  5’-GGTTCCTCGGTGCAGCAGACC-3’ 
Y144F NUCM  Y144Ff  5’-TTCGTGTCCATGATGACCAACG-3’ 
  NUCM Y144r (reverse)  5’-ATCCAGACGATCAAAGTATGG-3’ 
Y144H NUCM  Y144Hf  5’-CACGTGTCCATGATGACCAACG-3’ 
  NUCM Y144r (reverse)  5’-ATCCAGACGATCAAAGTATGG-3’ 
Y144I  occurred by chance when mutant Y144F was generated 
Y144W NUCM  Y144Wf  5’-TGGGTGTCCATGATGACCAACG-3’ 
  NUCM Y144r (reverse)  5’-ATCCAGACGATCAAAGTATGG-3’ 
V145F NUCM  V145Ff  5’-TTCTCCATGATGACCAACGAGCAG-3’ 
  NUCM V145r (reverse)  5’-GTAATCCAGACGATCAAAGTATG-3’ 8.1  Genes and primers 173 
Mutant Name  Sequence 
V145T NUCM  V145Tf  5’-ACGTCCATGATGACCAACGAGCAG-3’ 
  NUCM V145r (reverse)  5’-GTAATCCAGACGATCAAAGTATG-3’ 
M188C NUCM  M188Cf  5’-TGCTCCGTGTGTTCACACGCC-3’ 
  NUCM M188r (reverse)  5’-GAGATGGTTGAGCACTCGGGTG-3’ 
M188L NUCM  M188Lf  5’-CTGTCCGTGTGTTCACACGCC-3’ 
  NUCM M188r (reverse)  5’-GAGATGGTTGAGCACTCGGGTG-3’ 
M188Y NUCM  M188Yf  5’-TATTCCGTGTGTTCACACGCCATG-3’ 
  NUCM M188r (reverse)  5’-GAGATGGTTGAGCACTCGGGTG-3’ 
S192Y NUCM  S192Yf  5’-TACCACGCCATGGATGTCGGTGC-3’ 
  NUCM S192r (reverse)  5’-ACACACGGACATGAGATGGTTG-3’ 
F207W   NUCM F207Wf  5’-TGGGAGGAGCGAGAAAAGCTTATG-3’ 
  NUCM F207r (reverse)  5’-ACCCCAAAGGAAGGGGGTCAG-3’ 
R210I NUCM  R210If  5’-ATAGAAAAGCTTATGGAGTTCTAC-3’ 
  NUCM R210r (reverse)  5’-CTCCTCAAAACCCCAAAGGAAG-3’ 
E211Q NUCM  E211Qf  5’-CAAAAGCTTATGGAGTTCTACG-3’ 
  NUCM E211r (reverse)  5’-TCGCTCCTCAAAACCCCAAAG-3’ 
E218Q NUCM  E218Qf  5’-CAGCGAGTCTCTGGAGCCCGTC-3’ 
  NUCM E218r (reverse)  5’-GTAGAACTCCATAAGCTTTTCTC-3’ 
R224D  occurred by chance when mutant R224N was generated 
R224I NUCM  R224If  5’-ATTCTGCACGCCGCGTACGTGC-3’ 
  NUCM R224r (reverse)  5’-GGCTCCAGAGACTCGCTCG-3’ 
R224K  NUCM R224Kf   5’-AAGCTGCACGCCGCGTACGTGC-3’ 
  NUCM R224r (reverse)  5’-GGCTCCAGAGACTCGCTCG-3’ 
R224N NUCM  R224Nf  5’-AATCTGCACGCCGCGTACGTGC-3’ 
  NUCM R224r (reverse)  5’-GGCTCCAGAGACTCGCTCG-3’ 
L225A NUCM  L225Af  5’-GCGCACGCCGCGTACGTGCGACC-3’ 
  NUCM L225r (reverse)  5’-ACGGGCTCCAGAGACTCGCTC-3’ 
L225F NUCM  L225Ff  5’-TTCCACGCCGCGTACGTGCGACC-3’ 
  NUCM L225r (reverse)  5’-ACGGGCTCCAGAGACTCGCTC-3’ 
L225H NUCM  L225Hf  5’-CACCACGCCGCGTACGTGCGACC-3’ 
  NUCM L225r (reverse)  5’-ACGGGCTCCAGAGACTCGCTC-3’ 
L225V NUCM  L225Vf  5’-GTCCACGCCGCGTACGTGCGACC-3’ 
  NUCM L225r (reverse)  5’-ACGGGCTCCAGAGACTCGCTC-3’ 
K407H NUCM  K407Hf  5’-CACGGAGAGATGGGTGTCTACG-3’ 174   8  Appendix  
Mutant Name  Sequence 
  NUCM K407r (reverse)  5’-GGGGGCCTCGATGGCGGTGTAG-3’ 
K407R NUCM  K407Rf  5’-CGAGGAGAGATGGGTGTCTACG-3’ 
  NUCM K407r (reverse)  5’-GGGGGCCTCGATGGCGGTGTAG-3’ 
K407W NUCM  K407Wf  5’-TGGGGAGAGATGGGTGTCTACG-3’ 
  NUCM K407r (reverse)  5’-GGGGGCCTCGATGGCGGTGTAG-3’ 
 
8.1.2  NUKM gene (ACCESSION AJ250340) 
                                               GAATTCCCAGAGA     13 
CAGTTCTTCTCTGCGAAAACTGATATCCGAGCTGGGCTTTCTGCGGGCTCTGGACACGAG     73 
AAACAACCCCGAGACGGAGGAGTTCTATCCGGATCTCATGTCTGTTATGGGCACTCAGGC    133 
CGTGAACGGCAAGAGCATCTCGATCCAGTACACCAACACTCAGACGGCCGAGTTTGAGCG    193 
GGCATGGCAGGGTACAGACACCAAGTTTGTGCGCAACCTCAAGGCACACAATCGAGAGAC    253 
GTACGAGGACAGAATCCTGTACCAGACTCAGGCCATGCTTCGAGTGCATAACAAGGGCGG    313 
TCTGCTGTATTGGATGGACGGTGTGTTGCTTGGTAAGGACCCCAAGTACATTGAGTCGTA    373 
CAAGAAGCACGCTGCCAAGTGCTGGGCTGCTCGGGAGAAGCGACGCAAGCAGCAAGATGC    433 
TGAGGAGAGAGTTGCAGGGCTGTCGAAGGATGTTAACGATACCGCTATGGCTAGTGGAGA    493 
AGAGGCTTATGGATTCATTTAATGCTATATTTATTGTATTTTTACCCAAACGAATGAGAG    553 
AGCTGAGCTCGAAATGAAAATGAGAATACTGGTACGAGTAACTACAATTACTCGTACCGG    613 
TACTTGTGTGTAATTGGAATACTGAGCCAGTGGAGAGTGCGATTCTCCCGTTTTTGTACA    673 
TTATCTAGTGGATATAACTAACATTCGAATCAAAAAGCTATCTTGGTTCTGATTTTATAC    733 
TGTTTGACACCCCTGTCCATAGTAATATCTTAAGCAGTGGATGGAATCATGATCACTGTA    793 
TACTGTATACACCTTCATGATGTTTACAAGCGCTATACTGGTGATGTTGTCCCAACAGGT    853 
TAGGGTTTGATCCCTCCTCAGTGTGTTTGCACGTGATCTGGCGTCCAGCCAATAACAGCA    913 
ATCACAAGTGGTATTACCAAGAAGCGTGATTTTCGCGCGGTGGCGGTTTTCCCTCGTTGT    973 
TGCCGTCGGTTGGCAGTCTCGTTCTCTTCACACCAGGCCAACATTTCTTCAATTGCAACA   1033 
TTTTTCTACACTTGTAGGTGCATGTTTGGTGTTTGTCTGAGACGAGGGAGTGAGTCGGAG   1093 
ATGTGTTTTTTTTTAGCGAGGAGTGCTCGGAATTGGATATTTAAACACACAAAAACGGTA   1153 
 
 Primer SAPA/ORF/c 
──────────────────► 
ATTTCCGGTGGCTGGTGCGATTAAACACGTCGTCCTGTCACCAGCTTGTCTCGTACGCCC   1213 
CTTATATCTCTTCTTACCCCCAAACCACCTCCTCCATTAAGCTTCTGCATTGGCCAATCA   1273 
GGGCTTCCCATATTTGGGTAACGAAATTATGGTTGGAGGCTTCCACTATCGTATATTTGC   1333 
ACCAGCCAGCAGAGCACCTCACGCTTGTTGTATCGTCACAAAACCACACATCCCTACAGC   1393 
 
ATGCTCAGATCACAGATTGGCCGACTGGCTCTGCGACCGACGCTGGTCCCCGCCACTGTC   1453 
MetLeuArgSerGlnIleGlyArgLeuAlaLeuArgProThrLeuValProAlaThrVal     20 
 
ATCCCCCAGACCCGAGCATACTCCGCTCCCGCTGGAACCCCCCGAGTGTCGTCCTCCTCC   1513 
IleProGlnThrArgAlaTyrSerAlaProAlaGlyThrProArgValSerSerSerSer     40 
 
 
                            ── 
ATGCCCACCGACTTCCCTCTCCCCTCACAGCAGAAGCCCAACAGCGCCGTCGACTACACC   1573 
MetProThrAspPheProLeuProSerGlnGlnLysProAsnSerAlaValAspTyrThr     60 
 8.1  Genes and primers 175 
Primer SAPA/seq 
────────────────► 
CTGACCACTCTGGATGCCGTGGCCAACTGGGCTCGACAGGGCTCTTTCTGGCCCGTGACC   1633 
LeuThrThrLeuAspAlaValAlaAsnTrpAlaArgGlnGlySerPheTrpProValThr     80 
 
TTCGGTCTGGCGTGCTGTGCCGTCGAAATGATGCACGTGTCTGCCCCCCGGTACGATCAG   1693 
PheGlyLeuAlaCysCysAlaValGluMetMetHisValSerAlaProArgTyrAspGln    100 
 
GATCGTCTGGGTATCATTTTCCGAGCCTCCCCTCGACAGTCCGATATCATGATTGTGGCC   1753 
AspArgLeuGlyIleIlePheArgAlaSerProArgGlnSerAspIleMetIleValAla    120 
 
GGAACCCTCACAAACAAAATGGCCCCCGTGCTGCGTCAGGTGTACGACCAGATGCCCGAG   1813 
GlyThrLeuThrAsnLysMetAlaProValLeuArgGlnValTyrAspGlnMetProGlu    140 
 
CCCCGATGGGTCATCTCCATGGGCTCCTGCGCTAACGGTGGTGGATACTACCACTTCTCC   1873 
ProArgTrpValIleSerMetGlySerCysAlaAsnGlyGlyGlyTyrTyrHisPheSer    160 
 
TACTCGGTGGTGCGAGGCTGCGACCGAATCGTGCCTGTGGACGTCTACGTTCCCGGATGT   1933 
TyrSerValValArgGlyCysAspArgIleValProValAspValTyrValProGlyCys    180 
 
CCCCCCACCTCCGAGGCCCTCATGTACGGCGTCTTCCAGCTCCAGCGAAAGATGCGAAAC   1993 
ProProThrSerGluAlaLeuMetTyrGlyValPheGlnLeuGlnArgLysMetArgAsn    200 
 
ACAAAGATTACCCGAATGTGGTACCGAAAGTAAGCATAATAAACGTTTAGATAGTGAGTC   2053 
ThrLysIleThrArgMetTrpTyrArgLys***                               210 
 
GGCTGTGTGTAGCCAAAGCTCATCAACGCAGGTCCATTGGTCCGTGTGAGGTACATGTAG   2113 
ATCTTTTTACCATGCACCAGGTAGGTCTACGCACCCTCAATTCTGGATGGAGTGATGGTT   2173 
ATTGGTACTTCAAGACGCAGTATATTAGCTGTTGATGTTCGTTGTGTTATTCAATCACCT   2233 
GTCTACTAGTATCAAATACCGTACTTGTAGTAGAGGAATTC                      2274 
Table 8.3: Sequencing primers for the NUKM gene. 
Name   Sequence 
SAPA/ORF/c 5’-CTGTCACCAGCTTGTCTCG-3’ 
SAPA/seq 5’-CCCTGACCACTCTGGATGC-3’ 
Table 8.4: Mutagenesis primers for the NUKM gene. 
Mutant Name  Sequence 
A84V NUKM  A84Vf  5’-GTGTGCTGTGCCGTCGAAATGATG-3’ 
  NUKM A84r (reverse)  5’-CAGACCGAAGGTCACGGGCCAG-3’ 
V88F NUKM  V88Ff  5’-TTCGAAATGATGCACGTGTCTG-3’ 
  NUKM V88r (reverse)  5’-GGCACAGCACGCCAGACCGAAG-3’ 
V88L NUKM  V88Lf  5’-CTCGAAATGATGCACGTGTCTG-3’ 
  NUKM V88r (reverse)  5’-GGCACAGCACGCCAGACCGAAG-3’ 176   8  Appendix  
Mutant Name  Sequence 
V88M NUKM  V88Mf  5’-ATGGAAATGATGCACGTGTCTG-3’ 
  NUKM V88r (reverse)  5’-GGCACAGCACGCCAGACCGAAG-3’ 
 
8.1.3  NUHM gene (ACCESSION AJ250338) 
                              ATCCCAATCAGATGTACTTGTAATTTAGTT     30 
TGCCATTGAACACATATGTCCGATTAGTAAGCAAGAAACCCAGAGTGAATACACGTCCAA     90 
AATATAATGAAGCTCAAATCGTGTGTCTGGCGACATCAATCGCACAAGGGTGATCCGTTA    150 
ATCCGTATTTCATCCCCTCCTCCCTCCAGCCAATATCCTCCCTCCCAATTACTCAACCTT    210 
AATTCAGGTCATCAACCAATAGGCGTGGCCCAATTTCTGAAAAACTAACTCTGGAGCGTT    270 
 
           Primer 24k PB Seq1                Primer 24 PB3 
          ───────────────────►             ◄──────────────── 
TGGGTCAAGGGCACGAACATCTCCATCACCACAGCTTCAGCTCGACCTTCACACACAAAA    330 
 
                               Primer 24 PB1 
───                        ◄──────────────────── 
ATGCTCCGACTGATCCGACCCCGTTTGGCAGCTCTCGCCCGGCCCACCACTCGGGCCCCC    390 
MetLeuArgLeuIleArgProArgLeuAlaAlaLeuAlaArgProThrThrArgAlaPro     20 
 
                                        Primer 24k PB2 
                                    ────────────────────► 
CAGGCTCTCAATGCCCGAACTCACATTGTCTCTGTACACCGAAACACTGAGAACAACAAC    450 
GlnAlaLeuAsnAlaArgThrHisIleValSerValHisArgAsnThrGluAsnAsnAsn     40 
 
CCCAGCATTCCCTTTGAGTTCTCCCCCGAGAACATGAAGCGAGCTGAGGAGGTGATTGCC    510 
ProSerIleProPheGluPheSerProGluAsnMetLysArgAlaGluGluValIleAla     60 
 
AAGTACCCCCCTCAGTACAAGAAGGCTGCTGTTATGCCTCTTCTCGACATTGGCCAGCGA    570 
LysTyrProProGlnTyrLysLysAlaAlaValMetProLeuLeuAspIleGlyGlnArg     80 
 
CAGCTCGGTTATACCTCCATCTCCGTCATGAACTACGTGGCCAAGCTGCTGGAAATGCCC    630 
GlnLeuGlyTyrThrSerIleSerValMetAsnTyrValAlaLysLeuLeuGluMetPro    100 
 
CCCATGCGAGTCTATGAGGTGGCCACCTTCTACACAATGTACAACCGAACCCCTATGGGC    690 
ProMetArgValTyrGluValAlaThrPheTyrThrMetTyrAsnArgThrProMetGly    120 
 
CGGTACCATCTGCAGATCTGTACCACCACCCCCTGTCAGCTGTGTGGCTCCGACGGTATC    750 
ArgTyrHisLeuGlnIleCysThrThrThrProCysGlnLeuCysGlySerAspGlyIle    140 
 
ATGGAGGCTGTCCAGAACACCCTTAACATCAAGCCCGGTGAGACCACCAAGGACAACCTC    810 
MetGluAlaValGlnAsnThrLeuAsnIleLysProGlyGluThrThrLysAspAsnLeu    160 
 
TTCACTCTCTCTGAGGTTGAGTGTCTCGGAGCCTGTGTCAACGCCCCCATGATGGCCATC    870 
PheThrLeuSerGluValGluCysLeuGlyAlaCysValAsnAlaProMetMetAlaIle    180 
 
AACGACGACTACTACGAGGATCTCACTCCCGAGGGAACCGTCAAGCTTCTGGAGGACTGC    930 
AsnAspAspTyrTyrGluAspLeuThrProGluGlyThrValLysLeuLeuGluAspCys    200 8.1  Genes and primers 177 
AAGGCCGGCAAGATGCCCACTCCCGGCCCCGAGAACCACGTTCGACGAGACTGCGAGCCC    990 
LysAlaGlyLysMetProThrProGlyProGluAsnHisValArgArgAspCysGluPro    220 
 
GCCTCCGGCCAGAAGGTGCTGCTCAGCAAGGAGCCTCATAACGTGGCCGATTTCCTCCAG   1050 
AlaSerGlyGlnLysValLeuLeuSerLysGluProHisAsnValAlaAspPheLeuGln    240 
 
               Primer 24k GB2 
             ──────────────────► 
GAGGGTATTTAAGGGAAGGAGACTCATCACACAAGAGAAAGTCAAAAATGCCATGGCTGA   1110 
GluGlyIle***                                                    243 
 
TATGGCTGATATAGCATAACATTAGATTCGGAACGAGGGCGGCTGGGGGCAACGCCTCTT   1170 
TACAAGTTGGAGCGTAGTCTCAAAGTAGAAATGACACATGACAGAGATTATGTATTTATG   1230 
TACTTACACTGTCGTAGTTTCTTGTACTCG                                 1260 
Table 8.5: Sequencing primers for the NUHM gene. 
Name   Sequence 
24k PB Seq  5’-GCACGAACATCTCCATCACC-3’ 
24 PB3 (reverse)  5’-CATTTTTGTGTGTGAAGGTC-3’ 
24 PB1 (reverse)  5’-GGTGGGCCGGGCGAGAGCTGC-3’ 
24 PB2  5’-CACCGAAACACTGAGAACAAC-3’ 
24k GB2  5’-GGAAGGAGACTCATCACAC-3’ 
Table 8.6: Mutagenesis primers for the NUHM gene. 
Mutant Name  Sequence 
V166T NUHM  V166Tf  5’-ACTGAGTGTCTCGGAGCCTGTG-3’ 
  NUHM E165Er (reverse)  5’-CTCAGAGAGAGTGAAGAGG-3’ 
V166K NUHM  V166Kf  5’-AAGGAGTGTCTCGGAGCCTGTG-3’ 
  NUHM E165Er (reverse)  5’-CTCAGAGAGAGTGAAGAGG-3’ 
C168A NUHM  C168Af  5’-GCTCTCGGAGCCTGTGTCAACG-3’ 
  NUHM E167Er (reverse)  5’-CTCAACCTCAGAGAGAGTG-3’ 
C172A NUHM  C172Af  5’-GCTGTCAACGCCCCCATGATGG-3’ 
  NUHM A171Ar (reverse)  5’-GGCTCCGAGACACTCAACC-3’ 
A175S NUHM  A175Sf  5’-TCCCCCATGATGGCCATCAACG-3’ 
  NUHM N174Nr (reverse)  5’-GTTGACACAGGCTCCGAGAC-3’ 
A175K NUHM  A175Kf  5’-AAGCCCATGATGGCCATCAACG-3’ 
  NUHM N174Nr (reverse)  5’-GTTGACACAGGCTCCGAGAC-3’ 
M177H NUHM  M177Hf  5’-CACATGGCCATCAACGACGACTAC-3’ 178   8  Appendix  
Mutant Name  Sequence 
  NUHM P176Pr (reverse)  5’-GGGGGCGTTGACACAGGCTC-3’ 
M177K NUHM  M177Kf  5’-AAGATGGCCATCAACGACGACTAC-3’ 
  NUHM P176Pr (reverse)  5’-GGGGGCGTTGACACAGGCTC-3’ 
8.2  Amino acid sequences 
8.2.1  The 49-kDa subunit 
Y.lipolytica       ----MLRSAAARAVRAVRPR--------LSARYMATTALPQDPIPSGALGQKVPHVDESH  48 
N.crassa           MATTLFRLAGRNAKRHCMRQSTTIAHNLNSTRAFSASALRRYAEPS-YEGQGTRLVPTGD  59 
B.taurus           ------------------------------------------------ARQWQPDVEWAE  12 
H.sapiens          ----MAALRALCGFRGVAAQ-----------VLRPGAGVRLPIQPSRGVRQWQPDVEWAQ  45 
P.denitrificans    ------------------------------------------------------------ 
R.capsulatus       ------------------------------------------------------------ 
T.thermophilus     ------------------------------------------------------------ 
E.coli             ------------------------------------------------------------ 
                                                                                
 
Y.lipolytica       QDLLFRTSHMVEDLETYDED-SPINTSDANTRIRAFTINFGPQHPAAHGVLRLILELSGE 107 
N.crassa           DFAPNNDLYGLEALKADGAPRVPPQDHILARKVRHYTVNFGPQHPAAHGVLRLILELKGE 119 
B.taurus           QYG-GAVMYPTKETAHWKPPPWNDVDPPKDTLVSNLTLNFGPQHPAAHGVLRLVMELSGE  71 
H.sapiens          QFG-GAVMYPSKETAHWKPPPWNDVDPPKDTIVKNITLNFGPQHPAAHGVLRLVMELSGE 104 
P.denitrificans    ---------MDGDIRKNSLDDGSMDALTGEQSIRNFNINFGPQHPAAHGLLRMVLELDGE  51 
R.capsulatus       ---------MDGDIRHNSYDDGSEDVLTGEQSIRNFNINFGPQHPAAHGVLRMVLELDGE  51 
T.thermophilus     ---------MREEFLEEIPLDAPPEE-AKELRTEVMTLNVGPQHPSTHGVLRLMVTLSGE  50 
E.coli             -----------MEALTFKPEEWGMKRGTENE--DFMFLNLGPNHPSAHGAFRIVLQLDGE  47 
                                                        :*.**:**::** :*::: *.** 
 
Y.lipolytica       EIIRSDPHVGLLHRGTEKLIEYKTYMQALPYFDRLDYVSMMTNEQVFSLAVEKLLNVEVP 167 
N.crassa           EIVRADPHVGLLHRGTEKLCEYRTYLQALPYFDRLDYVSMMTNEQCFALAVEKLLNVEIP 179 
B.taurus           MVRKCDPHIGLLHRGTEKLIEYKTYLQALPYFDRLDYVSMMCNEQAYSLAVEKLLNIRPP 131 
H.sapiens          MVRKCDPHIGLLHRGTEKLIEYKTYLQALPYFDRLDYVSMMCNEQAYSLAVEKLLNIRPP 164 
P.denitrificans    IVERADPHIGLLHRGTEKLMESRTYLQNLPYLDRLDYVAPMNQEHAWCLAIERLTGTVIP 111 
R.capsulatus       IVERADPHIGLLHRGTEKLMESRTYLQNTPYFDRLDYVAPMNQEHAWCLAIEKLTGTAVP 111 
T.thermophilus     EVLEVVPHIGYLHTGFEKTMEHRTYLQNITYTPRMDYLHSFAHDLAYALAVEKLLGAVVP 110 
E.coli             EIVDCVPDIGYHHRGAEKMGERQSWHSYIPYTDRIEYLGGCVNEMPYVLAVEKLAGITVP 107 
                    :    *.:*  * * **  * ::: .  .*  *::*:    ::  : **:*:* .   * 
 
Y.lipolytica       LRGKYIRTMFGEITRVLNHLMSVCSHAMDVGALTPFLWGFEEREKLMEFYERVSGARLHA 227 
N.crassa           ERAKWIRTMFAEITRILNHLMSVLSHAMDVGALTPFLWGFEEREKLMEFYERVSGARLHA 239 
B.taurus           PRAQWIRVLFGEITRLLNHIMAVTTHALDIGAMTPFFWMFEEREKMFEFYERVSGARMHA 191 
H.sapiens          PRAQWIRVLFGEITRLLNHIMAVTTHALDLGAMTPFFWLFEEREKMFEFYERVSGARMHA 224 
P.denitrificans    RRASLIRVLYSEIGRILNHLMGVTTGAMDVGALTPPLWGFEAREELMIFYERACGARLHA 171 
R.capsulatus       RRASIIRVLFSEIGRILNHLLNVTTQAMDVGALTPPLWGFEEREKLMIFYERACGARLHA 171 
T.thermophilus     PRAETIRVILNELSRLASHLVFLGTGLLDLGALTPFFYAFRERETILDLFEWVTGQRFHH 170 
E.coli             DRVNVIRVMLSELFRINSHLLYISTFIQDVGAMTPVFFAFTDRQKIYDLVEAITGFRMHP 167 
                    * . **.:  *: *: .*:: : :   *:**:** :: *  *: :  : *   * *:*  
 
Y.lipolytica       AYVRPGGVSQDLPAGLLDDIYMWATQFGDRLDEIEELLTDNRIWKLRTVNIGTVTAQDAL 287 
N.crassa           AYVRPGGVHQDIPLGLLDDIYMWATQFGDRIDETEEMLTDNRIWIDRLRGIGVVSAADAL 299 
B.taurus           AYVRPGGVHQDLPLGLMDDIYEFSKNFSLRIDELEEMLTNNRIWRNRTVDIGIVTAEDAL 251 
H.sapiens          AYIRPGGVHQDLPLGLMDDIYQFSKNFSLRLDELEELLTNNRIWRNRTIDIGVVTAEEAL 284 
P.denitrificans    AYFRPGGVHQDLPPDLLDDIEEWCERFPKLVDDLDTLLTENRIFKQRLVDIGIVTEADAL 231 
R.capsulatus       NYFRPGGVHQDLPPDLIDDIEIWAKAFPQVLDDIEGLLTENRIFKQRNADICIITEAEIE 231 
T.thermophilus     NYIRIGGVKEDLPEEFVPELKKLLEVLPHRIDEYEALFAESPIFYERARGVGVIPPEVAI 230 
E.coli             AWFRIGGVADDLPRGWDRLLREFLDWMPKRLASYEKAALQNTILKGRSQGVAPMARKEAL 227 
                    :.* *** :*:*      :      :   : . :    :. *   *  .:  :.      8.2  Amino acid sequences 179 
 
Y.lipolytica       NLGLSGPMLRGSGIPFDIRKNAPYDAYDKVDFDVPVGM-NGDCYDRYLIRMAEFRQSLRI 346 
N.crassa           NLSFTGVMLRGSGVPWDIRKSQPYDAYDQVEFDVPVGI-NGDCYDRYLCRMEEFRQSLRI 358 
B.taurus           NYGFSGVMLRGSGIQWDLRKTQPYDVYDQVEFDVPIGS-RGDCYDRYLCRVEEMRQSIRI 310 
H.sapiens          NYGFSGVMLRGSGIQWDLRKTQPYDVYDQVEFDVPVGS-RGDCYDRYLCRVEEMRQSLRI 343 
P.denitrificans    DWGYTGVMVRGSGLAWDLRRSQPYECYDEFDFQIPVGR-NGDCYDRYLCRMAEMRESCKI 290 
R.capsulatus       KWGYSGVMVRGSGLAWDLRRAQPYECYDEFDFKVAVGK-NGDCYDRYLVRMAEMRESTKI 290 
T.thermophilus     DLGLTGGSLRASGVNYDVRKAYPYSGYETYTFDVPLGE-RGDVFDRMLVRIREMRESVKI 289 
E.coli             EWGTTGAGLRATGIDFDVRKARPYSGYENFDFEIPVGGGVSDCYTRVMLKVEELRQSLRI 287 
                   . . :*  :*.:*: :*:*:  **. *:   *.:.:*   .* : * : :: *:*:* :* 
 
Y.lipolytica       IEQCCNDMPAGA---VKVEDFKINSPPRNLMKEDMEALIHHFLLYTKGYSVPPGETYTAI 403 
N.crassa           IHQCLNKMPAGP---VRVEDYKISPPPRSAMKENMEALIHHFLLYTKGYAVPPGDTYSAI 415 
B.taurus           ISQCLNKMPPGE---IKVDDAKVSPPKRAEMKTSMESLIHHFKLYTEGYQVPPGATYTAI 367 
H.sapiens          IAQCLNKMPPGE---IKVDDAKVSPPKRAEMKTSMESLIHHFKLYTEGYQVPPGATYTAI 400 
P.denitrificans    MQQAVQKLRAEP-AGDVLARGKLTPPRRAEMKRDMESLIHHFKLYTEGFKVPAGEVYAAV 349 
R.capsulatus       ILQACAKLRAPDGQGDILARGKLTPPKRAEMKTSMEALIHHFKLYTEGFKVPAGEVYAAV 350 
T.thermophilus     IKQALERLEPGP---VRDPNPQITPPPRHLLETSMEAVIYHFKHYTEGFHPPKGEVYVPT 346 
E.coli             LEQCLNNMPEGP---FKRDHPLTTPPPKERTLQHIETLITHFLQVSWGPVMPANESFQMI 344 
                   : *.   :               ..* :      :*::* **   : *   * .  :    
 
Y.lipolytica       EAPKGEMGVYVVSDGSERPYKCKIRAPGFAHLGAFDHIARGHFLPDAVAIIGTMDLVFGE 463 
N.crassa           EGPKGEMGVYVVSDGSERPYRVHIRAPGFAHLGGFDHLSRGHMLADAVAVIGTMDLVFGE 475 
B.taurus           EAPKGEFGVYLVSDGSSRPYRCKIKAPGFAHLAGLDKMSKGHMLADVVAIIGTQDIVFGE 427 
H.sapiens          EAPKGEFGVYLVSDGSSRPYRCKIKAPGFAHLAGLDKMSKGHMLADVVAIIGTQDIVFGE 460 
P.denitrificans    EGPKGEFGVYLVADGTNKPWRAKLRAPGFAHLQSIDWMSRGHMLADVPAIIATLDIVFGE 409 
R.capsulatus       EAPKGEFGVYLVADGTNKPYRAKIRAPGYAHLQSIDAVAKGHQLADVSAIIGTMDVVFGE 410 
T.thermophilus     ESARGELGYYIVSDGGSMPYRVKVRAPSFVNLQSLPYACKGEQVPDMVAIIASLDPVMGD 406 
E.coli             EATKGINSYYLTSDGSTMSYRTRVRTPSFAHLQQIPAAIRGSLVSDLIVYLGSIDFVMSD 404 
                   *..:*  . *:.:**   .:: ::::*.:.:*  :    :*  :.*  . :.: * *:.: 
 
Y.lipolytica       VDR 466 
N.crassa           VDR 478 
B.taurus           VDR 430 
H.sapiens          VDR 463 
P.denitrificans    VDR 412 
R.capsulatus       IDR 413 
T.thermophilus     VDR 409 
E.coli             VDR 407 
                   :** 
Figure 8.1: Amino acid sequence alignment of the 49-kDa subunit from various organisms. 
Exchanged amino acid residues are highlighted as in Figure 3.3 – according to the their 
importance for complex I activity: Blue, all exchanges resulted in complex I activity 
comparable to the parental strain (>75%); green, complex I activity was reduced (25-75%); 
yellow, at least one exchange resulted in strongly reduced complex I activity (<25%); red, 
several exchanges strongly reduced complex I activity (<25%). Residues which change the I50 
value for DQA, rotenone or C12E8 are colored in orange. The HRGXE-motif is highlighted in 
pink. The NCBI sequences of Y. lipolytica  (ACCESSION CAG78336), N. crassa 
(ACCESSION CAA38368), B. taurus (ACCESSION P17694), H. sapiens (ACCESSION 
AAC27453),  P. denitrificans (ACCESSION P29916), R. capsulatus (ACCESSION 
AAC24988),  T. thermophilus (ACCESSION AAA97941) and E. coli (ACCESSION 
CAA48363) were aligned by the multiple sequence alignment program ClustalW. Invariant (*), 
highly (:) and weakly similar (.) positions are labeled. 
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8.2.2  The PSST subunit  
Y.lipolytica       MLRSQIG--RLALRP----TLVP--ATVIPQTRAYS--------APAGTPRVSSSSMPTD  44 
N.crassa           MMSSVRTGASMALRARPTAQIVPFRAAAVASISSSSRKDATGAVAPAGAQHGIARRERRE  60 
P.denitrificans    ----------------------------MTGLNTAG--------ADRDLATAELN-----  19 
R.capsulatus       -------------------------MGVMTGSNTAA--------VDMDVAAAALN-----  22 
B.taurus           -------MAALAALRLL-HPILAVRSGVGAALQVRG--------VHSSMAADSPSSTQPA  44 
H.sapiens          -------MAVLSAPGLRGFRILGLRSSVGLAVQARG--------VHQSVATDGPSSTQPA  45 
T.thermophilus     --------------------------MALKDLFERD------------------------  10 
E.coli             ------------------------MDYTLTRIDPNG----------ENDRYPLQKQEIVT  26 
                                                                                
 
Y.lipolytica       FPLPSQQKPN------SAVDYTLTTLDAVANWARQGSFWPVTFGLACCAVEMMHVSAPRY  98 
N.crassa           VPLPSQEGTK------GAVQYALTTLDSIVNWARQSSLWPMTFGLACCAVEMMHLSTPRY 114 
P.denitrificans    ----RELQDK---------GFLLTTTEDIINWARNGSLHWMTFGLACCAVEMMQTSMPRY  66 
R.capsulatus       ----RDLQDK---------GFLLTTAEDIINWARNGSLHWMTFGLACCAVEMMHTAMPRY  69 
B.taurus           VSQARAVVPKPAALPSSRGEYVVAKLDDLINWARRSSLWPMTFGLACCAVEMMHMAAPRY 104 
H.sapiens          LPKARAVAPK----PSSRGEYVVAKLDDLVNWARRSSLWPMTFGLACCAVEMMHMAAPRY 101 
T.thermophilus     ---VQELERE---------GILFTTLEKLVAWGRSNSLWPATFGLACCAIEMMASTDARN  58 
E.coli             DPLEQEVNKN----------VFMGKLNDMVNWGRKNSIWPYNFGLSCCYVEMVTSFTAVH  76 
                            :            . . : :  *.* .*:   .***:** :**:    .   
 
Y.lipolytica       DQDRLG-IIFRASPRQSDIMIVAGTLTNKMAPVLRQVYDQMPEPRWVISMGSCANGGGYY 157 
N.crassa           DQDRLG-IIFRASPRQSDVMIVAGTLTNKMAPALRQVYDQMPDPRWVISMGSCANGGGYY 173 
P.denitrificans    DLERFG-TAPRASPRQSDLMIVAGTLTNKMAPALRKVYDQMPEPRYVISMGSCANGGGYY 125 
R.capsulatus       DVERYG-FAPRASPRQSDVMIVAGTLTNKMAPALRKVYDQMPEPRYVISMGSCANGGGYY 128 
B.taurus           DMDRFG-VVFRASPRQSDVMIVAGTLTNKMAPALRKVYDQMPEPRYVVSMGSCANGGGYY 163 
H.sapiens          DMDRFG-VVFRASPRQSDVMIVAGTLTNKMAPALRKVYDQMPEPRYVVSMGSCANGGGYY 160 
T.thermophilus     DLARFGSEVFRASPRQADVMIVAGRLSKKMAPVMRRVWEQMPDPKWVISMGACASSGGMF 118 
E.coli             DVARFGAEVLRASPRQADLMVVAGTCFTKMAPVIQRLYDQMLEPKWVISMGACANSGGMY 136 
                   *  * *    ******:*:*:***   .****.::::::** :*::*:***:**..** : 
 
Y.lipolytica       HFSYSVVRGCDRIVPVDVYVPGCPPTSEALMYGVFQLQRKMRNTKI-------------- 203 
N.crassa           HYSYSVVRGCDRIVPVDIYVPGCPPTSEALMYGIFQLQRKMRNTKI-------------- 219 
P.denitrificans    HYSYSVVRGCDRIVPVDIYVPGCPPTAEALLYGILQLQR--RASGA-------------- 169 
R.capsulatus       HYSYSVVRGCDRIVPVDIYVPGCPPSAEALMYGILQLQRKIRRTGT-------------- 174 
B.taurus           HYSYSVVRGCDRIVPVDIYVPGCPPTAEALLYGILQLQKKIKREKR-------------- 209 
H.sapiens          HYSYSVVRGCDRIVPVDIYIPGCPPTAEALLYGILQLQRKIKRERR-------------- 206 
T.thermophilus     N-NYAIVQNVDSVVPVDVYVPGCPPRPEALIYAVMQLQKKVRGQAYNERGER-------L 170 
E.coli             D-IYSVVQGVDKFIPVDVYIPGCPPRPEAYMQALMLLQESIGKERRPLSWVVGDQGVYRA 195 
                   .  *::*:. * .:***:*:***** .** : .:: **.                      
 
Y.lipolytica       --TRMWYRK---------------- 210 
N.crassa           --TRMWYRK---------------- 226 
P.denitrificans    --PARW------------------- 173 
R.capsulatus       --LVR-------------------- 177 
B.taurus           --LRIWYRR---------------- 216 
H.sapiens          --LQIWYRR---------------- 213 
T.thermophilus     PPVAAWKRTRG-------------- 181 
E.coli             NMQSERERKRGERIAVTNLRTPDEI 220 
                                             
Figure 8.2: Amino acid sequence alignment of the PSST subunit from various organisms. 
As in Figure 3.3, exchanged amino acid residues are highlighted according to their importance 
for complex I activity: Green, complex I activity was reduced (25-75%); yellow, at least one 
exchange resulted in strongly reduced complex I activity (<25%). Residues which change the I50 
value for DQA, rotenone or C12E8 are colored in orange. Cysteine ligands of iron-sulfur cluster 
N2 are highlighted in yellow in the amino acid sequence from T. thermophilus. The NCBI 
sequences of Y. lipolytica (ACCESSION CAB65525), N. crassa (ACCESSION CAF06152), P. 
denitrificans (ACCESSION P29918), R. capsulatus (ACCESSION AAC24986), B. taurus 
(ACCESSION CAA46154), H. sapiens (ACCESSION AAI11518), T. thermophilus 
(ACCESSION AAA97939) and E. coli (ACCESSION BAA16121) were aligned by the 
multiple sequence alignment program ClustalW. Invariant (*), highly (:) and weakly similar (.) 
positions are labeled. 8.2  Amino acid sequences 181 
8.2.3  The 30-kDa subunit 
Y.lipolytica       MLSRFARIGSMG--IRPVAAARAT--FVTSARAAQAAPSWENIKDIRLDPKVHVDEVYEP  56 
N.crassa           MASKLCRSRALASALRSAKPSPAIRCLATTSRNLINMPEGPNPRQFPREP--LPGALNAA  58 
H.sapiens          ------------MAAAAVARLWWRGILGASALTRGTGRPSVLLLPVRRES---AGADTRP  45 
B.taurus           ----------MAAAVAAAAPGCWQRLVGSAAPARVAGRPSVLLLPVRRES---SAADTRP  47 
R.capsulatus       ------------------------------------------------------------ 
T.thermophilus     ------------------------------------------------------------ 
P.denitrificans    ------------------------------------------------------------ 
E.coli             ----------------------------------------------------MVNNMTDL   8 
                                                                                
 
Y.lipolytica       IVNPADRYLQHVSDLHQYAKYIMAALPKYIQGFSV-WKDELTLHVAPSAVIPVTTFLRDN 115 
N.crassa           VVNPADKYQSKADNLHKYGSWLMGCLPKYIQQFSV-WKDELTIYISPAGVIPVFSFLKYN 117 
H.sapiens          TVRPRNDVAHKQ--LSAFGEYVAEILPKYVQQVQVSCFNELEVCIHPDGVIPVLTFLRDH 103 
B.taurus           TVRPRNDVAHKQ--LSAFGEYVAEILPKYVQQVQVSCFNELEICIHPDGVIPVLTFLRDH 105 
R.capsulatus       --------MSEK--LQDLAAHVAQQRPGDVISAEV-VQGELTVTVKPEGIADFVRFLRDD  49 
T.thermophilus     ---------------MRLERVLEEARAKGYPIEDN-GLGNLWVVLPRERFKEEMAHYKAM  44 
P.denitrificans    ---------------MRLERVLEEARAKGYPIEDN-GLGNLWVVLPRERFKEEMAHYKAM  44 
E.coli             TAQEPAWQTRDHLDDPVIGELRNRFGPDAFTVQAT-RTGVPVVWIKREQLLEVGDFLKKL  67 
                                               .           .   : :    .     . :   
 
Y.lipolytica       TSTQYKSIIDITAVDYPS-------RENRFEVVYNFLSVR-----HNSRIRLKTYATEVT 163 
N.crassa           TAAEYTQVSDITAVDFPT-------KDQRFEVVYNLLSVR-----HNSRIRVKTYADEVS 165 
H.sapiens          TNAQFKSLVDLTAVDVPT-------RQNRFEIVYNLLSLR-----FNSRIRVKTYTDELT 151 
B.taurus           SNAQFKSLADLTAVDIPT-------RQNRFEIVYNLLSLR-----FNSRIRVKTYTDELT 153 
R.capsulatus       AGCRFTTLVDLTAVDWPE-------RVERFEMVWHFLSMW-----KNQRIRVKAGLAEDA  97 
T.thermophilus     GFNFLADIVGLDYLTYPDP------RPERFAVVYELVSLPGWKDGDGSRFFVRVYVPEED  98 
P.denitrificans    GFNFLADIVGLDYLTYPDP------RPERFAVVYELVSLPGWKDGDGSRFFVRVYVPEED  98 
E.coli             P-KPYVMLFDLHGMDERLRTHREGLPAADFSVFYHLISID-----RNRDIMLKVALAEND 121 
                          : .:  :               * :.:.::*:       .  : ::.   *   
 
Y.lipolytica       P-VPSITCLYEGANWFEREAYDMYGVFFEGHPDLRRIMTDYGFEGHPLRKDFPLTGYTEV 222 
N.crassa           P-VPSITPLYDGANWYEREVYDLFGVFFTGHPDLRRIMTDYGFDGHPLRKDFPMTGYTEI 224 
H.sapiens          P-IESAVSVFKAANWYEREIWDMFGVFFANHPDLRRILTDYGFEGHPFRKDFPLSGYVEL 210 
B.taurus           P-IESSVPVYKAANWYEREIWDMFGVFFANHPDLRRILTDYGFEGHPFRKDFPLSGYVEL 212 
R.capsulatus       M-CPSIVEVYPAANWYEREVFDMFGILFSGHPDLRRLLTDYGFRGHPLRKDFPTTGYIEL 156 
T.thermophilus     PRLPTVTDLWGSANFLEREVYDLFGIVFEGHPDLRKILTPEDLEGHPLRKDYPLGETPTL 158 
P.denitrificans    PRLPTVTDLWGSANFLEREVYDLFGIVFEGHPDLRKILTPEDLEGHPLRKDYPLGETPTL 158 
E.coli             LHVPTFTKLFPNANWYERETWDLFGITFDGHPNLRRIMMPQTWKGHPLRKDYPARAT--- 178 
                       : . ::  **: *** :*::*: * .**:**:::      ***:***:*        
 
Y.lipolytica       RWDEEKRRVVYEPLELTQAFRNFSAGSTAWEPVGPGRDDRPDSFKLPTPKPEEKEGDKK 281 
N.crassa           RYDEEKKRIVTEPLEMTQAFRNFEGGSSAWEQVGAGIDRKPESFKLPTPKPETKPEEKK 283 
H.sapiens          RYDDEVKRVVAEPVELAQEFRKFDLNS-PWEAF-PVYRQPPESLKLEAG--DKKPDAK- 264 
B.taurus           RYDDEVKRVVAEPVELAQEFRKFDLNS-PWEAF-PAYRQPPESLKLEAG--DTKPEAK- 266 
R.capsulatus       RYDEVQKRVVYEPVKLAQEYRQFDFLS-PWEG----------AQSVLPG--DEKRS--- 199 
T.thermophilus     FREGR----YIIPAEFRAALTGKDPGLTFYKGG------SRKGYRSLWADLKKAREVKG 207 
P.denitrificans    FREGR----YIIPAEFRAALTGKDPGLTFYKGG------SRKGYRSLWADLKKAREVKG 207 
E.coli             ---------EFSPFELTKAKQDLE----------------------------------- 193 
                               * ::       .                                     
Figure 8.3: Amino acid sequence alignment of the 30-kDa subunit from various organisms. 
The invariant aspartate 184, which forms salt bridges to amino acid residues from the 49-kDa 
subunit, is highlighted in green. The NCBI sequences of Y. lipolytica (ACCESSION 
XP_504891), N. crassa (ACCESSION XP_957689), H. sapiens (ACCESSION NP_004542), B. 
taurus (ACCESSION NP_777244), R. capsulatus (ACCESSION AAC24987), T. thermophilus 
(ACCESSION AAA97940), P. denitrificans (ACCESSION AAA97940) and E. coli 
(ACCESSION BAA16115) were aligned by the multiple sequence alignment program 
ClustalW. Invariant (*), highly (:) and weakly similar (.) positions are labeled. 182   8  Appendix  
8.2.4  The 24-kDa subunit 
Y.lipolytica       ---MLR--LIRPRLAALAR---------PTTRAPQALNAR--THIVSVHRNTENNNPSIP  44 
N.crassa           MATKLTPFLMRTAVRAATRLSTKPSTIAPVSRACLSISARRPSDTLMVHRNTPDNNPDIP  60 
H.sapiens          ---MFFSAALRARAAGLTAHWG-----RHVRNLHKTAMQNGAGGALFVHRDTPENNPDTP  52 
B.taurus           ---MFLSAALRARAAGLAAHWG-----KHIRNLHKTAVQNGAGGALFVHRDTPENNPETP  52 
P.denitrificans    ------------------------------------------------MLRRLSPIQPDS  12 
T.thermophilus     ------------------------------------------------------------ 
E.coli             -------------------------------------------------MHENQQPQTEA  11 
R.marinus          -----------------------------------MADFVKKPVVPLPELHPEPQIPADQ  25 
                                                                                
 
Y.lipolytica       FEFSPENMKRAEEVIAKYPPQYKKAAVMPLLDIGQRQLGYTSISVMNYVAKLLEMPPMRV 104 
N.crassa           FKFSADNEKVIEEIIKRYPPQYKKAAVMPLLDLGQRQHGFCSISVMNEVARLLEMPPMRV 120 
H.sapiens          FDFTPENYKRIEAIVKNYPEGHKAAAVLPVLDLAQRQNGWLPISAMNKVAEVLQVPPMRV 112 
B.taurus           FDFTPENYKRIEAIVKNYPEGHKAAAVLPVLDLAQRQNGWLPISAMNKVAEILQVPPMRV 112 
P.denitrificans    FEFTPANLEWARAQMTKYPEGRQQSAIIPVLWRAQEQEGWLSRPAIEYCADLLGMPYIRA  72 
T.thermophilus     MGFFDDKQDFLEETFAKYPPEGRRAAIMPLLRRVQQEEGWIRPERIEEIARLVGTTPTEV  60 
E.coli             FELSAAEREAIEHEMHHYED--PRAASIEALKIVQKQRGWVPDGAIHAIADVLGIPASDV  69 
R.marinus          LFFTEEEKAKIARFKEQYLE--PAGAVMKTLWLAQEKFGFLPPEVLQLVADELGIPYAQV  83 
                   : :   :         .*      .* :  *   *.: *:     :.  *  :  .   . 
 
Y.lipolytica       YEVATFYTMYNRTPMG-RYHLQICTTTPCQL--CGSDGIMEAVQNTLNIKPGETTKDNLF 161 
N.crassa           YEVASFYTMYNRTPVG-KFHVQACTTTPCQLGGCGSDVIVKAIKEHLGIKQGETTPDGLF 179 
H.sapiens          YEVATFYTMYNRKPVG-KYHIQVCTTTPCMLR--NSDSILEAIQKKLGIKVGESTPDKLF 169 
B.taurus           YEVATFYTMYNRKPVG-KYHIQVCTTTPCMLR--NSDSILEAIQKKLGIKVGETTPDKLF 169 
P.denitrificans    LEVATFYFMFQLQPVGSVAHIQICGTTTCMIC--GAEDLIRVCKEKIAPEPHALSADGRF 130 
T.thermophilus     MGVASFYSYYQFVPTG-KYHLQVCATLSCKLA--GAEELWDYLTETLGIGPGEVTPDGLF 117 
E.coli             EGVATFYSQIFRQPVG-RHVIRYCDSVVCHIN--GYQGIQAALEKKLNIKPGQTTFDGRF 126 
R.marinus          YGVATFYTQYYKEKKG-KYVLDVCTCFTCQVC--GGYDILHYLEEKLGIHKGETTPDGLF 140 
                     **:**        *    :  *    * :   .   :     : :       : *  * 
 
Y.lipolytica       TLSEVECLGACVNAPMMAIN-DDYYEDLTPEGTVKLLEDCKAG-----KMPTPGPENHVR 215 
N.crassa           TFIEVECLGACANAPMVQIN-DDYFEDLTPETIKQVLSALKESVTDVSKAPQPGPQ-SGR 237 
H.sapiens          TLIEVECLGACVNAPMVQIN-DNYYEDLTAKDIEEIIDELKAG-----KIPKPGPR-SGR 222 
B.taurus           TLIEVECLGACVNAPMVQIN-DNYYEDLTPKDIEEIIDELKAG-----KIPKPGPR-SGR 222 
P.denitrificans    SWEEVECLGACTNAPMAQIG-KDFYEDLTVEKLAALIDRFAAGE-----VPVPGPQ-NGR 183 
T.thermophilus     SVQKVECLGSCHTAPVIQVNDEPYVECVTRARLEALLAGLRAG----------------- 160 
E.coli             TLLPTCCLGNCDKGPNMMIDEDTHAH-LTPEAIPELLERYK------------------- 166 
R.marinus          TLQEVECLGACGSAPVLQVSNGPYVHNLTPEKVDQLLEDLKQGK-----LPPFVSLTLPQ 195 
                   :   . *** * ..*   :.   . . :*      ::                        
 
Y.lipolytica       RDCEPASG----------------------------QKVLLSKEPHNVADFLQEGI 243 
N.crassa           QTCENAAG----------------------------LTSLTS-EPYG-PEVTRSDL 263 
H.sapiens          FSCEPAGG----------------------------LTSLTE-PPKGPGFGVQAGL 249 
B.taurus           FSCEPAGG----------------------------LTSLTE-PPKGPGFGVQAGL 249 
P.denitrificans    FSAEALGGPTALADLKGGEAHNASVARALRLGDSIKRIDGTEVPITTPWLATQNGV 239 
T.thermophilus     -----------------------------------KRLEEIELPGKCGHHVHEVEV 181 
E.coli             -------------------------------------------------------- 
R.marinus          DEAELGGN---------------------------RRSDAEAVESYRTPPVAHHTR 224 
Figure 8.4: Amino acid sequence alignment of the 24-kDa subunit from various organisms. 
Exchanged amino acids are highlighted in red. The cysteine ligands of iron-sulfur-cluster N1a 
are highlighted in green. The NCBI sequences of Y. lipolytica (ACCESSION CAG80440), N. 
crassa (ACCESSION CAA54990), H. sapiens (ACCESSION CAG33209), B. taurus 
(ACCESSION P04394), P. denitrificans (ACCESSION AAA25588), T. thermophilus 
(ACCESSION AAA979421), E. coli (ACCESSION BAA16114) and R. marinus (ACCESSION 
AAY42999) were aligned by the multiple sequence alignment program ClustalW. Invariant (*), 
highly (:) and weakly similar (.) positions are labeled. 8.3  Structural formulas 183 
8.3  Structural formulas 
8.3.1  Ubiquinones 
8.3.1.1   DBQ 
 
 
Molecular Formula:   C19H30O4 
Molar mass:    322.4 g·mol
-1 
log P:      7.2 (cyclohexane/water)  4.7 (membrane/water) 
Solubility:    ethanol and DMSO 
E278-350 nm    ε = 12.5 mM
-1cm
-1 (in ethanol) 
 
8.3.1.2   Q0 
 
 
Molecular Formula:  C9H10O4 
Molar mass:    182.17 g·mol
-1 
log P:     0.39  (cyclohexane/water)   
Hazards:     irritant 
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8.3.1.3   Q1 
 
 
Molecular Formula:   C14H18O4 
Molar mass:    250.29 g·mol
-1 
log P:      2.65 (cyclohexane/water)  2.9 (membrane/water) 
Solubility:    ethanol and DMSO   
E275 nm      ε = 14 mM
-1cm
-1 
 
8.3.1.4   Q2 
 
 
Molecular Formula:  C19H26O4 
Molar mass:    318.41 g·mol
-1 
log P:      5.1 (cyclohexane/water)  4.0 (membrane/water) 
Solubility:    ethanol and DMSO 
E275 nm      ε = 14 mM
-1cm
-1 
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8.3.1.5   Menaquinone 
 
 
8.3.1.6   Duroquinone 
 
 
Molecular Formula:  C10H12O2 
Molar mass:    164.2 g·mol
-1 
log P:     2.45  (cyclohexane/water) 
Solubility:    ethanol and DMSO 
Hazards:     Irritant  
 
8.3.2  Inhibitors 
8.3.2.1   C12E8 
 
 
Inhibitor class:  Type C 
Molecular Formula:   C28H58O9 186   8  Appendix  
Molar mass:    538.75 g·mol
-1 
Solubility:   water 
Literatur:  (Helenius and Simons, 1972; Helenius et al., 1979; Neugebauer, 
1990; Neugebauer, 1992) 
 
8.3.2.2   DQA 
 
 
Inhibitor class:  Class I/Type A 
Molecular Formula:   C18N27H3 
Molar mass:    285.4 g·mol
-1 
Solubility:    ethanol and DMSO 
E291 nm      ε = 8.14 mM
-1cm
-1 in ethanol 
Literature:    (Hollingworth et al., 1994) 
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8.3.2.3   Rotenone 
 
 
Inhibitor class:  Class II/Type B 
Molecular Formula:   C23H22O6 
Molar mass:    394.42 g·mol
-1 
Solubility:    ethanol and DMSO 
Comment:   light  sensitive 
Literatur:   (Horgan  et  al., 1968;Ueno et al., 1996) 
Hazards:     toxic, dangerous for the environment 
 
8.3.2.4   EIPA 
 
 
Molecular Formula:   C11H18ClN7O 
Molar mass:    299.76 g·mol
-1 
Solubility:    ethanol and DMSO 
Hazards:     irritant 188   8  Appendix  
8.3.2.5   Antimycin A 
 
 
Molecular Formula:   C28H40N2O9 
Molar mass:    548.6252 g·mol
-1 
Solubility:    ethanol and DMSO 
Hazards:     toxic 
 
8.3.3  Other compounds 
8.3.3.1   ACMA 
 
 
Molecular Formula:   C14H11ClN2O 
Molar mass:    258.70 g·mol
-1 
Solubility:    ethanol and DMSO 
Hazards:     harmful 
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8.3.3.2   Valinomycin 
 
 
Molecular Formula:   C54H90N6O18 
Molar mass:    1111.32 g·mol
-1 
Solubility:    ethanol and DMSO 
Hazards:     very toxic 
 
8.4  Abbreviations 
ACMA 9-amino-6-chloro-2-methoxyacridine 
ADP   adenosine-5'-diphosphate 
APS     ammonium-persulfate 
ATP   adenosine-5'-triphosphate 
A.U.   arbitrary  units 
bp   base  pair 
BSA    bovine serum albumin 
C12E8   n-alkyl-polyoxyethylene-ether 
C-terminus carboxyl-terminus 190   8  Appendix  
DBQ     n-decylubiquinone 
DMSO   dimethyl-sulfoxide 
dNADH  deamino-nicotinamide-adeninedinucleotide, reduced form 
DQA   2-decyl-4-quinazolinyl-amine 
ds   double  stranded 
DTT   dithiothreitol 
EDTA   ethylenediaminetetraacetic acid 
EIPA   5-(N-ethyl-N-isopropyl)-amiloride   
EPR    electron paramagnetic resonance 
EtSH     2-mercaptoethanol 
Eu
II-DTPA Eu
IIdiethylenetriamine-N,N,N′,N′′,N′′-pentaacetate 
 
FAD    flavine-adenine-dinucleotide, oxidized form 
FADH2  flavine-adenine-dinucleotide,  reduced  form 
FCCP   carbonyl-cyanide-p-trifluoromethoxyphenylhydrazone 
FeS   iron-sulfur  cluster 
FMN   flavine-mononucleotide 
FPLC    fast protein liquid chromatography 
g   acceleration  of  gravity 
GLB     gel loading buffer  
GPN     gel buffer native  
HAR   hexaammineruthenium(III)-chloride 
Hepes   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
his-tag   affinity marker composed of six histidines 8.4  Abbreviations 191 
HMW    high molecular weight  
Hyg   hygromycin 
I50    inhibitor concentration, which inhibits an enzymatic reaction rate to 50 % 
K   Kelvin 
kb   kilobase 
kDa   kiloDalton 
app. Km  apparent Michaelis constant 
Mes   2-(N-morpholino)ethanesulfonic  acid 
Mops   3-(N-morpholino)propanesulfonic  acid 
mtDNA  mitochondrial deoxyribonucleic acid 
NAD
+   nicotinamide-adenine-dinucleotide, oxidized form 
NADH   nicotinamide-adenine-dinucleotide, reduced form 
NaN3   sodium-azide 
NaPi   sodium-dihydrogen-phosphate 
NDH2i    internal version of the alternative NADH-dehydrogenase 
Ni-NTA Ni
2+-nitrilotriacetic acid 
N-terminus amino-terminus 
OD   optical  density 
OG   octyl-β-D-glucopyranoside 
ORF    open reading frame  
OXPHOS oxidative  phosphorylation 
PAGE   polyacrylamide gel electrophoresis 
PCR    polymerase chain reaction 192   8  Appendix  
PEG   polyethylene-glycol 
Pi   inorganic  phosphate 
PIPO strain  Yarrowia lipolytica strain with a hexa histidine-tag  
    at the NUGM subunit (30-kDa subunit) of complex I 
PMSF   phenylmethanesulphonylfluoride 
Q   ubiquinone 
Q1   2,3-dimethoxy-5-methyl-6-(3-methyl-2-butenyl)-1,4-benzoquinone 
Q2   2,3-dimethoxy-5-methyl-6-geranyl-1,4-benzoquinone 
QH2   ubiquinol 
ROS    reactive oxygen species 
RT   room  temperature 
SDS   sodium-dodecyl-sulfate 
SEM   standard  error  of  mean 
ss    single stranded  
TEMED tetramethylethylenediamine 
Tricine   N-(tri(hydroxymethyl)methyl)glycine 
Tris   tris(hydroxymethyl)aminomethane 
Units   µmol  NADH/min 
UV   ultraviolet 
Vmax   maximum velocity of an enzymatic reaction 8.5  List of Figures 193 
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